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Abstract 
Going blind is incomprehensible and with an aging population the number of people 
with blinding disease is increasing. Glaucoma and age related macular 
degeneration (AMD) are two major causes of blindness affecting people as they 
age. The only proven treatment for glaucoma is lowering of the intraocular pressure 
(IOP) which is best done by surgically placing a channel from the anterior chamber 
to allow aqueous outflow to drain into the subconjunctival space. The drainage 
channel can be formed by the use of a glaucoma drainage device (GDD) or by 
glaucoma filtration surgery (GFS). Both GFS and the use of a GDD often fail over 
time because local fibrosis (scarring) in the subconjunctival space blocks aqueous 
outflow resulting in the increase of IOP and disease progression. It was 
hypothesised that a more biocompatible GDD could be fabricated from a hydrogel, 
and that the hydrogel material could be used to restrict aqueous outflow to control 
the IOP. Hydrogels are widely used in ophthalmic applications including contact 
lens and intraocular lens.  
Since hydrogels are widely examined for use in drug delivery, it was also 
hypothesised that a hydrogel implant could be made for the subconjunctival space 
after GFS to stop tissue adhesion and to deliver locally an anti-fibrotic or anti-
inflammatory drug to increase the chances for long-term surgical success. For 
AMD, the current treatment is intravitreal (IVT) injections of anti-VEGF antibodies 
approximately every 4-6 weeks. IVT injections are an invasive procedure and 
associated with some complications, but it is also becoming apparent that many 
healthcare systems around the world cannot cope with the increasing demands for 
IVT injections to treat AMD. To reduce the frequency for IVT injections, there is a 
need to develop formulations that allow a longer duration of action for therapeutic 
proteins in the back of the eye. Maintaining protein stability is a major challenge in 
formulation science and clinical use. It was further hypothesied that injectable 
hydrogels could also be used to formulate an antibody for IVT injection to display an 
extended residence time in the vitreous cavity.  
Free radical polymerisations of 2-hydroxyethyl methacrylate (HEMA) and 2-
methacryloyloxyethyl phosphoryl choline (MPC) in the presence of a cross-linker, 
poly(ethylene glycol diacrylate) (PEGDA) were conducted to prepare HEMA-MPC 
co-polymer hydrogel films. Both HEMA and MPC are widely used in ophthalmic 
hydrogel products and MPC is known to be exceptionally biocompatible, although it 
must only be used as a co-polymer to ensure there are suitable processing and 
mechanical properties in the resulting hydrogel. Different HEMA-MPC hydrogels 
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with increasing relative stoichiometries of MPC (0%-100% (w/w)) were prepared 
and characterised to determine if water flow through the gel was possible. 
Unfortunately the hydrogel films formed have low permeability (1.1×10-18 m2 s-1 pas-
1) compared to the permeability required to control flow at a rate of 2 µL/min under 
10-15 mmHg IOP, which is (6 ×10-14 m2 s-1 pas-1). Although the HEMA-MPC 
hydrogel films could not be used for flow control, they were further examined for 
use as potential implants for local tissue site drug delivery in subconjunctiva. 
HEMA-MPC hydrogels with 10% MPC were found to offer the best balance 
between water content, mechanical strength and drug loading and release that was 
required for the possible implantation drug loaded films derived from a range drugs 
(dexamethasone, pirfenidone and doxycycline).  
The process used for drug loading of dexamethasone was optimised by 
using, methanol and the in vitro half-life of DEX was increased from 1.8 to 9.1 days 
with release being sustained for more than 3 weeks. There are other causes of 
subconjunctival scarring, in particular trachoma, which is the main cause of 
blindness due to infection. Doxycycline is thought to be a good candidate drug for 
treating patients after trachoma surgery because it has both anti-bacterial and anti-
fibrotic properties. As a water-soluble drug, doxycycline release could not be 
sustained for more than 3 days, so the 10% MPC films were modified with the 
incorporation of β-cyclodextrin (β-CD) in an effort exploit the possible affinity of 
doxycycline with β-CD to prolong doxycycline release. Several methods were 
examined to introduce β-CD into the HEMA-MPC films including the formation of 
HEMA-MPC films with pendant β-CD, the embedding of β-CD cross-linked particles 
within the hydrogel network and formation of an interpenetrating network (IPN) of β-
CD and HEMA-MPC. Unfortunately, the release profile of doxycycline was similar in 
the modified and non-modified HEMA-MPC hydrogels.  
To evaluate hydrogels for use in IVT injections of antibodies, N-
isopropylacylamide (NIPAAm) thermoresponsive hydrogels were evaluated. Three 
different macromolecular hydrophilic cross-linkers were evaluated; PEGDA, 
phosphorylcholine 3059 (PC 3059) and acrylated hyaluronic acid (Ac-HA). The 
prepared hydrogels were characterised regarding physical properties such as water 
content, water retention thermoresponsivness and protein release. The thermal 
responsiveness decreased with increasing cross-linker percentage. Modification in 
the type and percentage of cross-linker used allowed the preliminary screening of 
the different formulations. Hydrogel formulations made with 40 mg NIPAAm as 
monomer and 8 µL PEGDA, 20 mg PC3059 or 4 mg Ac-HA were able to sustain the 
release of antibodies for a month in a validated in vitro model of the eye.   
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Chapter 1. Introduction 
Barriers to ophthalmic drug delivery: The big challenge 
The aim of any final dosage form is to deliver the drug molecule in a therapeutic 
concentration to the site of action for an optimal period of time. Systemic drug 
distribution is often accompanied by side effects due to off-target effects (Short 
2008; De Souza et al. 2010; Allen & Cullis 2004). Localised drug delivery to the site 
of action has the potential to minimise the amount of dose needed for efficacy.  
Systemic side effects can thus be minimised. Certain modes of administration allow 
for localised treatment, e.g.  pulmonary, transdermal, nasal, rectal, vaginal, buccal 
and ophthalmic routes (Parikh et al. 2014; Jannin et al. 2014; Chai et al. 2013; 
Frank et al. 2014). Local drug delivery to the eye can in some cases be 
accomplished, but there are major anatomical, biological and physicochemical 
barriers that can limit efficacy (Ali & Byrne 2008; Patel et al. 2015).  
Blinding eye disease has a huge impact on the quality of human life 
because vision impairment reduces people’s ability to live and move independently 
(Skalicky et al. 2012; Habtamu et al. 2015; Uchino & Schaumberg 2013). Most 
blindness occurs as people age. With aging population increasing, the number of 
people diagnosed as blind or with visual impairment is expected to increase. It is 
estimated there are approximately 39 million blind people worldwide while there are 
approximately 246 million people suffering visual impairment that ranges from 
moderate to severe (Scott et al. 2016). People with blinding eye diseases and those 
with visual impairment require constant medical care, medication and social care to 
improve their quality of life. The medical costs and the loss of economic output have 
far-reaching social and financial impacts (Köberlein et al. 2013). Worldwide, the 
cost of health care and medication was estimated to be $ 3 trillion in 2010 and 
expected to increase to $ 3.5 trillion by 2020. In addition to health care costs, 
economic loss due to the prevalence of blinding eye diseases in working 
populations is also high (Gordois et al. 2012). It is estimated that by 2020, the 
economic loss due to blinding diseases in the working population will grow to $110 
billion (Eckert et al. 2015).  
Delivery of medicines is often needed at the back of the eye because the 
majority of blinding diseases result in damage to the retina and optic nerve. An 
understanding of the barriers associated with ophthalmic drug delivery requires an 
understanding of the main parts of the eye and the function of each part. The eye 
consists of two compartments; the anterior segment (which is the front of the eye) 
and constitutes 1/3 of the globe while the other 2/3 of the globe is the posterior 
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segment (which is the back of the eye). The eye is in direct contact with the 
environment and protected by the eyelids, tear film and the cornea (McCaa 1982). 
The cornea is a transparent layer that covers the front of the eye (iris, which 
is the coloured part of the eye); it is highly innervated tissue with no blood supply. It 
refracts and transmits light to the lens and retina. It depends on the aqueous 
humour for nourishment and removal of waste products. The front surface of the 
cornea is covered with a tear film. The cornea consists broadly of three tissue 
layers each separated by a membrane (Molokhia et al. 2013). The cornea is a 
complex barrier for absorption of drugs into the eye. In addition to the cornea; tear 
turnover, nasolacrimal drainage and reflex blinking made topical administration of 
medicines using eye drop is only really appropriate to treat the periocular diseases 
(Figure 1:1) (Gaudana et al. 2010; Davies 2000).  
 
 
Figure 1:1 schematic illustration of the main parts of the anterior and posterior segments, 
barriers to ophthalmic drug delivery and routes of drug elimination from the vitreous. The 
location of ophthalmic barriers (encircled in red) are; I) the cornea and tear film; II) blood-
retinal barriers; III) blood-aqueous barriers. Routes of elimination from the vitreous 
(encircled in blue) are; 1) venous blood flow after diffusing across the iris surface; 2) 
aqueous humour outflow; 3) diffusion into the anterior chamber (1, 2 and 3 are referred to 
diffusion through the blood-aqueous barriers); 4) diffusion through the blood–retinal barrier 
(Nakhlband & Barar 2011).  
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The cornea is connected to the sclera through the limbus region. The sclera 
is the white part of the eye that is tough in nature and is mainly comprised of 
collagen fibres. It preserves the shape of the eye. The sclera is covered by a 
mucous membrane called the conjunctiva (which covers the inside of the eyelid as 
well). The conjunctiva is a thin, transparent, mucous tissue that covers the front of 
the eye, except the cornea. It is enriched with blood and lymph vessels that help to 
nourish the ocular tissues. Its surface is covered by the mucus that helps to 
lubricate the eye ball during movement and impart wettability to the ocular surfaces 
(Willoughby et al. 2010; McCaa 1982).  
The uvea comprises the iris, ciliary body, and the choroid plexus. The iris is 
the coloured part of the eye. The ciliary bodies are tissues located posterior to the 
iris and are responsible for the production of the aqueous humour and control vision 
by adjustment of the lens. The anterior chamber is the space between the iris and 
the cornea while posterior chamber is the space between the iris and the lens 
(posterior to the iris and anterior to the lens); both are occupied by the aqueous 
humour (Rawas-Qalaji & Williams 2012). The aqueous humour is a transparent fluid 
that fills the anterior and posterior chambers (Chowdhury et al. 2010). 
The main parts of the posterior segment are vitreous humour, retina, choroid 
and optic nerve. The vitreous humour is a clear viscous gel that fills the posterior 
cavity of the eye. It is located between the lens and the retina. The vitreous helps to 
maintain the structure of the eye. The retina is a complex tissue that lies between 
the vitreous and sclera. The choroid is the vascularised tissue comprising the 
blood-retinal-barrier and separates the retina from the sclera. The blood-retinal 
barrier is considered the main key barrier for the absorption of drugs into the 
posterior segment after systemic administration (Figure 1:1) (Willoughby et al. 
2010).  
Topical drug delivery through eye drops is the common route for the 
treatment of anterior segment eye diseases due the non-invasive nature of the 
route; however for posterior drug delivery topical route is ineffective (Hughes et al. 
2005). The amount of drug that can reach the posterior segment is below the 
therapeutic dose required. This is caused by drainage and loss of the drug through 
the nasolacrimal ducts and the inability of the drug to penetrate the cornea and 
blood-aqueous barriers of the eye in sufficient amount to induce therapeutic effect 
(Duvvuri et al. 2003; Moisseiev et al. 2014). Systemic administration is also 
ineffective most of the times due to blood-aqueous and blood-retinal barrier that 
restricts drug penetration to the vitreous. High oral doses will be required to allow 
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therapeutic level of the drug to be reached in ocular tissues which will increase 
dose related side effects (Hughes et al. 2005; Eljarrat-Binstock et al. 2010).  
Over the years different routes for posterior drug delivery have been 
investigated such as transscleral, suprachoroidal, posterior subtenon, 
subconjunctival, subretinal and intravitreal (IVT) injection (Figure 1:2). The above 
routes offer the advantage of overcoming the barriers and side effects associated 
with topical and systemic routes such as low penetration and faster elimination from 
ocular surfaces (Kang-Mieler et al. 2016; Yamada & Olsen 2015; Geroski & 
Edelhauser 2001; Holz et al. 2014).   
 
 
 
Figure 1:2 Different routes used and investigated for drug delivery to the anterior and 
posterior segments of the eye. The blue shapes represent the possible location for 
implantation of drug releasing implants or injections of the drug molecules for ophthalmic 
delivery. Topical route is mainly for anterior drug delivery and the other routes are for 
posterior drug delivery (Novack 2009). 
Currently in the clinic, the delivery of large and reproducible drug doses into 
the posterior segment was only achievable using IVT route. The IVT route offers the 
advantage of high intraocular concentration for a longer period of time compared to 
other routes (Nomoto et al. 2009). For example, Wang et al reported that a 
favorable pharmacokinetics was observed with single IVT injection of anti-
inflammatory drug ketorolac compared to suprachoroidal single injection in rabbits 
(Wang et al. 2012). The half-life in the retinal–choroid was (3.09 ± 0.13 hour) after 
IVT injection compared to (1.18 ± 0.27) hour after suprachoroidal Injection. The 
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mean residence time of the injected drug was also higher (4.04 ± 0.12 hour) after 
IVT injection compared to suprachoroidal Injection (1.58 ± 0.21 hour). 
Intravitreal dosage forms 
Drug molecules injected into the vitreous in the clinic are divided into two 
categories; high molecular weight proteins and small molecular weight molecules 
such as anti-inflammatory drugs (Sarao et al. 2014; Krohne et al. 2012; 
Magdelaine-Beuzelin et al. 2010). Injections and implants are the available dosage 
forms in the clinic through IVT route (Kuppermann & Loewenstein 2010).  
IVT injections are widely used in the clinic compared to other routes. IVT 
injections are directly injected into the vitreous which assures the delivery of the 
accurate therapeutic dose into the site of action. However, IVT injected drugs have 
short half-life in the vitreous due to rapid elimination from the vitreous. Drug 
elimination is through two main routes; posterior and anterior elimination (Raghava 
et al. 2004; Shen et al. 2007). Drugs with large molecular weight and high water 
solubility, such as proteins, are eliminated by permeation through blood aqueous 
barriers to the anterior chamber followed by elimination through aqueous turnover 
and uveal blood flow. Hydrophobic drug molecules and small molecular weight 
drugs are eliminated through posterior route by permeation through blood retinal 
barriers (Figure 1:1) (Urtti 2006; Kidron et al. 2012). The short half-life of 
medications in the vitreous requires multiple injections which are often associated 
with complications such as inflammation, vitreous haemorrhage and retinal 
detachment in addition to the burden placed on patients financially and mentally 
(Sampat & Garg 2010; Falavarjani & Nguyen 2013).   
Solid implants are used as drug delivery systems (DDSs) to increase drug 
efficacy in the posterior segment. It is hoped that with the development of IVT 
implants, patients do not have to endure frequent IVT injections. Intraocular 
implants are divided into two types; biodegradable, such as Ozurdex® 
(dexamethasone in poly(lactic-co-glycolic acid) PLGA), and non-biodegradable, 
such as Vitrasert® (ganciclovir with polyvinyl alcohol (PVA) and ethylene vinyl 
acetate), Retisert® (fluocinolone acetonide with silicone and PVA), Iluvien® 
(fluocinolone acetonide with polyimide and PVA) (Figure 1:3) (Haghjou et al. 2011; 
Bansal et al. 2016). 
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Figure 1:3  Examples of IVT implants and the possible position of the implants in the eye 
(Kuno & Fujii 2011). 
For non-biodegradable implants the main advantage is relatively better 
control over the release of the drug compared to biodegradable ones over 
prolonged period of time (Bansal et al. 2016). The implants are formulated as 
reservoir systems in which a pellet of drug is surrounded by a semipermeable 
polymeric membrane to control drug diffusion (with the exception of Iluvien® which 
is in matrix form). The main disadvantage is surgery which is required for 
implantation and removal of the empty implant and surgery is often associated with 
side effects such as inflammation and infection (Choonara et al. 2010). The only 
exception is Iluvien® which could be injected through 25G needle and remain in the 
vitreous when the entire drug loaded is released. Iluvien® was developed to deliver 
a very low dose of fluocinolone acetonide to the retina for up to 3 years as a 
treatment for diabetic macular edema (Kane et al. 2008). Non-biodegradable 
implants are often used for the treatment of chronic conditions in the eye (da Silva 
et al. 2010). For biodegradable implants the need of surgery for removal and 
application is eliminated; however they offer relatively less control over drug release 
compared to non-biodegradable implants and it is very difficult to retrieve the 
implant when side effects start to show (Bansal et al. 2016; da Silva et al. 2010).  
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Several new approaches for IVT implants have been investigated such as 
the use of refillable delivery systems and cell encapsulated technology (Chen 
2015). Ciliary neurotrophic factor (CNTF) delivery through cell encapsulated 
technique has been investigated for the treatment of dry age related macular 
degeneration (AMD) and retinitis pigmentosa. The device is composed of sealed 
semipermeable membrane of polyethylene terephthalate surrounding human retinal 
pigment epitheliums cells (ARPE-19) genetically modified to secrete recombinant 
human CNTF (Kuno & Fujii 2011). Microelectromechanical systems (MEMS) are 
intraocular DDS that can be refilled with drug solution for long term therapy. The 
device consists of refillable drug reservoir with flexible canula. The device would be 
implanted in the subconjunctival space and allow the canula to be directed into the 
vitreous or the anterior chamber (Figure 1:3)  (Bansal et al. 2016). 
Clinically registered implants or implants under development for the 
posterior segment have been predominantly developed with steroids as the active 
drug agent. Current ocular implants that utilise steroids can provide a sustained 
release from months to over two years. The choice of steroids is due to the 
favorable properties of the drug molecules (Falavarjani 2009). Steroids inhibit 
inflammation and would be expected to minimise a foreign body response to an 
implant. Steroids are generally poorly water soluble, low MW actives that are stable 
within an implant. For the delivery of proteins Intravitreal (IVT) injections are the 
only available dosage form in the clinic (Hariprasad et al. 2006; Stewart et al. 2011).   
 Over 68% of the leading causes of blindness and severe visual impairment 
in older population are related to two diseases; glaucoma and AMD and the number 
is subjected to increase due to improvement of quality of life and diagnosis 
techniques in developed countries (Bunce & Wormald 2006). Understanding these 
two conditions will help in improving treatments available. 
Glaucoma 
Glaucoma is defined as a group of disorders that leads to optic nerve neuropathy. 
Glaucoma is one of the main causes of irreversible blindness in the world with more 
than 66 million people having high prevalence of glaucoma (Quigley & Broman, 
2006; Jonas et al., 2014). There are several types of glaucoma but the main 
modifiable risk factor is the increase in the intraocular pressure (IOP) of the 
eye(Coleman & Miglior 2008). The IOP is controlled by a balance between the 
secretion and drainage of the aqueous humour, so the pressure inside the eye is 
maintained at normal level (around 12 mmHg). The aqueous humour consists of 
98% water, electrolytes, ascorbic acid, amino acids, oxygen, carbon dioxide, low 
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amount of proteins and glutathione. It nourishes the lens and the cornea, removes 
waste products and stabilises the ocular structure (Brubaker 1982). The aqueous 
humour is secreted from the ciliary bodies, which are located behind the lens, into 
the posterior chamber and the aqueous flows into the anterior chamber through the 
pupil of the iris. The aqueous humour fills the posterior and anterior cavity of the 
eye and maintains the eye structure. The aqueous humour is in continuous 
production at a rate of approximately 2-2.5 µL/min. Aqueous drains from the eye 
into the blood circulation through two pathways. The first is through the trabecular 
meshwork, which is located in the limbal region (the limbal region is where the 
cornea and sclera meet). The trabecular meshwork is a spongy tissue that is 
converted into the schlemm’s canal which is connected to the episcleral vein and 
venous circulation, this is called conventional pathway (Figure 1:4) (Goel et al. 
2010). 
  
Figure 1:4 The release of aqueous humour from the ciliary body and its movement towards 
trabecular meshwork for drainage through conventional pathway. The aqueous humour is 
released from the ciliary muscles behind the lens and move to the anterior chamber 
followed by elimination through the trabecular meshwork and schlemm’s canal (the dotted 
arrow). Adapted from (Goel et al. 2010). 
The trabecular meshwork acts as a resistance barrier for the flow of the 
aqueous humour. A positive intraocular pressure in the eye is needed for the 
aqueous humour to drain from the eye. Drainage through the trabecular meshwork 
is considered the major pathway for aqueous drainage. The second drainage 
pathway is through the uveal meshwork into the ciliary muscles and out through the 
sclera. This is called non-conventional pathway (Siggers & Ethier 2012).  
Problems with drainage of the aqueous humour from the conventional 
pathway, such as blockage of the trabecular meshwork, will cause an increase in 
pressure inside the eye (Tomarev 2001). Over time the elevated pressure affects 
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the retinal ganglionic cells, retinal cell axons and blood vessels, which lead to the 
death of the nerve ganglions and to optic nerve damage. The loss of vision does 
not happen instantly but gradually. First the peripheral vision is lost followed by 
deterioration in the central vision and blindness (Lee & Higginbotham 2005). 
Current glaucoma treatments 
Glaucoma treatments range from eye drops to surgery depending on the stage of 
the disease and the complications associated with each patient. Medication in the 
form of eye drops is often the first choice to control the elevated IOP (Babić 2015). 
Several drugs are available for the control and management of increased 
intraocular pressure. Beta-receptors play an important role in the regulation and the 
production of aqueous humour from the ciliary body. Blocking these receptors 
reduce the production of aqueous humour. Selective and non-selective beta-
blockers (such as betaxolol) are used to treat glaucoma (Rait 1999). Carbonic 
anhydrase inhibitors also reduce the production of aqueous humour but by different 
mechanism. Carbonic anhydrase is an enzyme important in the production of the 
aqueous humour; therefore by inhibiting its effects, the rate of aqueous production 
is reduced (Supuran & Scozzafava 2000).  
Prostaglandin analogues (such as latanoprost) increase the flow of the 
aqueous humour through the non-conventional pathway. Adrenergic agonists (such 
as epinephrine) are also used. They act by both reducing rate of production of 
aqueous humour and increase rate of flow through the trabecular meshwork 
through complex processes that involves the activation of both alpha and beta 
receptors (Sambhara & Aref 2014). Miotics (such as pilocarpine) are a class of 
drugs that act by improving the drainage efficiency of the aqueous humour through 
the trabecular meshwork. They cause contraction of the ciliary muscle, which leads 
to relaxation of the trabecular meshwork (Alward 1998). 
Laser surgery is also used in certain cases. There are three types of laser 
surgery; the first is called argon laser trabeculoplasty. In this type of treatment the 
laser makes small burns (holes) in the trabecular meshwork to increase fluid 
drainage and open the blocked channels (Heijl et al. 2011). The second type of 
laser surgery is selective laser trabeculoplasty which selectively targets the 
pigmented cells of the trabecular meshwork, thus preserving the trabecular 
meshwork structure (Mahdy 2008). It is safer and there are fewer side effects 
compared to the argon laser trabeculoplasty (Kramer & Noecker 2001). The third 
type of laser therapy is called transscleral diode laser cyclophotocoagulation, which 
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destroys the tissues responsible for the formation of aqueous humour (Ansari & 
Gandhewar 2007). 
If the progression of glaucoma is not halted, then a type of drainage surgery 
is required. The most widely used surgical procedure is known as trabeculectomy 
or glaucoma filtration surgery (GFS) (Chiselita 2001). This surgery involves creating 
a new channel to drain the aqueous humour into the subconjunctival space. A small 
space called the bleb is often formed to allow the aqueous humour to drain from the 
eyeball and be absorbed into the systemic circulation (Figure 1:5) (Yu et al. 2009). 
The GFS is a complex surgery and often associated with complications such as 
endophthalmitis, hypotony, bleb leakage, scarring and corneal complications 
(Watson et al. 1990). In patients where the risk of GFS complications is high or the 
patient underwent previous failed GFS, glaucoma drainage devices (GDDs) were 
introduced.  
   
 
Figure 1:5 Glaucoma filtration surgery (GFS); the red arrow represent the alternative flow 
pathway created during the surgery where the fluid directed to the subconjunctival space.  
GDDs are implants used to create an alternative aqueous drainage pathway 
from the anterior chamber. A new drainage channel is formed by the tube to direct 
the aqueous flow into the subconjunctival space (Gedde et al. 2007). Generally 
these devices are designed with a tube that is attached to a spacer plate. One end 
of the tube goes into the anterior chamber and the other end is attached to the 
plate, which is placed in the subconjunctival space (Figure 1:6) (Minckler et al. 
1987). The tube is approximately 300 microns in diameter. This size of tube does 
not offer pressure control, so many GDDs had values designed to better control 
outflow and to provide pressure resistance. The spacer plate is designed to disrupt 
subconjunctival fibrosis that often occurs after surgery. The spacer plate serves to 
provide a drainage pathway for the aqueous after it drains from the eyeball (Patel & 
Pasquale 2010).  
A fibrovascular capsule develops around the spacer and acts as the primary 
pressure resistance mechanism that controls the aqueous flow from the anterior 
Bleb 
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chamber. The inner layer of the capsule is collagen and the outer layer is 
vascularised tissue. The aqueous humour is directed from the anterior chamber to 
the capsule and cleared through the vascularised tissues to the systemic circulation 
(Dempster et al. 2011). The formation of the capsule varies between (4-6) weeks 
after implantation depending on the patient response (Mills et al. 1996). 
Early stage pressure control is often achieved by temporarily suturing the 
tube until the capsule develops around the spacer. There is a need to develop other 
strategies for long term pressure control rather than rely on the formation of a 
fibrovascular capsule around the spacer plate since the foreign body reactions 
necessary for capsule formation can vary widely in patients.  
 
                                
Figure 1:6 The position of the tube and plate of GDD in the eye. The tube is placed in the 
anterior chamber while the plate is placed in the subconjunctival space. The tube will direct 
the aqueous humour from the anterior chamber to the subconjunctival space.  
The first glaucoma drainage device was developed by Molteno in 1969 
(Molteno et al. 1976). The Molteno GDD had a tube without a valve. Unless 
considerable care is taken by sutering the tube, there is a lack of control over the 
IOP that can result in hypotony (very low IOP), which can result in the eye 
collapsing. The problems observed with non-valved devices led to the development 
of the valved GDD. The first valved GDD was introduced in 1976 by Krupin (Krupin, 
1976), which was a unidirectional valve to provide resistance to the aqueous flow to 
prevent hypotony after the implantation of the device. When the IOP reaches (11-
14) mmHg the valve opens. In 1993, the Ahmed glaucoma device (AGD) was 
introduced. The valve in the AGD is designed to open when the IOP is (8-12 
mmHg). These devices have been developed over the years in different shapes 
and sizes (Figure 1:7 and Table 1:1) (Molteno et al. 1976; Schwartz et al. 2006; 
Wilson-Holt et al. 1992; Good & Kahook 2011; Nyska et al. 2003; Rivier et al. 2007; 
Knowlton 2009; Hueber et al. 2013; Acosta et al. 2006; Siegner et al. 1995; 
Ceballos et al. 2002; Ayyala, Zurakowski, et al. 1998). 
Unfortunately many of the valved GDDs fail because a fibrovascular capsule 
still develops around the spacer plate resulting in IOP increases (Thieme et al. 
Tube 
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2011). The only recourse for the patient is to have the site of surgery ‘needled’ 
where an ophthalmologist must try to break up the capsule to allow aqueous to 
flow. In severe cases another surgery is required where another GDD is implanted, 
but this strategy is not ideal since a non-functioning device often remains in the eye. 
Continued foreign body response occurs and the need to implant the second device 
in a suboptimal place in the eye all contribute to there being a greater chance for 
long term problems requiring considerable follow up to ensuring there is control of 
IOP. 
 
 
Figure 1:7 Different types of glaucoma drainage devices that are available in the clinic, A) 
Ahmed device, B) Cypass stent, C) Hydrus stent, D) AqueSys stent, E) Gold Micro Shunt, 
F) Double Molteno device and G) ExPress shunt device, H) Baerveldet device, I) Istent. All 
the devices have a tube and spacer to control the IOP while stents have no spacer and the 
inner diameter of the device itself is the resistant mechanism to control IOP. The choice of 
the device is based on the medical condition of the patient.  
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Table 1:1 Different GDDs and the description of each device. The table highlights the materials used for each device, the mechanism of control of pressure 
and the size of each device.   
Device name Description 
Valved / 
Non- valved 
Size of the device 
Molteno single plate and 
double plate 
Silicone tube attached to a single or 
double polypropylene end plate 
Non-valved 
134 mm
2
 size of the single end  plate and 268 mm
2
 for the double end  
plate, 340 µm inner diameter of the tube 
Baerveldet 
Silicone tube attached to a barium 
impregnated silicone end plate 
Non-valved 
The end plate is of three sizes 250 mm
2
, 350 mm
2
 and 500mm
2
, 300 
µm inner diameter of the tube 
ExPress R50 
Stainless steel tube with no end plate 
with disc like flange at one end and 
spur like projection at the other end 
Non-valved 3 mm long, 50 µm and 200 µm inner diameter of the tube available 
Ahmed GV 
Silicon tube connected to a 
polypropylene end plate 
Valved End plate is 185 mm
2
, 300 µm inner diameter of the tube 
Krupin 
Silicone tube attached to a silicone end 
plate 
Valved End plate is 180 mm
2
, 300 µm inner diameter of the tube 
AqueSys Cross-linked gelatin tube Non-valved 6 mm long, 50 μm inner diameter, 150 μm outer diameter 
MIDI-Arrow 
Poly(styrene-b-isobutylene-b-styrene) 
[SIBS] tube 
Non-valved 8.5 mm long, 70 μm inner diameter, 350 μm outer diameter 
SOLX Gold shunt 24 carat gold Non-valved 
flat implant with numerous microtubular channels (5.2 mm long and 
3.2 mm wide) 
Schocket Silicone Non-valved 
Width 4 mm (#20 band), 6 mm (#220 band), circumferential diameter 
24 mm (at equator) 
Optimed PMMA Valved Width 10 mm, length 14 mm, plate thickness 1.3 mm 
Istent Titanium Non-valved Length 1 mm (body), 250 µm (snorkel), Length 360 µm 
Hydrus Nitinol Non-valved Length 15 mm 
Cypass Polyimide Non-valved Length 6.35 mm 
Aquashunt Polypropylene Non-valved Width 4 mm, length 10 mm, plate thickness 0.75 mm 
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Recently developed devices are based on different design concepts 
compared to the Molteno and Ahmed devices. These included the ExPress R50, 
Gold Micro Shunt, Istent, InnFocus and AqueSys (Table 1:1). The ExPress R50 is a 
stainless steel tube with no end plate and a disc like flange at one end and spur like 
projection at the other end. These modifications were introduced to prevent 
migration and extrusion of the tube. First it was placed underneath the conjunctiva 
(similar to the previous devices). Problems such as conjunctival erosion and 
hypotony were predominant so now it is placed under the sclera. Pressure 
resistence in the ExPress tube is achieved because the diameter of the tube is 
blocked to have an inner diameter of approximately 50 µm (Filippopoulos & Rhee 
2008).  
The Gold Micro Shunt is based on different approach which directs the 
aqueous humour to the suprachoroidal space (Hueber et al. 2013). The Istent is a 
(1 mm) long heparin coated titanium tube that is inserted surgically into the eye 
through the trabecular meshwork into the schlemm’s canal. This creates a 
permanent opening in the trabecular meshwork to direct the aqueous humour 
directly to the schlemm’s canal. AqueSys is a gelatin tube inserted into the eye 
through a specialised inserter without dissection to drain the aqueous humour from 
the anterior chamber to the subconjunctival space (Saheb & Ahmed 2012).  
The use of a spacer with a tube may give better long term outcomes 
because aqueous can be channelled away from the drainage point from the 
eyeball. The formation of the fibrovascular capsule can vary widely, so there is an 
opportunity to develop a more biocompatible spacer. The choice of the biomaterial 
used for the synthesis of the spacer is important because it affects the initial 
inflammatory response to the implant (Ayyala 2000). Materials that are used for a 
GDD design should have biocompatibility, flexibility and the mechanical strength for 
implantation. The consideration of a more biocompatible spacer requires that there 
also be consideration for how outflow resistance will be achieved to control IOP.      
Problems with current glaucoma treatments 
As mentioned earlier glaucoma treatments are available in the form of eye drops, 
laser surgery, GDD and GFS. Most of the dosage forms available for glaucoma 
treatments are eye drops; however there are several barriers for topical drug 
delivery. First is the low efficacy because of the removal of the administered eye 
drops by tears and nasal drainage and poor penetration through the corneal 
barriers (Ghate & Edelhauser 2008). Since glaucoma is a chronic disease, cost and 
low patient adherence also play an important role in reducing the benefits of using 
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eye drops (Friedman et al. 2007; Rylander & Vold 2008). The eye drops need to be 
used several times a day which is inconvenient for patients and half of them 
discontinue the treatment or do not use the eye drops regularly (Tsai 2009; Sleath 
et al. 2006). The long term use of eye drops increases the sensitivity of the eye 
tissues and renders the eye more susceptible to inflammation and less responsive 
to treatment over time. This is mainly due to the chronic use of preservatives (such 
as benzalkonium chloride), which is a common component in eye drops (Noecker 
2001).  
Implantable drug delivery devices that can provide medication for prolonged 
time to overcome these problems have been investigated for years but they also 
offer a great challenge in terms of safety and prolong effect (Manickavasagam & 
Oyewumi 2013). Laser surgeries have short term and variable effect depending on 
the patient and still some of the patients need medication after the surgery. Irregular 
IOP after the surgery is noticed in many patients. This is due to the blockage of 
some of the newly formed channels (Wise 1987). 
The main problem associated with current GDDs is lack of control on flow in 
the first few weeks before the fibrous capsule formation, which may cause hypotony 
(which is IOP lower than 5 mmHg). To overcome these problems certain surgical 
techniques are used, such as using external absorbable ligatures or internal 
removable suture stents to temporary control the aqueous flow over the first 4 
weeks until the capsule is formed (Melamed & Fiore 1990; Molteno et al. 1986). 
Modifications in the design of the implant such as increasing surface area of the 
end plate and designing a subsidiary pressure ridge to reduce post-operative 
hypotony was also introduced but still no significant improvement were observed 
(Molteno 1990; Luong et al. 2014). Elevated IOP also may occur due to tube 
obstruction caused by excessive capsule formation and fibrosis around the tube 
and the end plate due to foreign body response to the material used for the device 
(Chaudhry et al. 2012). Modification in the devices was introduced but still no 
significant improvement observed (Luong et al. 2014). 
 Most of the available GDD devices are made of silicone or polypropylene. 
Stainless steel and gold are also used for tubes and drainage channel (Hueber et 
al. 2013; Rivier et al. 2007). Although these materials have been used for years 
they still produce inflammation, irritation and scarring due to foreign body response 
(Ayyala 2000). Recently other materials have been used such as cross-linked 
gelatin and poly (styrene-b-isobutylene-b-styrene) [SIBS] (Pinchuk et al. 2008). 
There is still a need for the development of a biocompatible material that could be 
used in a GDD and produce less inflammation and less fibrous capsule formation 
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(Knowlton 2009; Acosta et al. 2006). In general devices available in the clinic now 
lack the consistency to control the IOP in patients (Chaudhry et al. 2012).  
The major problem with GFS is the wound healing. During the wound 
healing process inflammation, collagen deposition and scarring occur at the surgical 
site. This may cause the closure of the newly formed channel and failure of the 
operation (Skuta & Parrish 1987). A scar is a fibrous tissue that replaces a 
damaged tissue and considered as the last part of the wound healing process and 
could also be a result of pathological condition such as myocardial infarction and 
trachoma (Gurtner et al. 2008). Trachoma is main cause of blindness due to 
infection. Inflammation and fibrosis cause the eyelid to contract and the eyelashes 
to turn inward, so that blinking causes damage to the cornea resulting in blindness.  
While a scar in the skin is not usually a function problem, a scar in the eye 
tissues often causes a loss of function resulting in blindness (Hsu et al. 2000; Tovell 
2011; Bowman 1999). Most blinding conditions are characterised by fibrosis. 
Wound healing is broadly characterised by four phases which are the i) coagulative 
phase, (ii) inflammatory phase, (iii) proliferation and tissue repair (iv) remodelling 
(scar formation) phase. Although these phases are distinct from each other, they 
overlap during the healing process  which can last for a long time (Figure 1:8) 
(Gurtner et al. 2008). 
 
 
Figure 1:8 The wound healing process is recognised by four phases which are i) 
coagulative phase, (ii) inflammatory phase, (iii) proliferation and tissue repair (iii) 
remodelling (scar formation) phase. These phases overlap with each other during the 
healing process (Van Bergen et al. 2014). 
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During coagulation there will be the release of inflammatory mediators 
causing inflammation to occur. The inflammatory response involves several 
inflammatory mediators secreted from immune cells, e.g. macrophages and 
neutrophils. Inflammation plays an important role in regulation of the healing 
process during the first week after surgery (Eming et al. 2007). Proliferation starts in 
parallel with the inflammation phase, and includes epithelialisation, angiogenesis 
and the formation of a temporary extracellular matrix ECM. Proliferation will result in 
the activation of fibroblasts that will cause wound contraction to close the exposed 
area of the wound. The final phase includes tissue remodelling and scar formation. 
This process could start as early as 8 days after surgery and continue for months. 
The main cell responsible for this phase is the fibroblast. Targeting any of these 
phases will in principle modulate wound healing to potentially mediate scar 
formation (Witte & Barbul 1997).   
Several approaches and medications have been investigated to modulate 
wound healing and to achieve a greater chance for bleb survival after GFS (Seibold 
et al. 2012). The most widely used medicines are the off label use of mitomycin C 
(MMC) and 5-fluorouracil during GFS or GDD implantation. Both of these medicines 
are cytotoxic agents used to treat malignant disease. The mechanism of action of 
both medications is by inhibiting DNA synthesis, which leads to cell apoptosis, 
including fibroblasts. Fibroblasts play an important role in collagen synthesis and 
fibrosis.  
During glaucoma surgery a sponge soaked with MMC is placed in the 
subconjunctival space at the site of surgery for 5 minutes. The MMC will prevent 
excessive scarring by reducing cell growth and division during the healing process. 
Although the success of GFS was significantly improved by the treatment with 
MMC, the risk of side effects such as infection was also increased due to the 
toxicity of these drugs (Wu et al. 2013; Khaw et al. 2012). Topical corticosteroids 
such as dexamethasone and prednisolone have been reported to effectively 
improve the outcomes of GFS by supressing the inflammation process. In the clinic 
topical eye drops of corticosteroids are prescribed after surgery. Dexamethasone 
drops are used between 2-4 weeks after surgery. 
Other strategies have been investigated over the years to modulate the 
scarring process. These include targeting one or more of the overlapping wound 
healing phases and the mediators involved in the phases (Lockwood et al. 2013; 
Georgoulas et al. 2008; Schlunck et al. 2016; Masoumpour et al. 2016). A wide 
range and number of drugs have been evaluated preclinically for subconjunctival 
use after glaucoma surgery including ilomastat, pirfenidone, doxycycline and anti-
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vascular endothelial growth factor (VEGF) proteins in different dosage forms; 
however none are yet available in the clinic (Jung & Park 2016; Cui et al. 2008; Wu 
et al. 2013; Fakhraie et al. 2016; Martorana et al. 2015). 
Age related macular degeneration 
In England and Wales approximately 57% of blindness is related to age related 
macular degeneration (AMD) because of the aging population. Approximately 9% of 
global blindness is caused by AMD (Bunce & Wormald, 2006; Jonas et al., 2014). 
With age, the macula (which is the part of the retina responsible for central vision) 
degenerates and damaged due to local angiogenesis that damages the retinal 
tissue. Localised inflammation and fibrosis also occurs and the tissue damage 
cause loss of central vision. Often a patient has blurred vision and an inability to 
clearly see objects in detail.  
There are two types of AMD; dry and wet AMD. Dry AMD is characterised 
by deposition of yellow debris comprised of lipids and fatty proteins (drusen) under 
the retina causing damage to the macula (Coleman et al. 2008). Wet AMD is 
characterised by excessive growth of abnormal blood vessels underneath the 
macula. These new blood vessels will leak blood and fluids in the area surrounding 
the retina and damage the macula (Figure 1:9). While dry AMD slowly progresses 
and take years to develop, wet AMD, if untreated, may end with severe vision loss 
within days (Kulkarni & Kuppermann 2005). This growth of blood vessels is driven 
by growth factors including vascular endothelial growth factor (VEGF). 
Overexpression of VEGF is observed in wet AMD (Coleman et al. 2008). 
 
Figure 1:9 Normal macula and diseased one (wet and dry AMD). In dry AMD deposition of 
yellow debris is observed. In wet AMD excessive growth of abnormal blood vessels 
underneath the macula is observed. Adapted from (Patel 2016). 
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There is no available treatment for patients with dry AMD. Patients with wet 
AMD were previously treated by laser surgery (photodynamic therapy), but first line 
treatment is the intravitreal (IVT) injection of anti-VEGF antibodies. Photodynamic 
therapy can be used in an effort to halt the progression of the disease by destroying 
the abnormal blood vessels. The treatment involves the intravenous infusion of 
photosensitising agent (verteporfin) followed by laser activation of the drug.  
Unfortunately there is a high recurrence of angiogenesis (50%) and restoration of 
vision is limited after the photodynamic therapy (Lim et al. 2012; Yonekawa et al. 
2015). 
 Currently the most widely used treatment is the IVT injection of anti-VEGF 
antibody based medicines Lucentis (ranibizumab; Genentech) and Eylea 
(aflibercept; Regeneron). These medicines are approved around the world for the 
treatment of wet AMD and are now widely used in the clinic (Meadows & Hurwitz 
2012). Avastin (bevacizumab; Genentech) is a full antibody that targets VEGF and 
is licensed to treat angiogenesis in malignant disease.  Bevacizumab is widely used 
unlicensed to treat AMD because it is much cheaper per dose than either 
ranibizumab or aflibercept (Avery et al. 2006). An early anti-VEGF drug derived 
from a poly(ethylene glycol) conjugated aptamer called Macugen (pegaptanib; 
Valeant Ophthalmics) was the first anti-VEGF drug to market, but is not widely used 
since the antibody based drugs have been approved. Since AMD is a chronic 
condition, it is often necessary to treat patients for many years. Ranibizumab is 
labelled for monthly administration and aflibercept is administered about every 6-8 
weeks. Repeat IVT injections can be associated with several problems such as 
infections, retinal detachment and poor patient compliance (van Wijngaarden et al. 
2005). The frequency of IVT injections is also costly. There is a need to determine if 
it is possible to increase the duration of action for these antibodies based medicines 
so that the frequency of IVT injections can be decreased.  
Hydrogels a possible solution to current treatment problems 
Glaucoma and AMD are considered as the main causes of preventable blindness 
worldwide. For each condition different treatments are available; however all the 
current treatments have limitations and problems.  
GDDs were considered as a second line treatment in glaucoma and now 
they have been introduced as a first line treatment (Ayyala, Pieroth, et al. 1998). 
The main problem associated with GDDs is the lack of control on flow in the first 
few weeks before the fibrous capsule formation, which may cause hypotony. The 
other problem is foreign body response to the material used for the device 
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manufacture which often causes too much scarring around the device resulting in 
the failure of the device to control pressure (Chaudhry et al. 2012).  
Implantable devices generally have sub-optimal biocompatibility with an 
associated foreign body response (Anderson 2001). When an implant is placed in 
the human body the initial inflammatory reactions often result in the formation of a 
fibrous capsule to encapsulate the implant.  In drug delivery, encapsulation can 
completely ruin the release profile of the drug from the implant. In the case of 
GDDs, encapsulation often results in surgical failure by an increase in IOP that 
allows progression of the glaucoma. The foreign body response is varied based on 
many factors related to the material that is to fabricate the implant and the physical 
properties of the implant itself (e.g. surface smoothness, lack of sharp edges) 
(Onuki et al. 2008).  
To overcome the problem of foreign body response, implants can potentially 
be coated with a biocompatible polymer (e.g. coronary stents).  It is also possible to 
fabricate an implant from a biocompatible material (e.g. intraocular lens). Yu et al 
reported that coating a polyurethane glucose sensor with poly (hydroxyethyl 
methacrylate-2,3-dihydroxypropyl methacrylate-N-vinyl-2-pyrrolidone) hydrogels 
reduce the inflammatory response around the implant. The glucose sensor was 
subcutaneously implanted in rats for 28 days. There was a thin fibrous capsule and 
less inflammatory cells surrounding the sensor after 28 days implantation compared 
to non coted sensors (Yu et al. 2008).  
An ideal GDD will (i) have minimal foreign body response, (ii) be able to 
control the IOP over a wide range of patients for a prolonged period of time, (iii) be 
easily implanted with minimum incision and (iv) be affordable for patients around 
the world. A GDD made from hydrogels may offer a better solution to the problems 
associated with the current devices available in the clinic. Hydrogels are known to 
be biocompatible materials that may elicit a decreased fibroblast reaction commonly 
seen with other materials (Poppas et al. 2016). Reduction in the inflammatory 
response will minimise scarring in the conjunctiva around the spacer plate if coated 
or fabricated from a hydrogel.  
Hydrogels are also polymer networks where the polymer chains are cross-
linked by covalent bonds or non-covalent associations. Cross-linking the polymer 
chains can render them to be a permeable network capable to transfer molecules 
such as oxygen and loaded drugs through the entangled polymer chain structure 
(Brennan et al. 1987). A GDD made from a hydrogel could control the IOP by 
restricting the flow of the aqueous humour at a constant rate from the anterior 
chamber. For example using an existing tube, it might be possible to allow outflow 
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into a spacer fabricated from a hydrogel. Depending on the character of the 
hydrogel (e.g. cross-link density, polymer molecular weight, water association 
properties), it might be possible to restrict aqueous flow through to control IOP.  
Hydrogels could also be used to improve the outcome of GFS which is 
jeopardised by the excessive scarring after the surgery. A GDD could be made 
entirely from a hydrogel or a hydrogel could be used to fabricate a spacer 
connected to a tube (Figure 1:10). A drug could also be loaded into the device for 
the synthesis of GDD that have the ability to release drugs (combination device) to 
further decrease the foreign body response. The use of a hydrogel film made with 
biocompatible polymers for the delivery of anti-scarring or anti-inflammatory agents 
for subconjunctival implantation after GFS could also be considered as a way of 
improving success rate of GFS by reducing inflammation and scarring associated 
with GFS. A hydrogel film could also help to mechanically separate and prevent 
adhesion between the conjunctiva and episcleral surface after GFS (Figure 1:10).  
 
Figure 1:10 The position of a hydrogel GDD and releasing spacer (green) after GFS. For a 
GDD one end of the tube will be in the anterior chamber and the other end attached to a 
hydrogel plate placed in the subconjunctival space. For the spacer the drug will be released 
to the surrounding area of the implant in GFS (black arrows).   
For the treatment of wet AMD, longer, more extended release formulations 
of anti-VEGF antibodies are required to reduce the frequency of injections. 
Extended release in the vitreous body could potentially be achieved either by 
formulating the protein into a solid implant or into a highly concentrated form 
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(Stewart 2016; Agarwal & Rupenthal 2013; Li et al. 2012; Rauck et al. 2013). 
Formulating a protein into a solid implant is challenging due to protein instability and 
the sensitivity of these molecules to aggregate and misfold (Mitragotri et al. 2014; 
Jiskoot et al. 2012). It would be also difficult to maintain the activity of the protein 
throughout device fabrication and so it is not surprising that no implants of 
therapeutic protein have been approved for clinical use in the eye or elsewhere in 
the body (Frokjaer & Otzen 2005).  
Injectable hydrogels could be used to overcome the problems associated 
with solid implants. They have long been examined to encapsulate drugs for 
sustained local release. Due to the hydrophilic nature of the hydrogels they could 
help in preserving the activity of the protein while sustaining its release through the 
formation of semisolid implant. In order to explore the potential of hydrogels as 
delivery systems in the eye general knowledge on hydrogels is required. 
Understanding the unique properties, types, and the potential issues of hydrogels in 
drug delivery is important.  
What are hydrogels 
Hydrogels are three dimensional polymeric cross-linked networks that have the 
ability to absorb hundred to thousand times the dry weight of the hydrogels of water 
in the dry state and swell without dissolving or changing chemical structure (the 
swelling behaviour is a reversible process) (Figure 1:11). Hydrogels can be soft to 
display similar mechanical properties to tissues and extracellular matrix (they 
contain large amount of water and highly flexible). Hydrogels preserve the three 
dimensional shape upon swelling due to the presence of cross-linking points 
(junction points) (Buwalda et al. 2014). These points are physical or chemical cross-
linking points that will form a meshwork structure which will prevent complete 
solubilisation of the polymer matrix. 
The cross-links in hydrogels can either be covalent or non-covalent (e.g. 
ionic, metal chelated). Covalently cross-linked hydrogels can be prepared during 
polymerisation by the addition of cross-link monomers, which possess more than 
one polymerisable function. An example of covalently cross-linked hydrogels are 
those used in contact lenses. Many contact lenses are made using 2-hydroxyethyl 
methacrylate (HEMA). HEMA monomers are acrylates which undergo free-radical 
polymerisation. HEMA can be covalently cross-linked using a diacrylate (e.g. 
ethylene glycol dimethacrylate) (Han et al. 2009). Schmedlen et al described 
another chemical hydrogel using poly(vinyl alcohol) (PVA) prepared by 
photopolymerisation as tissue engineering scaffolds. The PVA was modified by 
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introducing photosensitive group into the PVA structure and mixed with 
photoinitiator. Once the mixture exposed to long wavelength a hydrogel is formed 
(Schmedlen et al. 2002).  
  
 
 
 
 
 
 
Figure 1:11 Swelling and deswelling behaviour of hydrogels. Dry hydrogel once placed in 
water swollen due to the formation of hydrogen bonds. The hydrogel increases in size 
several times. Once the water is removed the hydrogel returns to its original size and shape. 
Hydrogels that are cross-linked by non-covalent interactions are sometime 
referred to as physical hydrogels. Non-covalent interactions between the polymer 
chains that can occur to give a material with hydrogel-like properties include ionic, 
hydrophobic, entanglement, hydrogen or van der Waals bonds. PVA hydrogels can 
be formed by physical cross-linking through freeze/thaw cycles. These cycles will 
help to generate intermolecular hydrogen bonds between the hydroxyl groups in the 
polymer chains and formation of the hydrogel (Stasko et al. 2009). Alginate 
hydrogels have been synthesised by physical cross-links through the formation of 
an ionic bond between alginates and multivalent cations (e.g. Ca+2) (Bruchet & 
Melman 2015).  
In both covalent and non-covalent hydrogels these bonds can be called 
junction points. The number of junction points is also referred to as the degree of 
cross-linking or the cross-linking density determines the many physical and 
mechanical properties of the hydrogel. The amount of polymer chain entanglement 
and the internal volume of the hydrogel, often referred as the hydrogel pore size 
can often be correlated to the cross-link density which is usually determined by the 
percentage of cross-linker used during the polymerisation reaction. Generally the 
higher formed and the cross-link density, the smaller the pore size or less 
permeable will be the hydrogel (Jadhav et al. 2012). Often the cross-link density is 
varied in an effort to vary hydrogel properties. For example, alginate hydrogels with 
different pore sizes were synthesised by varying the percentage of Ca+2 (cross-
linking agent). An increase of Ca+2 concentration from 36 mM to 72 mM cause a 
reduction in the pore size from 247 µm to 52 µm. A further increase of Ca+2 
Junction point 
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concentration to144 mM resulted in a decrease in pore size to 30 µm (Jang et al. 
2014). Another factor that could be affected by the degree of cross-linking is the 
rheological and flow properties of the prepared hydrogels. Generally hydrogels 
made with a relatively low cross-linking density may be partially soluble and 
injectable. In contrast hydrogels with a higher cross-linking density would require 
implantation as if being a device.  
Types of hydrogels 
Hydrogels were first described in 1960 by Wichterle and have since been 
extensively investigated. Many types of hydrogels have now been described 
(Hoffman 2001). Hydrogel classification can be done by considering fabrication 
(e.g. cross-linker/monomer composition and process method) and by considering 
the intended use (e.g. degradable/non-biodegradable, stimuli responsive, drug 
release/tissue regeneration). 
As mentioned previously hydrogels are cross-linked polymers. Based on the 
starting polymer hydrogels can be classified as natural, semisynthetic and 
synthetic. Natural polymers such as polysaccharides, cellulose, starch, chitin, 
gelatin and hyaluronic acid (HA) are widely used for food and pharmaceutical 
applications (Shanmugam et al. 2005). These natural polymers are often used in 
the manufacture of different dosage forms (such as tablets, micro and 
nanoparticles, films, beads) being used as binders, fillers, stabilisers, thickening 
agents and disintegrators. For example, gelatin is used in food, tablet coating and 
hard and soft gelatin capsule synthesis. Hyaluronic acid (in the form of sodium 
hyaluronate) is used as in eye drops to treat dry eye (Shanmugam et al. 2005). 
Hydrogels made from common natural polymers already used in healthcare 
applications tend to be more biocompatible, available for sourcing, safe and can 
have minimal (if no) side effects. However; many of these polymers are found to 
suitable lack mechanical properties, are subjected to batch to batch variability and 
may cause immunogenic reaction in parenteral applications (Vishakha Kulkarni, 
Kishor Butte 2012) .  
Semisynthetic and synthetic polymers are also widely examined, sometimes 
in an effort to overcome the limitations of natural polymers. Semisynthetic polymers 
are derived by the modification of natural polymers. The resulting hydrogels can 
display more tunable mechanical properties (Zhu & Marchant 2011). An example is 
chitosan, which is the deacetylated derivative of natural polymer chitin. While chitin 
is poorly soluble in both aqueous and organic solvents, the deacetylated form of 
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chitin (chitosan) has been widely investigated and is much more commonly used in 
drug delivery due to its improved solubility (Dash et al. 2011). 
The use of synthetic polymers offers the potential to further control the 
properties such as pore size, degradation time and mechanical strength of 
hydrogels (Ahmad et al. 2012). Many synthetic hydrogels are prepared by the free 
radical polymerisation of acrylate and methacrylate derived monomers. Examples 
of widely used monomers to makes synthetic polymers include derivatives of 
phosphoryl choline (PC) and acrylic acid (especially HEMA), and PVA and poly (N-
vinyl pyrrolidone) (Gong et al. 2012; Kim et al. 2015). 
Hybrid hydrogels synthesised from a mixture of synthetic and natural 
polymers can possess the advantages of both. Nguyen et al reported the synthesis 
of polyvinyl alcohol (PVA)-gelatin hydrogel for bone regeneration (Nguyen et al. 
2016). Although PVA has low toxicity and good mechanical strength for 
implantation, it is limited for allowing proliferation and growth of cells. By combining 
PVA with gelatin, the hydrogel has 32% increased bone formation after 15 weeks 
compared to control. 
Hydrogels can further be classified based on how they are prepared. The 
polymer chains can be homopolymers (derived from a single monomer), 
copolymers, block copolymer and interpenetrating networks (IPN). An IPN is the 
cross-linking of a polymer chain in the presence of another polymer (semi-IPN) or 
another monomer mixture (IPN) (Figure 1:12) (Dragan 2014). The two polymer 
chains are entangled with each other without chemical cross-linking between them 
(Aminabhavi et al. 2015). 
For the synthesis of IPN two monomer mixtures are used. They are either 
polymerised together in the same time at the same pot (in situ) or sequentially 
polymerised. In both methods the two monomer systems should not undergo 
polymerisation with each other. In sequential polymerisation the first monomer 
mixture is polymerised. Following the polymerisation the mixture is impregnated in 
the other monomer mixture and polymerised again allowing the formation of 
entangled matrix of two different hydrogels. For in situ IPN synthesis the two cross-
linkers used for one monomer mixture should not interact with the other monomer 
mixture (Aminabhavi et al. 2015). Park & Kim reported that a IPN made from glycol 
chitosan and PVA will have higher mechanical strength compared to glycol chitosan 
hydrogels alone (Park & Kim 2006).  
For semi-IPN synthesis a polymer and a monomer mixture are used. The 
monomer mixture is polymerised in the presence of the polymer. Mixing two 
different polymers is often difficult to achieve, so a semi-IPN offers the chance to for 
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two polymers to be more intimately entangled. A cross-linked IPN hydrogel often 
has better mechanical properties, e.g. greater strength than non-IPN hydrogels. IPN 
hydrogels can be prepared in one pot (in situ) or the monomer mixture cross-linked 
first then impregnated in the polymer solution (which is called sequential synthesis) 
(Samanta & Ray 2014). Mahdavinia et al reported that when chitosan is 
polymerised around polyacrylic acid (PAA) to form semi-IPN hydrogels the swelling 
behaviour of the synthesised hydrogel was affected by the degree of cross-linking 
of chitosan. The swelling ratio of the semi-IPN hydrogel increased in acidic pH and 
decreased in neutral pH with increasing chitosan ratio (Mahdavinia et al. 2008). 
 
  
 
 
 
 
Figure 1:12 Classification of hydrogels based on hydrogel preparation method. They are 
divided into homopolymer, copolymer, multipolymer, full IPN and semi-IPN hydrogels. 
Homopolymer hydrogels 
Copolymer hydrogels 
Multipolymer hydrogels 
Monomer A B 
Cross-linker A  
IPN hydrogels 
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Cross-linker A 
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Cross-linker A B 
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Hydrogels can also be classified into Non-biodegradable and biodegradable. 
Non-biodegradable hydrogels are often covalently cross-linked hydrogels, and a 
well-known example is soft contact lenses (López-Alemany et al. 2002). The 
resistance of some hydrogels to degradation made them good candidates for some 
applications in tissue replacement, coating of medical devices and wound healing 
dressings (Bach et al. 2013; Butruk et al. 2012). Ma et al reported that a non-
biodegradable hydrogel synthesised using PVA and PVP polymers could be used 
as articular cartilage replacement (Ma et al. 2009).   
Degradable or resorbable hydrogels are designed to clear from the human 
body after a specified period of time (Stauffer & Peppast 1992). The degradation 
products must be biocompatible and non-toxic. There are examples of hydrogels 
that have been designed to clear either within days or months (Lawyer et al. 2012; 
Bhattarai et al. 2010; Lee et al. 2015). The degradable element can be either in the 
polymer main chain or within the cross-links of a hydrogel. For example Bryant and 
Anseth reported that the degradation behaviour of a poly(lactic acid)-b-
poly(ethylene glycol)-b-poly(lactic acid) diacrylate cross-linker could be modified 
using poly (ethylene glycol) dimethacrylate (PEGDM) to support the growth of 
chondrocytes and the formation of extracellular matrix that is similar to human 
tissues (Bryant & Anseth 2003). 
Hydrogels can also be classified into non-responsive (conventional 
hydrogels) and stimuli responsive (smart hydrogels). Non-responsive hydrogels 
once swollen will remain in the same shape and size with changing conditions such 
as pH, temperature and ionic strength. This type of hydrogel is often used for tissue 
replacement applications and coating of medical devices (Gonzalez & Alvarez 
2014). PVA hydrogels have been widely investigated for the repair and replacement 
of articular cartilage because of similar physical properties (e.g strength, and 
frictional and lubricating behaviour to articular cartilage) (Spiller et al. 2011).  
Stimuli responsive hydrogels change conformation with changes in 
surroundings (e.g. pH and ionic strength). The physical and mechanical properties 
of stimuli responsive hydrogels can be changed, including swelling and pore size 
when there is a change in the local environment surrounding the hydrogel. Change 
in hydrogel properties can be reversible once the stimulus is removed. In addition to 
changes in pH and ionic strength, other stimuli include changes in temperature, 
electricity, magnetic field, pressure, and biological changes such as enzyme, 
antibody, and glucose concentrations (Figure 1:13) (Soppimath et al. 2002). 
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Figure 1:13 Factors affecting the swelling and collapsing process of smart hydrogels. The 
swelling and deswelling is reversible and depending on the stimuli such as pH, temperature, 
radiation and ionic strength.   
Stimuli responsive hydrogels have been examined to develop gels that 
undergo conformational change, such as collapsing after injection to form a semi-
solid depot to prolong the release of drug from the hydrogel. Known as in situ 
forming gels, these collapsing hydrogels have been evaluated in many applications, 
e.g. eye drops (Kumar et al. 2013). Stimuli responsive hydrogels that change 
properties at a pH have widely investigated due to the different range of pH values 
in body. Polymers with basic groups, such as poly (2-vinylpyridine), and with acidic 
groups, such as polyacrylic acid (PAA) have been examined (Li et al. 2016; Sensitif 
et al. 2015).  
Hydrogels that collapse at a specific temperature are known as thermo-
responsive hydrogels.  Much effort has focused on hydrogels that are swollen at 
ambient temperature but which collapse at physiological temperature entrapping 
the drug inside and slowing its release. The gel transition can be fast, within 
seconds once the transition temperature is reached (Lue et al. 2011). The transition 
temperature for hydrogels that collapse is called the low critical solution 
temperature (LCST). LCST is the temperature below which a polymer or hydrogel 
exists in an extended form. When the LCST is reached, the polymer conformation 
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changes as the polymer chain interactions increase to expel water (and entrapped 
drug) with the polymer collapsing to a more globular form (Figure 1:14) (Patil et al. 
2013).  
 
 
Figure 1:14 The effect of temperature on the conformation of PNIPAAm polymer in water 
solution. Below LCST the polymer chain is relaxed and extended. Above LCST the polymer 
becomes insoluble in water and collapse (the process is reversible). 
At temperatures below the LCST, the hydrogel is swollen with water with 
hydrogen bonds between the polymer chains and water. Once the temperature 
increases above the LCST, the hydrophobic interactions between the polymer 
chains begins to predominate over the hydrophilic non-covalent interactions the 
polymer chains have with water. This causes the polymer to collapse becoming 
insoluble in water. The term volume phase transition temperature (VPTT) is also 
used to describe the temperature at which the hydrogel undergoes a transition from 
a completely swollen form to a solid form (deswelled) (Chang et al., 2015; 
Constantin, Cristea, Ascenzi, & Fundueanu, 2011). 
Natural polymers that could be used for the synthesis of thermoresponsive 
hydrogels are cellulose, chitosan and gelatin. Upon deswelling drug molecules 
could be entrapped in the hydrogel matrix and slow release of the drug could be 
achieved. The most widely investigated synthetic polymer for thermoresponsive 
hydrogel formulation is poly (N- isopropylacylamide) (PNIPAAm). It has an LCST of 
approximately 32oC (Stile et al. 1999; Lue et al. 2011; Schild 1992).   
Hydrogel synthesis  
Hydrophilic polymers tend to be used in biomedical studies because they can 
interact with water through common hydrophilic groups such as –OH, -CONH, -
CONH2, -COOH and –SO3H. Hydrogels prepared from hydrophilic polymers are 
soft and often lack mechanical strength. Hydrophobic polymers cannot be used 
alone for hydrogels that are destined to be used in an aqueous application. 
Hydrophobic polymers are either copolymerised with hydrophilic ones or a 
Water 
Polymer chain 
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hydrophilic group applied onto the polymer structure to modify the polymer  
properties and improve their interaction with water (Volkmer et al. 2013). 
Several chemical and physical cross-linking methods are used for hydrogel 
synthesis depending on the properties of the cross-linking bonds required (such as 
covalent or ionic bonds) but the most widely used method is free radical 
polymerisation (Hennink & Nostrum, 2002; Brazel & Peppas, 1995). In this process 
a mixture of monomers, cross-linker and initiator is used. Decomposition of the 
initiator causes the polymerisation by free radical addition to occur. Variation in the 
amount of monomers, cross-linker, initiator and polymerisation conditions will result 
in the formation of different hydrogels (Gelfi & Righetti 1981). Chung et al reported 
the synthesis of dextran-hydroxyethyl methacrylate microspheres and 
macrohydrogels with different mechanical properties was obtained when the 
preparation conditions modified. When the initiator concentration increased the 
gelation time reduced and the mechanical strength of the spheres increased 
(Chung et al. 2005).  
There are several types of polymers that could be used for non-biodegradable 
hydrogel synthesis in ophthalmic applications. Among the groups of polymers that 
are of interest, widely investigated and used for ophthalmic applications are HEMA 
and MPC.  
2-hydroxyethyl methacrylate (HEMA) 
Since their first discovery in 1960 by Wichterle and Lim, HEMA hydrogels have 
become the corner stone for hydrogel development. Hydrogels made from HEMA 
have been investigated for many years for different biomedical and pharmaceutical 
applications such as contact lenses, drug delivery and implantation (Tomar, Tomar, 
Gulati, & Nagaich, 2012; Stirbu et al., 2011). HEMA is from the family of acrylate 
polymers in which several other polymers are also available and used such as poly 
(methyl methacrylate) (PMMA), which is used for IOL synthesis (Figure 1:15). 
 
Figure 1:15 Chemical structure of poly (hydroxyethyl methacrylate) (PHEMA) and poly 
(methyl methacrylate) (PMMA).  
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Monomers used in hydrogel synthesis are generally toxic while the resulting 
polymers are not toxic. As a polymer, HEMA, being a polyester is not soluble in 
water in nature but when cross-linked into a hydrogel the gel matrix swells in water 
or biological fluids. The swelling behaviour is related to the hydrophilic hydroxylethyl 
pendant groups available along the polyHEMA main chain that are capable of 
forming hydrogen bonds with water. HEMA hydrogels are known to be 
biocompatible. This is due to the reduction of protein adsorption onto polyHEMA 
surfaces and improved biocompatibility with blood cells. HEMA has been used for 
the synthesis of soft contact lenses, ophthalmic implants such as Esnoper-V2000® 
and Esnoper clip®. These implants are investigated to improve the outcome of deep 
scleretomy surgery for glaucoma patients. HEMA has also been modified by 
copolymerisation with other polymers for hydrogel synthesis to improve their water 
uptake, mechanical properties and modify their drug releasing properties when 
used for drug delivery (dos Santos et al. 2008; Goda & Ishihara 2006).  
2-methacryloyloxyethyl phosphoryl choline (MPC) 
Zwitterionic polymers are biocompatible materials that are used as coating material 
or for the synthesis of biocompatible implants (L. Zhang et al. 2013). Zwitterionic 
means the overall charge of the surface of the molecule is zero. Hydrogels 
prepared from zwitterionic polymers are considered more biocompatible than other 
types of hydrogels. One of the most widely investigated zwitterionic polymers is 
phosphorylcholine polymers (PC). PC polymers have zwitterionic pendant groups 
that are similar in structure to head group of PC lipids in the cell membrane bilayer 
(Figure 1:16) (Bretscher & Raff 1975).   
 
Figure 1:16 The resemblances of 2-methacryloyloxyethyl phosphoryl choline (MPC) to the 
phospholipid bilayer comprising the cell membrane.  
Hydrophilic head  
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The zwitterionic charge is thought to be a key property which renders PC 
polymers to be biocompatible with body tissues and results in decreased protein 
adsorption and foreign body response (Lewis et al. 2002; Schlenoff 2014). The 
neutral charge on the PC group helps to reduce the electrostatic charge on the 
surface of the polymer chains which will reduce interactions between proteins and 
the polymer. The highly polar nature of the PC polymer head results in strong 
hydration of the PC group. A layer of water molecules will surround the PC polymer 
surfaces making it difficult for proteins and cells to bind irreversibly to a PC surface 
(Jiang & Cao 2010). It is this antifouling nature that PC can impart on biomaterials 
to improve biocompatibility of the materials. They also have excellent blood 
biocompatibility (Ishihara, Aragaki, Ueda, Watenabe, & Nakabayashi, 1990; Andrew 
L. Lewis, 2000).  
Several PC based polymers are clinically available and widely used in many 
applications including coating of heart stents, blood filtration and processing 
devices and contact lenses. Vertellus Biomaterials specialises in the synthesis of 
PC based polymers (http://www.pcbiomaterials.com/). The nomenclatures of the PC 
polymers that are commonly used clinically are PC-1059, PC-1036 and PC-1015. 
Each product number represents a copolymer derived from a different formulation 
in which 2-methacryloyloxyethyl phosphoryl choline (MPC) is always included 
(Lewis 2006). For example PC-1036 is a cross-linked co polymer of MPC, 
laurylmethacrylate, 2-hydroxypropyl methacrylate and trimethoxysilyl propyl 
methacrylate and used for coating of BiodivYsioTM heart stent (Goreish et al. 2004; 
Iwasaki & Ishihara 2005).  
Ophthalmic implants made of HEMA alone and devices coated with PC 
polymers are available in the clinic. Ophthalmic implants made of HEMA such as 
Esnoper-V2000® which is used in deep sclerotomy surgery of the eye (Stirbu et al. 
2011). In the year 2000 FDA has approved the use of BiodivYsioTM AS PC coated 
heart stent. This device is a small stainless steel wire mesh stent coated with 
phosphorylcholine (PC). This implant is to be implanted permanently in the blocked 
coronary arteries to improve blood flow. PC was used as a coating to improve the 
biocompatibility of the metal stent (Butany et al. 2005). Combining both HEMA and 
MPC in an implant will have the potential of higher biocompatibility and less foreign 
body response compared to using each alone.     
N-isopropylacrylamide (NIPAAm) 
The most widely used and investigated synthetic polymer for thermoresponsive 
hydrogel formulation is poly (N- isopropylacylamide) (PNIPAAm). It is a water 
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soluble polymer with an LCST of approximately 32oC (Stile et al. 1999; Lue et al. 
2011; Schild 1992). PNIPAAm has gain popularity due to its ability to copolymerise 
with other monomers. Copolymerisation strategies provide a means to engineer a 
hydrogel with varying VPTT and properties (e.g. hydrophilicity). When 
copolymerised with hydrophilic polymers, the VPTT of PNIPAAm often increases 
(Villa et al. 2014; Alexander et al. 2014; Lee & Lu 2013). This is an advantage in 
formulating thermoresponsive hydrogels for pharmaceutical applications as the 
transition temperature can be closer to physiological body temperature. Also when 
polymerised with pH sensitive polymers a hydrogel with dual activity can be 
prepared (Zhang et al. 2007; Gao et al. 2013). When NIPAAm and chitosan were 
polymerised and used for the synthesis of a thermosensitive in situ hydrogel for the 
delivery of timolol maleate as eye drops, there was a two-fold increase in the 
maximum concentration of timolol maleate when compared with conventional eye 
drops in the rabbit eye. The control of IOP was also improved by using the in situ 
hydrogel (Cao et al. 2007).   
The characteristics and physical properties of NIPAAm hydrogels are often 
affected by the co-monomer and cross-linker used to fabricate the hydrogel. The 
thermal responsiveness of NIPAAm hydrogels is controlled by a balance between 
hydrophilic and hydrophobic interactions between the polymer chains and the 
surrounding medium (Stewart et al. 2011; Gan et al. 2016). This balance is affected 
by the type and percentage of cross-linker used. Lee and Lin reported that the 
swelling behaviour of NIPAAm-co-(ethylene glycol) methylether acrylate (NIPAAM-
co-PEGMEA) hydrogels was affected by the cross-linker that was used. When 
tetraethylene glycol diacrylate (TEGDA) was used as the cross-linker, the swelling 
ratio (SR) was 23 compared to 7 for N,N-methylene bisacrylamide (NMBA) and 6 
for ethylene glycol dimethacrylate (EGDMA) when they were used as cross-linkers 
in the same molar ratio. Lee and Lin also reported that the SR of NIPAAm 
hydrogels decreased with increasing the molar ratio of TEGDA as cross-linker. The 
reported SR was 23, 20 and 11 for 5 mol%, 10 mol% and 15 mol% respectively 
(Lee & Lin 2006). 
In case of proteins, the use of a hydrophilic cross-linker could create a 
hydrophilic environment around the loaded protein that helps to preserve its stability 
and activity during formulation and use.     
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Hydrogels in ophthalmic applications  
Hydrogel have been examined in applications such as tissue engineering, artificial 
replacement of organs, coating of implantable devices, drug delivery, gene delivery, 
scaffolding and wound dressings (Du et al. 2012; Vashist et al. 2014; Hoffman 
2012). One of the major successes for the use of hydrogels is as wound dressings. 
Hydrogel wound dressings can absorb exudates from wounds are useful to treat 
necrotic wounds. Examples of the available hydrogel wound dressings in the clinic 
are Intrasite®, Neoheal®, Purilon® and AquafloTM (Calo & Khutoryanskiy 2015).  
Hydrogels are also used as sealants during surgery. Duraseal® is used as a 
Spine Sealant System in spinal surgery. This product consists of two solutions 
(polyethylene glycol (PEG) ester and trilysine amine) that undergo reaction during 
injection to form a hydrogel (Annabi et al. 2015). Spaceoar® is another hydrogel and 
is used to reduce rectal injury in men receiving prostate cancer radiation therapy 
(RT) by acting as a spacer pushing the rectum away from the prostate. Spaceoar® 
consists primarily of water and PEG. Upon injection of the liquid precursors the 
hydrogel solidifies without producing measurable heat. The hydrogel maintains 
space during radiation therapy and then gradually liquefies, and is cleared from the 
body (Pinkawa et al. 2011). These hydrogels are non-medicated hydrogels.  
Medicated hydrogels are also available in the clinic. For example, Supprelin® 
LA is a subcutaneous implant for the treatment of children with central precocious 
puberty. This product consists of 2-hydroxyethyl methacrylate, 2-hydroxypropyl 
methacrylate, trimethylolpropane trimethacrylate, benzoin methyl ether, perkadox-
16, triton X-100 hydrogel incorporating 50 mg of histrelin acetate, which is delivered 
over 12 months (du Toit et al. 2016). Another hydrogel product is Atridox® which is 
a subgingival controlled-release formulation of doxycycline for infection. This 
system consists of two solutions; Atrigel® polymeric formulation of poly(DL-lactide) 
dissolved in N-methyl-2-pyrrolidone and contains doxycycline hyclate. Upon contact 
with the crevicular fluid, the liquid product solidifies into a gel and then allows for 
controlled release of drug for a period of 7 days (Gad et al. 2008). In ophthalmic 
applications hydrogels are widely used as contact lenses and implants. They are 
also investigated as drug delivery systems and vitreous substitute (Figure 1:17). 
 
50 
 
 
Figure 1:17 Different forms of hydrogels and the possible application sites of the hydrogels 
in the eye for ophthalmic drug delivery (Kirchhof et al. 2015). 
In ophthalmic applications the most successful area for hydrogel products is 
soft contact lenses (SCL). Contact lenses are widely used for vision correction and 
cosmetic purposes. Some contact lenses are used for medical purposes such as 
bandage contact lenses and intraocular lenses (IOL) (Lai 2013). The first SCL was 
synthesised from poly (2-hydroxyethyl methacrylate) (pHEMA) hydrogel. Since then 
several polymers have been developed and used for contact lens including 
methacrylic acid and N-vinylpyrrolidone (Nicolson & Vogt 2001).  
An important development was the introduction of silicone hydrogel contact 
lenses. The silicone in the contact lens structure offers the advantage of higher 
oxygen permeability compared to SCL which allowed extended wear overnight and 
for several days (González-Méijome et al. 2006). Bandage contact lenses are used 
to protect the cornea after injury or surgery and allow it to heal properly (Fraunfelder 
& Cabezas 2011). Contact lenses have been thoroughly investigated as ocular 
delivery systems (Christie, 1999; Gupta & Aqil, 2012; Maulvi, Soni, & Shah, 2016). 
Kim et al reported the potential extended release of timolol and dexamethasone for 
more than 4 weeks from silicone hydrogel contact lens depending on the monomer 
mixture used for the synthesis of the lenses and the loading method used (Kim et 
al. 2008).  
SCLs have also been examined as a platform for the delivery of other 
dosage forms such as liposomes, micro and nanoparticles. Gulsen et al reported 
the dispersion of a lidocaine loaded dimyristoyl phosphatidylcholine liposomes into 
a HEMA contact lens. The release of the drug was sustained to up to 7 days with 
65% of the loaded drug being released during this period (Gulsen et al. 2005).       
Ophthalmic hydrogel implants have also been used for several clinical 
applications. IOLs are used in cataract surgery. Cataract is the opacification of the 
51 
 
natural eye lens and can be treated by surgery. The surgery involves the removal of 
the natural lens and replacing it with an IOL (Hollick et al. 1999). IOLs generally are 
made from acrylic polymers such as polymethylmethacrylate (PMMA) and pHEMA. 
The AcrySof® IOL is made of copolymer of phenylethyl acrylate and phenylethyl 
methacrylate.  
The flexibility of the hydrogel materials allowed the synthesis of foldable 
IOLs that can be implanted with minimum incision (Bozukova et al. 2010). 
Hydrogels are also used as sealant of corneal incisions when IOL implanted after 
cataract surgery. Resure® sealant (which has similar composition with Duraseal) is 
currently available in the clinic (Masket et al. 2014). In addition to contact lenses, 
HEMA was used for the synthesis of ophthalmic implants. Esnoper® (HEMA 
Implant) is used as a spacer in deep sclerotomy which is an operation used for the 
treatment of glaucoma patients (Stirbu et al. 2011). Hydrogels are also investigated 
as a biomaterial for vitreous substitution in the posterior segment. Giannetti et al 
demonstrated the possibility of using hydrogels synthesised from PVA and tri-
sodium trimetaphosphate as a substitute for the vitreous humour  (Parikh et al. 
2014). Chang et al also reported the synthesis of in situ hydrogel made from 
zwitterionic sulfobetaine methacrylamide and acryloyl cystamine monomers as 
substitute. These gels demonstrates excellent biocompatibility when in vivo studies 
were performed in rabbits (J. Chang et al. 2015).   
Hydrogels have been widely investigated as potential drug delivery systems 
for different ophthalmic applications. Hydrogels were investigated to prolong the 
corneal contact time of eye drops in efforts to improve bioavailability and patient 
compliance. An in situ hydrogel that is applied as a solution that then forms a gel 
led to the development of Timpotic XE®, which is a gel forming solution of timolol 
maleate that is used to treat glaucoma. The formulation is present in a solution form 
of timolol maleate and anionic gellan gum polymer. Once instilled into the eye, the 
aqueous gellan gum solution starts to gel by forming a complex with the cations in 
the tear film and prolong the contact time of the drug with ocular tissues. It is used 
once daily compared to the traditional timolol eye drops, which are used twice a day 
(Khare et al. 2015; Shedden et al. 2001).  
Injectable thermoresponsive hydrogels were widely investigated as IVT 
injections to sustain the release of therapeutic proteins in the posterior segment of 
the eye. Xie et al reported the sustained release of Avastin for up to 14 days in vitro 
when a poly(lactic-co-glycolic acid)-poly(ethylene glycol)-poly(lactic-co-glycolic acid) 
(PLGA-PEG-PLGA) hydrogel was injected in rats. This formulation was compared 
to Avastin injection which lasts only 3 days (Xie et al. 2015). In spite of the 
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extensive research in the area of hydrogels in ophthalmic drug delivery only 
Timpotic XE® is clinically available.  
Hydrogels and water  
Hydrogels have many advantages as implantable materials because they are 
biocompatible and the ability of hydrogels to load and release drugs. These two 
characteristics are highly affected by the amount, type and distribution of water 
inside the hydrogel (Shi et al. 2012). The relationship between water and hydrogels 
has long been the focus of researchers and has been investigated for many years 
(Lee et al. 1975; Jhon & Andrade 1973). The water inside hydrogels can be thought 
to have two main functions; (i) control the transport of materials (nutrients, cells, 
drugs) in and out of the hydrogel and (ii) to provide flexibility and an environment 
similar to body tissues.  
The water in hydrogels is often classified as free (bulk) and bound water, 
which is non-covalently associated to the polymer within the hydrogel. Bound water 
is further classified into slightly and tightly bound water (Li et al. 2005). When a dry 
hydrogel device (e.g. film) is placed in an aqueous environment the water binds 
initially to the polar, hydrophilic groups through tight hydrogen bonding leading to 
what is called (primary bound water) and the matrix starts to swell. Once the gel 
matrix swells, hydrophobic groups will be exposed to water. Extra water entering 
the gel will interact with the hydrophobic groups forming (secondary bound water); 
both are called total bound water (Hoffman 2012; Hatakeyama & Hatakeyama 
1998). The polymeric matrix continues to absorb water until it reaches equilibrium 
and complete swelling is observed. This extra water will fill the pores and spaces 
within the hydrogel, and once equilibrium is reached, this water is called free or bulk 
water (Figure 1:18) (Wang & Gunasekaran 2006). The total water in a hydrogel is 
the sum of free and bound water. Sometimes water in hydrogels is classified 
according to its ability to freeze. Non-freezable water is a term used to describe 
water molecules that are tightly bound to the polymer matrix. The bulk and loosely 
bound water is called freezable water (Tranoudis & Efron 2004). 
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Figure 1:18 Interactions of water with hydrogels. First the water binds only to hydrophilic 
groups forming the primary bound water. Extra water binds with hydrophobic groups and 
form secondary bound water. Excess water fills the voids in the hydrogel matrix and called 
bulk water. 
The amount of water at the polymer surfaces can play an important role in 
biocompatibility (platelet and protein adhesion) and drug release from hydrogels 
(He et al. 2008). Higher water content often results in a softer hydrogel that has less 
effect on the surrounding tissues (less inflammation and foreign body response) 
(Morais et al. 2010). The presence of water also reduces the interaction between 
polymer and protein, and typically reduces protein adsorption on the surface of 
hydrogel device leading to increased biocompatibility. Proteins display less 
conformational change in the presence of associated water around a hydrated 
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surface and the adsorption of a protein to the hydrogel surface can be reversible 
(Ishihara et al. 1998).  
In general when the total water content increased the biocompatibility of a 
hydrogel matrix increases as well. Researchers were in disagreement on which 
type of water responsible for biocompatibility; free, slightly bound or bound water. 
Shi et al reported that free or bulk water is largely responsible for the improvement 
in biocompatibility (Shi et al. 2012). Tanaka and Mochizuki reported that the slightly 
bound water on the polymer surface is the type of water responsible for the 
reduction in protein adsorption while He et al suggested that bound water is the key 
player (He et al. 2008; Tanaka & Mochizuki 2010).  
Limitation of hydrogels  
While hydrogel derived devices (e.g. SCL and IOLs) are available in the clinic, the 
number of hydrogel based products used for drug delivery system is limited. One 
challenge is the large amount of water that is usually associated within most 
biomedical hydrogels. Dissolved substrates tend to rapidly diffuse throughout 
hydrogel. The drug is usually loaded by two main methods; soaking (drug 
imbibition) and in situ loading (during polymerisation) (Figure 1:19) (Kim et al. 
1992). Unfortunately release of the drug is often too rapid once the drug-loaded 
hydrogel is placed in a drug free environment.   
In situ loading involves the polymerisation of the hydrogel matrix in the 
presence of the drug. This method of drug loading is limited by the requirement to 
remove leachable monomer components after polymerisation. Removal of toxic 
leachables will be accompanied by loss of the drug which is of special concern for 
small molecules especially hydrophilic drugs. In situ loading may better entrap large 
molecular weight drugs such as proteins within the hydrogel matrix. It is difficult for 
a protein to mix within a hydrogel. Large molecules do not effectively mix, which is 
nearly impossible when one of the macromolecules is a cross-linked network. 
Another disadvantage is the polymerisation conditions may result in side reactions 
with the drug. To avoid these problems soaking methods are often used. 
In the soaking method the hydrogel matrix is prepared in advance and the 
xerogel (which is the fully dried hydrogel) is allowed to hydrate in the drug solution 
allowing the drug to be absorbed within the swollen hydrogel (Figure 1:19). The 
amount of drug absorbed depends on the solubility of the drug, drug conformation, 
molecular weight, interaction with the hydrogel, concentration of the drug in the 
loading solution and the degree of swelling of the hydrogel in the loading solution 
(Maulvi et al. 2014). 
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Figure 1:19 Drug loading method for hydrogels; soaking method and in situ method. In 
soaking method a dried hydrogel is incubated in the drug solution until equilibrium is 
reached between the hydrogel and the solution (a fraction of the drug will be entrapped). In 
in situ method the monomer and/or cross-linker polymerised in the presence of the drug 
(100% entrapment of the drug).  
The large amount of water in hydrogels facilitates the loading of low molecular 
weight hydrophilic drugs, but subsequent release is often too fast and is 
accompanied by a burst effect. In most cases the burst release is problematic 
especially with narrow therapeutic index drugs and may cause toxicity to the tissues 
surrounding the hydrogel. Drugs with low water solubility can be released slowly 
from hydrogels depending on the drug solubility; however drug loading efficiency is 
low because of the limited drug solubility in water which makes it difficult to load 
therapeutic doses (Kirchhof et al. 2015). Although extensive research has been 
conducted over the years to address such problems there is limited number of drug 
releasing hydrogels in the clinic to this day (e.g. Supprelin® LA, Atridox®, Timpotic 
XE®). 
Hydrogels with higher water content also tend to lack mechanical strength 
and may be subjected to rupture during implantation (Calvert 2009). Sterilisation is 
also a problem with implantable hydrogels as they may be subjected to chemical or 
physical changes under the influence of thermal, chemical or radiation sterilisation 
(Kanjickal et al. 2008; Stoppel et al. 2014).    
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Hypothesis and aims 
Hydrogels are potentially good candidate materials for continued development in 
ophthalmic applications. Hydrogels may be exploited in ocular drug delivery and as 
ocular implants to offer possible solutions to improve the treatment of blinding eye 
diseases that affects most of the aging populations around the world (glaucoma and 
AMD). As hydrogels are used as lens materials for both contact and intraocular 
lens, the work in this thesis set out to examine the use of hydrogels in two different 
parts of the eye: (i) subconjunctiva and (ii) vitreous cavity.   
Hydrogels can be made to associate with a large amount of water, so they 
are soft and may better match tissue properties for a hydrogel based implant. 
Athough hydrogels have limitations (e.g. easy to tear), they may be more 
biocompatible (low foreign body response) than currently used implant materials 
(e.g. silicone). It was hypothesised that a GDD made using a hydrogel could be 
used within the subconjunctival space to restrict aqueous outflow to control 
pressure so that the IOP could be maintained at 10 mm Hg.   
Use of a hydrogel in a GDD could reduce complications due to 
biocompatibility that are associated with current GDDs. Since HEMA and MPC are 
used in widely used ophthalmic devices (e.g. contact lens), these materials would 
be used to fabricate hydrogel films to be examined for use as a possible GDD. The 
initial aim was that by modifying the water content of the hydrogel the permeability 
of the hydrogel could be controlled to allow the constant outflow of the aqueous 
humour at a rate of 2 µL/min. It was thought by modification of the molecular 
porosity of a hydrogel, that there would be an opportunity to develop a material that 
could control the rate of diffusion of aqueous humour and control IOP in a more 
effective way than is currently possible. 
It is also hoped that a hydrogel based GDD could be folded and used in 
such a way that only a small incision in the eye would be required for implantation. 
If this can be achieved, it is possible that a device can be developed that can be 
implanted requiring less surgical skill. It was first a necessary aim to determine the 
hydraulic conductivity and permeability of hydrogel films to determine if they could 
in fact be used to control the aqueous outflow. 
Should the HEMA-MPC hydrogels not be able to control the aqueous outflow, 
then it was hypothesised that a HEMA-MPC hydrogel film could also be used as a 
drug releasing spacer to reduce subconjunctival scarring to improve the success 
rate of GFS. The hydrogel film would act as drug delivery system of an anti-
inflammatory or anti-scarring agent and at the same time could also act as a spacer 
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that could mechanically separate the conjunctival tissue from the sclera to prevent 
adhesion due to localised scarring.  
Since the treatment of AMD utilises antibody based drugs that are administered 
by IVT injections, hydrogels were also evaluated for IVT injection into the vitreous 
cavity. It was hypothesised that it could be possible to utilise a hydrogel to slow the 
clearance of a protein-based medicine from the vitreous cavity. The challenge was 
to develop a strategy to both mix the protein within the hydrogel and to determine if 
the presence of the hydrogel delayed protein clearance. Thermoresponsive 
hydrogels made from NIPAAm using a hydrophilic cross-linker were examined to 
determine if the clearance time for proteins from the vitreous cavity could be 
increased while maintaining the activity and stability of the protein.  
The aim of this work is the fabrication of HEMA-MPC hydrogels as GDD. The 
fabricated hydrogels will be studied and compared regarding water permeability as 
a mean to control aqueous outflow. The hydrogels will also be examined regarding 
total water content, water distribution and swelling in different solvents. The 
promising formulation will be loaded with anti-inflammatory drug, dexamethasone, 
for the formulation of combination device or drug releasing subconjunctival spacer. 
The aim is also to formulate stimuli responsive NIPAAm hydrogel for protein 
delivery to the vitreous. NIPAAm thermoresponsive hydrogels with different types of 
cross-linker will be prepared. The cross-linker percentage and type will be varied 
and the effect of formulation variation will be studied regarding VPTT, swelling ratio, 
water retention percent and protein loading and release.  
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Chapter 2. Materials and methods 
Materials 
Chemicals and solvents used are listed in Table 2:1. Reagents were all used as 
received without further purification. Spectrophotometric and instruments used for 
characterisation are all described in the methods section below. 
Table 2:1 List of chemicals and solvent used.   
Material Cat no supplier 
2-hydroxyethyl methacrylate 
(HEMA) 130.14 g/mole 
Density 1.073 g/mL 
128635 
Sigma-Aldrich Chemicals 
(UK) 
Polyethylene glycol diacrylate-Mn 
700 (PEGDA) 
Density 1.12 g/mL 
455008 
Sigma-Aldrich Chemicals 
(UK) 
2,2-azobis(2-methylpropionitrile) 
(AIBN) (MW 164.21 g/mole) 
441090 
Sigma-Aldrich Chemicals 
(UK) 
2-methacryloyloxyethyl phosphoryl 
choline (MPC) (MW 295.27 g/mole) 
88J4253P Vertellus biomaterials (UK) 
Pirfenidone 
(MW 185.2 g/mole) 
13986 
Cayman chemical 
company (UK) 
Acetonitrile HPLC grade 75-05-8 
Fisher Scientific Ltd 
(UK) 
Trifluoroacetic acid T6508 
Sigma-Aldrich Chemicals 
(UK) 
Methanol HPLC grade M/4056/17 
Fisher Scientific Ltd 
(UK) 
Phosphate buffered saline tablets 
PBS 
188912014 
ThermoFisher Scientific 
Ltd 
(UK) 
Dexamethasone 
(MW 392.46 g/mole) 
D4902 
Sigma-Aldrich Chemicals 
(UK) 
Pirfenidone 13986  
Doxycycline hyclate 
(MW 512.94 g/mole) 
D9891 
Sigma-Aldrich Chemicals 
(UK) 
Beta-cyclodextrin (βCD) 
(MW 1134.98 g/mole) 
W402826 
Sigma-Aldrich Chemicals 
(UK) 
Glycidyl methacrylate (GMA) 
(MW 142.15 g/mole) 
density (1.042 g/mL) 
151238 
Sigma-Aldrich Chemicals 
(UK) 
Dimethylformamide 
MW 80.14 
Density 1.03 g/mL 
227056 
Sigma-Aldrich Chemicals 
(UK) 
Sodium chloride  7647-14-5  
Fisher Scientific Ltd 
(UK) 
Sodium hydroxide 1310-73-2 Fisher Scientific Ltd (UK) 
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Polyethylene glycole diglycidyle 
ether (Mn 500) 
Density (1.1 g/mL) 
475696 
Sigma-Aldrich Chemicals 
(UK) 
N-isopropylacrylamide 97% 
(MW 113.16 g/mole) 
415324 
Sigma-Aldrich Chemicals 
(UK) 
PC 3059 Gift from Vertellus biomaterials (UK) 
Ammonium persulfate 
(APS) 
(MW 228.2 g/mole) 
A3678 
Sigma-Aldrich Chemicals 
(UK) 
N,N,N′,N′-
Tetramethylethylenediamine 
(TEMED) ~99%  (MW 116.2 
g/mol) density (0.775 g/mL) 
T9281 
Sigma-Aldrich Chemicals 
(UK) 
Bevacizumab (Avastin® 25 
mg/mL) 
(Genentech, South San Francisco, California) 
were supplied from the left over syringes and 
purchased from Moorfields Eye Hospital 
Acrylated-HA (~50 KD)  Synthesised in our lab 
Infliximab 
Vial of 10 mg/mL for Iv infusion from 
HEALTHCARE CELLTRONTM 
 
Methods  
Fabrication of HEMA-MPC hydrogel films 
HEMA-MPC hydrogel films were fabricated according to compositions described in 
(Table 2:2) by thermally induced free radical polymerisation. MPC monomer was 
weighed and dissolved in HEMA monomer in a 14 mL glass tube with a magnetic 
stirrer to prepare the monomer mixture solution. When a clear mixture was visually 
observed, the cross-linker, poly(ethylene glycol diacrylate) (PEGDA) and the 
initiator, 2,2-azobis(2-methylpropionitrile) (AIBN) were added to the monomer 
solution and mixed until a clear mixture was observed using a magnetic stirrer. A 
suba-seal was attached to the lid of the glass tube and an outlet needle (yellow) 
was placed at the top of the tube. Argon was passed through the long needle 
directly into the reaction mixture and degassed for 5 minutes in an effort to displace 
dissolved oxygen, which can inhibit the polymerisation reaction. The reaction 
mixture was then injected into a polypropylene mould using 23G needle. Care must 
be taken during injection to avoid air bubbles inside the mould.  
After injection of the polymerisation mixture, the mould was placed flat in the 
oven at 70oC for 6 hours to polymerise. After 6 hours the polymeric xerogel was 
formed. The term xerogel is used to describe a hydrogel in a completely dried, 
unhydrated state. The xerogel was then removed from the mould and immersed in 
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(50 mL) of water for hydration and to remove leachable molecules including 
unreacted monomer and oligomeric species. The water was changed twice daily 
and the washing water was scanned with UV visible spectrophotometer over a 
range of 400-200 nm to detect any unreacted monomers. The washing of the 
hydrogel continued for several days. The hydrogels were considered clean when no 
signals were detected by UV from the water used to wash the films. Typically for a 
hydrogel film with the dimensions of 30 × 80 mm and 1 mm thickness 4 days are 
required to complete the washing process. The hydrogels were then stored in 
plastic containers in (50 mL) of water to be used later. The storage water was 
changed every week to avoid mold growth. Three different batches of films were 
prepared for each monomer-cross-linker formulation. 
Table 2:2 Compositions of different HEMA-MPC hydrogel films prepared by free radical 
polymerisation. The MPC weighed and dissolved in HEMA with PEGDA and AIBN. For the 
preparation of 100% MPC formulation the MPC was dissolved in 1 mL DW.  
Code 
HEMA (g) 
(mmole) 
MPC (g) 
(mmole) 
PEGDA (µL) 
(0.076 mmole) 
AIBN (g) 
(0.45 mmole) 
~MPC% 
(w/w) 
S1 
9.87 
(75.84) 
0 50 0.074 0 
S2 
9.45 
(72.61) 
0.42 
(1.42) 
50 0.074 5 
S3 
8.95 
(68.77) 
0.92 
(3.12) 
50 0.074 10 
S4 
8.45 
(64.93) 
1.42 
(4.81) 
50 0.074 15 
S5 
7.95 
(61.09) 
1.92 
(6.5) 
50 0.074 20 
S6 
6.95 
(53.4) 
2.92 
(9.89) 
50 0.074 30 
S7 
4.93 
(37.88) 
4.94 
(16.73) 
50 0.074 50 
S8 0 
1.0 
(3.39) 
50 0.074 100 
Abbreviation: 2-hydroxyethyl methacrylate (HEMA), polyethylene glycol dimethacrylate-
700 Da (PEGDA), 2,2-azobis(2-methylpropionitrile) (AIBN), 2-methacryloyloxyethyl 
phosphoryl choline (MPC).  
  
The polypropylene and silicone moulds were prepared and assembled as 
shown. (Figure 2:1). The dimensions were 40 × 90 mm and 30 × 80 mm for the 
polypropylene and silicone sheets respectively. The thickness of the silicone sheet 
used was 1 mm. Both polypropylene and silicone sheets were first sonicated with 
isopropanol for 10 minutes for cleaning followed by drying in the oven at 50oC for 30 
minutes. After assembling the mould the polymer mixture was injected slowly and 
carefully starting from the edges to avoid air bubbles 
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Figure 2:1 The mould used for the hydrogel fabrication before and after assembly. The 
mould consists of two polypropylene sheets and one silicone sheet sandwiched between 
them. 
Characterisation of the hydrogel films  
General appearance 
Once removed from the oven, the HEMA-MPC films were characterised regarding 
their general appearance. The thickness of the dried films (xerogel) and the 
resulting hydrated gels were measured using a caliper and the values recorded. 
The effect of MPC on the general appearance and thickness of the gels was noted 
and recorded.  
Equilibrium water content percent measurements (EWC%) 
The term equilibrium water content percent (EWC%) refers to the maximum 
percentage of water absorbed by a xerogel to reach full hydration. To calculate the 
EWC% a hydrogel discs of 1 cm in diameter were cut from fully hydrated hydrogel 
films and weighed which is considered as the weight of the disc in equilibrium with 
water (We). The discs were then fully dried by placing them in vacuum oven at 70oC 
until they reached constant weight (Wd). Equation 1 was used for the calculation of 
EWC% (Rohindra et al. 2004).  
 
                                    𝑬𝑾𝑪 (%) = (
𝑾𝒆−𝑾𝒅
𝑾𝒆
) × 𝟏𝟎𝟎                                (1) 
Polypropylene sheet 
Silicone sheet 
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Swelling ratio (SR) measurements in different solvents and solvent mixtures 
The term swelling ratio (SR) refers to the ratio between the weight of solvent 
absorbed by the hydrogel and the dry weight of the gel. It gives an indication to the 
increase in size of the dry xerogel when fully hydrated. To calculate the SR a 
hydrogel discs of 1 cm in diameter were cut from fully hydrated hydrogel film and 
weighed. The discs were then fully dried by placing them in vacuum oven at 70oC 
until they reached a constant weight (Wd). To measure the SR in different solvents 
each dry discs was placed in 5 mL of water, methanol, ethanol, water: methanol 
(1:1) or water: ethanol (1:1) at 25oC. The SR was measured in different solvent 
systems to allow loading of a wide range of drugs with different solubilities. The 
discs were left in the solvents for 48 hours to ensure complete hydration. After 48 
hours the discs removed from the solvents; the surfaces of the discs were wiped 
carefully to remove extra solvents and weighed at equilibrium (We). Equation 2 was 
used for the calculations.  
                                     𝑺𝑹 = (
𝑾𝒆−𝑾𝒅
𝑾𝒅
)                                                   (2) 
Measurement of hydraulic conductivity (L) and permeability (K) 
The permeability measurement for each sample was calculated using a dynamic 
method which involves placing the sample into a flow chamber and allowing water 
to pass from the fluid reservoir to the flow chamber. The system used was an 
established system by Dr Ali Hussain in UCL Institute of Ophthalmology for 
measuring hydraulic conductivity and permeability of bruch’s membrane of the eye. 
The flow chamber and the reservoir were connected using a three-way valve. One 
opening of the three-way valve was attached to the flow chamber and another 
opening was attached to the fluid reservoir through a tube. The third opening of the 
value remained closed and was used to remove air bubbles if any were entrapped 
in the tube. The fluid reservoir is a vertical capillary tube that was filled with water 
and which served as a manometer. The flow chamber consisted of a glass plate 
and a capping plate. The capping plate can be fixed on the glass plate with screws. 
The glass and capping plate had a small circular indentation with a radius of (3 mm) 
for sample placement. The sample places were on the circular indentation of the 
glass plate with the capping plate placed on top and screwed to seal the flow 
chamber. Two different flow chambers were used. In the first, the capping plate was 
open at top of the sample (open system) while in the other chamber, the capping 
plate had no opening (closed system) (Figure 2:2). 
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Figure 2:2 The system used for measurement of hydraulic conductivity where we can see 
the fluid reservoir and the flow chambers. The position of the sample and the three way 
valve that is used to control the flow of water to the sample is highlighted.  
Once the apparatus was assembled and the sample was fixed, it was 
necessary to avoid air bubbles in the tubes and chamber. A (4 × 4 mm) sample was 
cut from each fully hydrated film because the sample size should be bigger than the 
radius of the opening in the middle of the chamber (3 mm) to allow the film to be 
fixed and ensures no water can escape from the edges of the film. Once the sample 
was fixed to the chamber, water was allowed to run through the system from the 
fluid reservoir to the flow chamber. The water moved down the column to the flow 
chamber through the tube and three way valve. The height of the fluid in the column 
decreases with time. The water levels were recorded at different time points over a 
period of 24 h. The values of the height of water verses time were plotted and the 
gradient was used for calculating the hydraulic conductivity (L) using Equation 3:  
 
                                            𝑳 = − 
𝒓𝟐
𝒂𝟐 ƿ 𝒈
  𝑮                                                      (3) 
 
Where (L) is the hydraulic conductivity, (r) is the radius of the water column, (a) is 
the radius of the sample, (ƿ) is the density of water and (g) is the gravitational 
constant (9.81 m/sec2).   
Sample 
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The hydraulic conductivity value (L) was used to calculate the permeability (K) 
using Equation 4 where (T) is the thickness of the film. An example of the 
calculation used can be seen in the appendix 
 
        𝑲 = 𝑳 × 𝑻                                                         (4) 
Preparation of 10% MPC hydrogels to contain a pouch 
Two approaches were used to attempt to create a pouch in a HEMA-MPC hydrogel 
film; ablation using a femtosecond laser and polymerisation around soluble powder 
as a positive mould. A femtosecond laser was used to try to create a pouch in 
HEMA hydrogel films with 15% MPC. The femtosecond laser that is used for 
cataract surgery in Moorfields Eye Hospital was used for the creation of a pouch in 
the hydrogel. The hydrogel was fully hydrated when the laser beam was directed to 
create a pouch. 
A phosphate buffer solution (PBS) tablet was also used to try to fabricate a 
pouch within a HEMA-MPC hydrogel film. The PBS tablet was crushed using mortar 
and pestle into large particles. The monomer mixture of 10% MPC was used to fill 
half of the mould used for the fabrication of HEMA-MPC hydrogels. The crushed 
PBS tablet was spread in the liquid monomer mixture. The mould was then filled 
with the monomer mixture. Care must be taken to make sure that all the PBS 
particles were covered in the monomer mixture. After polymerisation a film was 
formed and placed in DW for hydration and washing of unreacted monomers. 
Distribution of water inside the hydrogel, free to bound water ratio 
Differential scanning calorimetry (DSC) is a technique that can be used to measure 
the free to bound water ratio of hydrogels. The principle is that only free water and 
slightly bounded water are frozen so the endotherm obtained from DSC represents 
the amount of frozen water only. Equation 5 assumes that the heat of fusion of 
freezable water in hydrogels is the same as ice. The amount of bound water is the 
difference between the total water content and freezable water. The melting 
enthalpies achieved from DSC were used to calculate the bound to free water ratio 
as in Equation 5 ,where (Wb) is the amount of bound water, (Wf) is the amount of 
free water, (Wfb) is the amount of lightly bound water, (Qendo) is the melting 
enthalpies derived from the DSC chart and (Qf)  is the melting enthalpies of free 
water which is the same as ice 79.9 cal/g  (Rohindra et al. 2004). 
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                             𝑾𝒃(%) = 𝑬𝑾𝑪% − (𝑾𝒇 + 𝑾𝒇𝒃) × 𝟏𝟎𝟎,                       
                     𝑾𝒃(%) = 𝑬𝑾𝑪% − (𝑸𝒆𝒏𝒅𝒐/𝑸𝒇) × 𝟏𝟎𝟎,                       (5) 
 
Experiments were performed on DSC Q2000 (TA instruments, Waters, LLC) 
using a rate of 3°C/min from -40 to 20°C. Typical sample size range from 4-10 mg. 
Calibration with indium (Tm = 156.6, ∆Hf =28.71 J/g) was performed according to the 
manufacturer instructions. Nitrogen was used as a purge gas with a flow rate of 50 
mL/min for all the experiments. TA zero aluminium hermetic pans and lids were 
used. Data were analysed using TA Instruments Universal Analysis 2000.  
Swelling and deswelling kinetic studies 
The swelling and deswelling of the HEMA-MPC hydrogel films were measured by 
measuring the change in SR with time using a gravimetric method. For the swelling 
measurement, a fully dried hydrogel disc was weighed (Wd) and immersed in 5 mL 
PBS, pH 7.4 at 25oC. The disc was removed from PBS at predetermined time 
intervals (every 10 minutes for the first hour followed by every hour for 12 hours) 
and weighed (We). When removed the surface of the disc carefully wiped to 
remove any extra liquid. The SR for each time point was calculated as in Equation 
2. 
For deswelling measurements a fully dried disc was weighed (Wd) and 
allowed to swell completely in PBS, pH 7.4 for 24 h at 25oC. The fully hydrated disc 
was removed from hydration solution and weighed (We) then placed on the bench 
at ambient temperature. After removing from solution the weight of the disc was 
measured at different time intervals and the SR was calculated at each time point 
using Equation 2.   
Mechanical testing using Instron 
An Instron Universal testing Instrument based in UCL School of Pharmacy (Model 
5567, Instron Ltd, Norwood, USA) was used to measure the mechanical properties 
of the hydrogel films. Films were cut into a ‘dog bone’ shape using a dog bone 
shape punch. The films were cut in dog bone shape to avoid having a break in the 
area being gripped and they were cut from fully hydrated films. The dimensions of 
each sample were 15.5 mm length, 3.6 mm width and 1 mm thickness. The 
samples were put between the clamps of the machine and were pulled apart at a 
rate of 10 mm/min and 100 N static load (2 Kg). The sliding of the films in the 
clamps was prevented by covering the surface of the clamps with a piece of wetted 
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cloth. Samples were sprayed with water as they were mounted on the grips prior to 
testing to ensure they remain fully hydrated; they were also sprayed every 30 
seconds during testing to ensure they remained fully hydrated. The cut-off point 
was at failure when the film was completely separated into two pieces. The tensile 
modulus of elasticity (represented by Young’s modulus) for each sample was 
determined as the slope of the linear part of the stress–strain curves. The data were 
analysed using Bluehill software 2 (version 6).  
Scanning electron microscopy SEM 
Quanta TM Scanning Electron Microscopy (FEI Quanta200 FEGESEM, Eindhoven, 
The Netherlands) which is maintained at the UCL School of Pharmacy was used for 
the examination of the inner structure of the hydrogels and their pore size. The 
hydrogel samples were freeze-dried prior to SEM analysis. The fully hydrated gels 
were frozen at -40oC then dried using VIRTIS- Advantage freeze-dryer for three 
days. The dried samples were cut and adhered onto aluminium SEM stubs using 
carbon-coated double-sided tape. In order to make them electrically conductive, 
they were sputter coated with gold prior to imaging.  
Drug loading into hydrogel films  
The drug soaking method was used for the loading of 0%, 10% and 30% MPC 
hydrogels. Discs of 1 mm thickness and 1 cm in diameter were cut from fully 
hydrated films. The discs were then fully dried to remove all water at 70oC in 
vacuum for 24 hours. The fully dried discs were then soaked in drug solution for 24 
hours. After incubation the discs were removed carefully from the drug solution and 
placed in 3 mL DW for 30 seconds to remove extra drug presumably adsorbed to 
the surface of the films and dried at ambient temperature under vacuum for 24 
hours and stored to be used for release studies. The amount of drug loaded for 
each disc was calculated as the difference in UV absorbance reading between the 
starting solution and the solution left after loading. The loading efficiency was also 
calculated. The loading efficiency is a representation of the percentage of drug 
loaded from the actual amount placed in the loading solution. It can be calculated 
using Equation 6.  
 
          𝐋𝐨𝐚𝐝𝐢𝐧𝐠 𝐞𝐟𝐟𝐢𝐜𝐢𝐞𝐧𝐜𝐲 = (  
𝐚𝐦𝐨𝐮𝐧𝐭 𝐥𝐨𝐚𝐝𝐞𝐝 
𝐚𝐜𝐭𝐮𝐚𝐥 𝐚𝐦𝐨𝐮𝐧𝐭 𝐢𝐧 𝐥𝐨𝐚𝐝𝐢𝐧𝐠 𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧
   ) × 𝟏𝟎𝟎                (6) 
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Two different solutions were used for pirfenidone loading, the first was (1 
mg/mL, 1 mL) in water and the second was (1 mg/mL, 1 mL) in water:ethanol (1:1). 
For dexamethasone (DEX), based on its solubility (DEX is poorly soluble in water), 
two different solvents were used as loading solutions which are water: ethanol (1:1) 
and methanol. When water:ethanol mixture was used as a solvent, the 
concentration of DEX in the loading solution was (1 mg/mL, 1 mL). DEX 
concentration was (15 mg/mL) when methanol was used. In the first method once 
removed from the incubation solution the discs were placed in 4 mL of ethanol for 1 
minute to remove any drug attached to the surface of the discs followed by drying 
under vacuum for 24 hours. In the second method the discs were placed after 
removal from incubation solution in 2 mL of water for 4 hours with mild agitation 
followed by drying under vacuum for 24 hours. The amount of drug lost in the 
washing was quantified using HPLC. 
For doxycycline hyclate (DOXy) loading, aqueous solutions with different 
concentrations (6 mg/mL, 15 mg/mL and 30 mg/ml, 1 mL) in PBS were used as 
incubation solutions. DOXy was also loaded from non-aqueous solutions using 
different solvents and solvent combinations which are water, ethanol, methanol, 
water: ethanol (1:1) and water: methanol (1:1) ratios at a concentration of (15 
mg/mL, 1 mL). The loaded discs were washed similar to pirfenidone loaded discs.  
Release of the drug from the hydrogel films 
The intended use of the hydrogels films is in the subconjunctival space. To 
determine the release profile a flow rig model was used. This model mimics the 
bleb formed in GFS. A similar aqueous flow rate to that in the subconjunctival space 
was maintained in the rig using a pharmaceutical dispensing pump set to dispense 
2 µL of PBS per minute. The rig had a capacity of 400 µL (Figure 2:3). A fully dried 
loaded disc was placed in each rig. The rig had both input and output tubes. The 
input tube was connected to a multi-channel dispenser (ISMATEC pump, 
Switzerland) to pump PBS buffer (pH 7.5) at a flow rate of 2 µL per minute. The 
output tube was used for collection of samples. Samples were collected at various 
time points and quantified using HPLC. The flow rigs were immersed in a preheated 
oil bath adjusted to 37°C.  
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Figure 2:3 Schematic representation of the flow rig used for the release studies of drugs 
loaded into hydrogel films with a picture of the peristaltic pump and the flow rig used.  
HPLC and UV methods for drug quantification 
Pirfenidone samples were analysed by a HPLC system Agilent 1200 series (Agilent, 
Wokingham, Berkshire, UK) equipped with Chemstation software (Agilent, 
Wokingham, Berkshire, UK). The stationary phase was a Synergi 4u Hydro- RP 80 
A (150 x 4.6 mm, 4 micron) column (Phenomenex Co., California, USA) kept at 
40oC. The mobile phase was composed of 50% (v/v) acetonitrile in water. The 
mobile phase flow rate was 1 mL/min, the injection volume was 20 μL and the 
detection wavelength 315 nm. The retention time for pirfenidone was 3.2 min. The 
correlation coefficient of the calibration curve was R2: 0.999 for a concentration 
range of (100-3.125 μg/mL), indicating acceptable linearity. The samples for the 
calibration curve were made using PBS, pH 7.4 as solvent.  
Analysis of pirfenidone by UV spectroscopy was performed using Hitachi U-
2800A spectrometer. The detection wavelength was 310 nm and the correlation 
Pump at 2 µL/min 
Sample collection 
Output 
Input 
Hydrogel film Flow chamber 
Flow rig 
Output 
Input 
Pump at 2 µL/min 
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coefficient of the calibration curve was R2: 0.999 for a concentration range of (25-
1.56 μg/mL), indicating acceptable linearity. The samples for the calibration curve 
were made using water as solvent.  
The same HPLC system and column used for pirfenidone detection was 
used for DEX and DOXy detection. For DEX the mobile phase composed of 
acetonitrile and aqueous trifluoroacetic acid solution (0.1% v/v) at 40/60 volumetric 
ratio. The mobile phase flow rate was 1 mL/min, the injection volume was 10 μL 
and the detection wavelength 240 nm. The retention time for DEX was 4.8 min. The 
correlation coefficient of the calibration curve was R2: 1 for a concentration range of 
100-3.125 μg/mL, indicating acceptable linearity. 
For the detection of DOXy HPLC gradient method was used. The mobile 
phase composed of acetonitrile and aqueous trifluoroacetic acid (TFA) solution 
(0.1% v/v) at 30/70 volumetric ratio at the start. The gradient used shown in (Table 
2:3). The mobile phase flow rate was 1 mL/min, the injection volume was 10 μL and 
the detection wavelength 347 nm. The retention time was 4.8 min. The correlation 
coefficient of the calibration curve was R2: 0.998 for a concentration range of 250-
6.25 μg/mL, indicating acceptable linearity. 
Table 2:3 Gradient method for the detection of DOXy using HPLC. 
Time minutes Acetonitrile% (0.1% TFA)% 
0 30 70 
12 80 20 
12.1 30 70 
15 30 70 
 
Analysis of DOXy in by UV spectroscopy was performed using Hitachi U-
2800A spectrometer. The detection wavelength was 350 nm and the correlation 
coefficient of the calibration curve was R2: 0.999 for a concentration range of 50-
3.125 μg/mL, indicating acceptable linearity. 
Modifications of the films to extend the half-life of water soluble drugs 
Use β-CD as affinity barrier in the 10% MPC films 
β-Cyclodextrin (β-CD) was used as affinity complexing agent to create an affinity 
barrier that may potentially slow the release of loaded drugs in 10% MPC films. 
Three different methods were used to incorporate β-CD into 10% MPC films. Before 
incorporating β-CD into the hydrogel film, the ability for β-CD to form a complex 
DOXy was examined. For the preparation of the complex equal molar weights of β-
CD and DOXy were mixed and dissolved in 5 mL of DW. After mixing, the mixture 
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was sonicated for 1 hour and placed in freeze dryer for three days. For the 
preparation of physical mixture, equal molar weights of β-CD and DOXy were 
mixed. DSC analysis was performed on the β-CD, DOXy, physical mixture and 
inclusion complex of both. The melting enthalpies from the DSC graphs were 
compared. Experiments were performed on DSC using a rate of 10°C/min from 30 
to 280°C.         
Preparation of 10% MPC films with pendant β-CD 
One of the widely used methods for pending CD into a hydrogel is the use of 
glycidyl methacrylate monomer (GMA). 10% MPC films were prepared with different 
percentages of GMA. The 10% MPC monomer mixture was prepared as described 
previously. To each 1 mL of the 10% monomer mixture different amounts of GMA 
(1%, 2.5%, 5% and 9% (w/v)) was added and allowed to mix until a clear solution 
was formed. After mixing the mixture placed in mould to polymerise at 70oC for 6 
hours. After polymerisation the films left to hydrate in water. After hydration for 24 
hours discs with 1 cm in diameter were cut and each disc was placed in (6 mL) 
activation solution to activate the GMA and conjugate β-CD to it. The activation 
solution consists of dimethylformamide DMF: 0.5 M NaCl (1:1) that contains 0.08 M 
β-CD and 0.18 g NaOH. The discs were incubated in the activation mixture at 80oC 
for 24 hr. After incubation the discs were washed for 3 days with water to remove 
any residual DMF and dried under vacuum to be used later for drug loading.  
 Another method used to incorporate β-CD is in situ polymerisation of 10% 
MPC monomer solution and 20% (w/v) β-CD solution in 0.2 M NaOH in the 
presence of GMA. The two monomer solutions were prepared separately and 
mixed in different volume ratios with different amounts of GMA (Table 2:4). The 
formulations were then the injected into the mould and placed in the oven for 
polymerisation at 80oC for 6 hours. After polymerisation the xerogels formed were 
removed and examined. 
Table 2:4 Different formulations for in situ hydrogel synthesis using 10% MPC monomer 
solution and 10% w/v β-CD solution in 0.2 M NaOH in the presence of GMA. 
Formulation No 10% MPC (mL) 20% (w/v) β-CD (mL) GMA (g)  
1 1 1  0.5 
2 1 1 0.2 
3 1 1 0.1 
4 1 0.5 0.5 
5 1 0.5 0.2 
6 1 0.5 0.1 
  Abbreviations: Glycidyl methacrylate (GMA), 2-methacryloyloxyethyl phosphoryl choline 
(MPC), Beta-cyclodextrin (β-CD).   
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Preparation and embedding of β-CD cross-linked particles in 10% MPC films  
β-CD hydrogels were synthesised by a step polymerisation reaction. β-CD powder 
(1.5 g) was dissolved in 0.2 M NaOH (10 mL) solution at a concentration of (15% 
w/v). The β-CD solution vortexed for 1 minute and poly(ethylene glycol)diglycidyl 
ether (PEGDE) was added as cross-linker in volume ratios of (1:1, 1:2, 2:1) with β-
CD solution. The mixture then vortexed for another minute and placed in glass vial 
in the incubator at 50oC for 12 hours at 150 RPM. The hydrogel was then removed 
from the incubator and allowed to cool for 1 hr then placed in 20 mL of 0.5 M 
hydrochloric acid (HCl) for 1 hr to stop the reaction followed by soaking the 
hydrogel in water for 24 hours. The resulting hydrogel in the hydrated form was 
then crushed first using a mortar and pestle then passed through a 40 mesh sieves 
(500 µm in diameter) to create uniform particles. The particles were then freeze 
dried for three days to remove any residual water and stored in a tight container 
ready to use. 
To embed the β-CD particles in 10% MPC films a 10% MPC monomer 
solution with cross-linker and initiator was prepared. The freeze dried particles were 
then suspended in the monomer solution at a concentration of 1% and 2% (w/v), 
injected into polypropylene mould and placed in the oven to polymerise at 70oC for 
6 hours. After polymerisation the xerogel was washed to remove any unreacted 
monomers. Discs with 1 cm in diameter were cut from the hydrated hydrogel, dried 
under vacuum and stored to be used for drug loading. 
Formulation of IPN of 10% MPC and cross-linked β-CD 
To formulate an interpenetrating network (IPN) of HEMA-MPC film with cross-linked 
β-CD hydrogel, the two monomer mixtures were mixed together and polymerised at 
the same time in the same pot (in situ). To ensure that each monomer system 
underwent separate, orthogonal polymerisation reactions as much as possible, the 
HEMA-MPC hydrogel formulation was prepared using PEGDE as cross-linker. The 
10% MPC monomer solution was prepared and the 50 µL of PEGDA was replaced 
with 50 µL PEGDE. The monomer mixture was injected into a mould and placed in 
the oven at 70oC for 6 hours. β-CD monomer mixture was also prepared by 
replacing 50% (v/v) of PEGDE with 50% (v/v) PEGDA in the monomer mixture. The 
monomer mixture was placed in a glass vial and incubated at 50oC for 12 hours at 
150 RPM. A monomer solution of 10% MPC with PEGDA as cross-linker was 
prepared and incubated at 50oC for 12 hours at 150 RPM.  
For the preparation of the IPN a monomer solution of 10% MPC and 89.5% 
(w/w) HEMA and a β-CD monomer solution with different percentages of β-CD in 
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0.2 M NaOH (15%, 30% and 50% w/v) were prepared. To the β-CD monomer 
solution PEGDE as cross-linker was added at a concentration of 50% (v/v). The two 
monomer mixtures (10% MPC and β-CD) were mixed in 1:1 volume ratio and 
vortexed for 1.0 minute. The mixture was injected into a mould and placed at the 
incubator at 50oC for 12 hours at 150 RPM. After polymerisation the xerogel was 
removed and washed with DW. Another two IPN formulations were also prepared. 
β-CD monomer solution made with 30% (w/v) β-CD and 50% (v/v) PEGDE was 
mixed in two different ratios with 10% MPC monomer solution (1:2, 2:1 30% (w/v) β-
CD:10% MPC). The mixtures were then injected into a polypropylene mould and 
placed in the incubator at 50oC for 12 h at 150 RPM to for a hydrogel film.  
Another method to prepare an IPN is by sequential polymerisation where 
one monomer is polymerised in the presence of the other monomer mixture 
followed by polymerisation of the second monomer mixture. First a 10% MPC 
monomer mixture was prepared by replacing AIBN with N,N,N′,N′-
tetramethylethylenediamine/ammonium persulfate (TEMED/APS) as initiator 
system. The 10% MPC and 89.5% (w/w) HEMA monomer mixture was prepared by 
replacing AIBN with 4 mg APS. β-CD monomer solution with 30% (w/v) β-CD and 
50% (v/v) PEGDE was also prepared. The two monomer mixtures were mixed in 
equal volumes (1 mL each) thoroughly. After mixing 30 µL of TEMED was added to 
the mixture to start the polymerisation process of HEMA-MPC hydrogels. The 
mixture was quickly injected into the polypropylene mould and allowed to 
polymerise for 30 minutes at the bench. After 30 minutes the mould was placed in 
the incubator at 50oC for 12 h at 150 RPM to start the polymerisation process of β-
CD. In both methods the Xerogel was washed to remove unreacted monomers. 
Discs with 1 cm in diameter were cut from the hydrogel, dried under vacuum and 
stored to be used for drug loading. 
Preparation of thermoresponsive NIPAAm hydrogels with and without protein  
Different NIPAAm hydrogels with varying amounts of PEGDA as cross-linker were 
synthesised by free radical polymerisation. For the preparation of empty hydrogel 
(i.e without protein), NIPAAm monomers (40 mg which is equivalent to 0.35 M) 
were weighed and dissolved in deionised water (1 mL) at room temperature 
(~25°C). The contents were stirred until a clear solution was visually observed. 
Different amounts of PEGDA (2, 4, 8, 12 and 15 μL which are equivalents to 3.2, 
6.4, 13, 19 and 24 mM respectively) were measured and added to the above 
solution and thoroughly mixed. To each mixture APS (initiator) was weighed (4 mg 
which is equivalent to 17.5 mM) and added to the solution. After mixing for 5 
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minutes, (20 μL which is equivalent to 0.13 M) TEMED (accelerator) was added to 
each formulation and vortexed for ~10 seconds. The monomer solution started to 
gel within one minute of the addition of TEMED and the entire system was left to 
polymerise in the fridge at 4oC for 24 hours. The hydrogels were then washed 5 
times (15 minutes each time with 4 mL of PBS) in a total volume of 20 mL (Drapala 
et al. 2011). 
For the preparation of NIPAAm hydrogel with MPC as a monomer, the 
NIPAAm monomer mixture was prepared as described previously. To 1 mL of the 
mixture two different amounts of MPC were added (1 mg and 5 mg). The MPC was 
dissolved in the monomer mixture and the hydrogel polymerised as described 
previously. 
The same method used for synthesis of PEGDA cross-linked hydrogels was 
used for the synthesis of phosphoryl choline (PC) and acrylated hyaluronic acid 
(Ac-HA) cross-linked hydrogels. Different NIPAAm hydrogels with different 
percentages of the biocompatible PC 3059 as cross-linker (9, 15, 20, 25 and 30 mg 
which represents 13%, 20%, 25%, 30% and 33.5% (w/w) respectively) were 
prepared. For the preparation of Ac-HA hydrogels PC was replaced with different 
amounts of Ac-HA (2, 4, 7 and 10 mg which represents 3.2%, 6.3%, 10.5% and 
14.4% (w/w) respectively). 
The proteins used for hydrogel loading and release were bevacizumab and 
infliximab, both have a molecular weight of 150 kDa. For the loading of 
bevacizumab using imbibing method, NIPAAm hydrogel with 8 µL cross-linker was 
prepared and freeze dried for 3 days. The dried hydrogel was incubated in 1 mL of 
bevacizumab solution (12.5 mg/mL in PBS) for 48 hr at 4oC. After incubation, the 
hydrogel was removed from the incubation solution and then rinsed gently 5 times, 
4 mL each time in PBS; each wash cycle was 15 minutes long. Each wash fraction 
was analysed by HPLC to calculate how much of the protein was lost during the 
wash. The drug loading was the difference between the starting solution and the 
amount lost during washing  
For the preparation of bevacizumab or infliximab loaded hydrogels using the 
in situ method the NIPAAm monomers were dissolved in (1 mL) of protein solution 
(25 mg/mL from vial for bevacizumab) and (9.4 mg/mL from vial for infliximab) 
prepared in the same way as the unloaded hydrogels. After polymerisation, the 
protein loaded hydrogels were rinsed gently similar to empty hydrogels washing. 
Each wash fraction was analysed by HPLC to calculate how much protein was lost 
during the wash. The work reported for Ac-HA was in collaboration with Mr Abdullah 
Abubakre.  
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Characterisation of NIPAAm hydrogels 
The characterisation was studied for both empty and protein loaded hydrogels. 
Volume phase transition temperature (VPTT) and injectability 
The VPTT was measured using differential scanning calorimeter (DSC). The fully 
swollen samples were placed in DSC and the temperature increased from 20 to 
50°C at a rate of 2°C/min. Calibration with Indium (Tm = 156.6, ∆Hf =28.71 J/g) was 
performed according to the manufacturer instructions. Nitrogen was used as the 
purge gas with a flow rate of 40 mL/min for all the experiments. The onset 
temperature of the DSC endothermic peak was considered as the VPTT. A 2 mL 
syringe with 23G needle was used to determine the injectability of the hydrogels 
prepared. Injectability was qualitatively determined based on the ease of injection of 
the prepared hydrogels.    
Swelling ratio (water content) of the hydrogels  
The same method that was used to measure the SR of MPC hydrogel films was 
used to measure the SR of NIPAAm hydrogels in water. The SR was calculated at 
three different temperatures 25oC, 37oC and 48oC.  
Percentage water retention percent (deswelling) of the hydrogels  
The percentage of water retention (WR%) was measured using a gravimetric 
method at 48oC. Hydrogel samples were freeze-dried for 3 days and weighed (Wd) 
then fully hydrated at room temperature (~25oC) in (10 mL) deionised water for 48 
hours. The fully hydrated samples were weighed at equilibrium (We) and quickly 
transferred to pre-heated water at 48oC in the incubator. The samples were 
weighed at predetermined time intervals (Wt) (1, 3, 5, 10, 20, 30, 40, 60 and 120 
minutes). Before each measure the sample was removed from incubator, quickly 
weighed and returned back to the incubator. Water retention was calculated for 
each time point using Equation 7. 
 
                                 𝐖𝐑% = 𝟏𝟎𝟎 × [
   𝐖𝐭−𝐖𝐝  
𝐖𝐞
]                                   (7) 
 
In vitro release of protein from injectable NIPAAm hydrogels 
The NIPAAm hydrogels are intended to be injected in the posterior segment (back 
of the eye) for protein delivery. To mimic the flow and conditions in the posterior 
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segment an in vitro PK-Eye model was used for release studies. This model is a 
prototype known as the pharmacokinetic eye (PK-Eye) and is a 2-compartment 
model of the eye that is fabricated from polyacrylate with an anterior cavity (200 μL) 
and a posterior (4.2 mL) cavity integrated within. A washer with a Visking 
membrane of a molecular weight cut off (MWCO) of 12-14 kDa separates the two 
segments. The inlet port was connected to the same peristaltic pump used for the 
previous release studies and the flow rate was adjusted to (2 μL/min). One outlet 
port is present in the anterior segment of the model for continuous sampling and an 
injection port is present in each segment with a diameter of 2-3 mm to allow 
administration of the desired formulation into the model (Figure 2:4) (Awwad et al. 
2015). Prior to starting each experiment, the PK-Eye model was unscrewed and the 
washer with a fresh Visking membrane was adjusted inside the model. The PK-Eye 
models were assembled together with PBS, pH 7.4. The models were immersed in 
a preheated oil bath adjusted to 37°C for 2 hours to equilibrate prior to the release 
studies. Temperature was maintained at 37oC using a probe connected to a 
hotplate heater.  
After equilibrating the models, bevacizumab solution and hydrogel were 
injected via the injection port in the posterior cavity of the PK-Eye. Samples were 
collected from the outlet port of the anterior segment and quantified by HPLC. 
Bevacizumab samples were analysed by HPLC system Agilent 1200 series 
(Agilent, Wokingham, Berkshire, UK) equipped with Chemstation software (Agilent, 
Wokingham, Berkshire, UK). The stationary phase was an Agilent Zorbax GF-250 
column kept at 25oC. The mobile phase was PBS, pH 7.4 buffer previously purged 
with argon and sonicated. The mobile phase flow rate was 1 mL/min, the injection 
volume was 100 μL and the detection wavelength 280 nm. The retention time was 
2.3 min. The correlation coefficient of the calibration curve was R2: 0.996 for a 
concentration range of (1000-0.97 μg/mL), indicating acceptable linearity. The work 
reported for release was in collaboration with Dr Sahar Awwad. 
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Figure 2:4 Schematic representation and a picture of PK-Eye release model used for 
studying the release of protein from NIPAAm hydrogels. The peristaltic pump used with eye 
flow rig is used with PK-Eye model. 
Data analysis 
All results are presented as the mean and standard deviation (± SD) of three 
samples unless stated otherwise and data were plotted using OriginPro 9.1. Half-
lives was calculated according to the best fitting model in OriginPro. First-order 
kinetic rate constants (k) were derived from the monoexponential curve and half-
lives were calculated using the equation: 0.693/k. The analysis of variance (one-
way and repeated measure ANOVA) with Tukey’s post hoc test was carried out to 
evaluate differences between the experimental data (mean values) using OriginPro 
9.1 (software, Origin lab cooperation, USA) and IBM SPSS statistics 23. Probability 
values less than 0.05 (p<0.05) were considered as indicative of statistically 
significant differences.   
Pump at 2 µl/min 
Outlet 
Sample collection 
Inlet 
Injection port 
Posterior chamber Anterior chamber 
Outlet 
Inlet 
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Chapter 3. HEMA-MPC hydrogels for the subconjunctiva 
There is an estimated 60.5 million people (2010 figures) that are suffering from 
glaucoma. The number of people suffering from this blinding disease is estimated to 
increase to 111.8 million by 2040 (Tham et al. 2014; Quigley & Broman 2006). 
Current treatments available in the clinic or under development have limitations in 
terms of properly controlling of IOP with current GDDs and lack of anti-scarring drug 
delivery dosage forms to improve success rate of GFS. 
The main problem associated with current GDDs is the limited ability to 
control pressure in an effective way for a long enough period of time and with 
consistency among patients. The current materials that are used, such as silicone 
and polypropylene, cause excessive foreign body response that may affects the 
function of the GDD in controlling flow. There is a need to develop implantable 
devices for use in the subconjunctival space that do not elicit a strong foreign body 
response. Although the use of metals can reduced foreign body response, such as 
gold and stainless steel, variability in response among patients is still a problem. 
With current GDDs, medication is also needed at least during the first few weeks 
after implantation. 
One of the new approaches investigated to improve the outcome of current 
GDDs is to coat them with biocompatible materials and in some cases loading the 
coat with anti-scarring for the fabrication of combination device (Gökce et al. 1996; 
Lee et al. 2014; Hovakimyan et al. 2015; Siewert et al. 2012). This strategy is used 
to make coronary stents that are now widely used. With better control of scarring 
there is a chance for better control of IOP. Current GDDs fail by the formation of an 
intractable, fibrous capsule that might be more thin and permeable with a more 
biocompatible material.  
Ponnusamy et al reported that a coat made of PLGA and loaded with 
mitomycin C and 5-FU has the ability to reduce sacrring after GDD implantation 
(Ponnusamy et al. 2013). Sahiner et al  reported that attaching HEMA loaded 
mitomycin C into the lower part of Ahmed GDD  will improve the outcome of the 
device (Sahiner et al. 2009). When the modified GDD was implanted in rabbit eyes 
the fibrous capsule formed was significantly thinner compared to the non-modified 
device. Even with the use of a biocompatible polymer such as SIBS for the 
synthesis of GDD there is still a need to use MMC to improve the success of the 
GDD (Pinchuk et al. 2015).  
The focus of the current research was for the development of biomaterials, 
coatings and the use of anti-scarring agent with current GDDs to improve the 
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success rate of GDDs in controlling IOP in a more effective way; however, new 
methods to modify aqueous outflow through GDDs to control IOP were less 
investigated. There is still a gap to be filled with current GDDs that are available in 
the clinic. Developing a combination device that is able to control flow with 
minimum, if no, inflammation and release medication at the same time is essential. 
Hydrogel biomaterials are usually considered to have a reduced propensity to 
cause a foreign body response (L. Zhang et al. 2013). As networks, hydrogels are 
also considered to be porous polymeric materials that are permeable at least to 
gases as in contact lens and for water transport in the context of drug delivery 
(López-Alemany et al. 2002; Gemeinhart et al. 2000). Water flow through hydrogel 
contact lenses has been reported (Monticelli et al. 2005). Pishko et al suggested 
that contact lenses have hydraulic permeability and allow water to flow through 
them under low pressure (Pishko et al. 2007). They reported that the permeability of 
HEMA-methacrylic acid contact lens with 686 µm thickness under <3 KPa was 1.80 
x 10-14 m4/N s.   
Based on favourable biocompatibility and potential water flow characteristics, 
hydrogels may be considered as materials for the development of new GDDs or 
drug eluting implants within the subconjunctival space. It might be possible to use a 
hydrogel material to control water flow from the anterior chamber through a tube 
into a hydrogel spacer in the subconjunctival space. Such a GDD would potentially 
not require surgical manipulation to adjust water flow; hence pressure control could 
be achieved in a new way that might be easier to maintain clinically.  
A hydrogel spacer would be expected to have a negligible foreign body 
response resulting in minimal scarring. Considering the current clinical use of 
biomaterials, it is possible that a drug could be incorporated into the spacer to 
mediate the healing response after implantation. A biocompatible ophthalmic 
implant with extended delivery of an anti-inflammatory or anti-fibrotic medication 
could reduce the foreign body response. A long acting form of a less toxic agent 
than mitomycin C would potentially be beneficial to modulate the wound healing 
process after surgery over extended time periods. One of the more difficult aspects 
of glaucoma surgeries is the administration of toxic medicines such as mitomycin C. 
One reason for the use of mitomycin C is that it is so toxic, thus killing the activated 
fibroblasts at the site of surgery. However, exposure to the drug is short. What is 
needed are less toxic drugs with longer local tissue exposure times. 
Hydrogels when used as biomaterial are generally fabricated from hydrophilic 
polymers. The fabrication conditions, monomer content and type, percentage and 
type of cross-linker used and initiator concentration all play important roles in 
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determining the final characteristics of the prepared hydrogels (Ahmed 2015; Bajpai 
& Singh 2006). Chavda et al reported that the characteristics of a superporous 
hydrogel were affected by the percentage of cross-linker used (Chavda & Patel 
2011). When the percentage of cross-linker increased from 7.37% to 14.36% the 
density increased from 0.63 g/cc to 0.85 g/cc and the percentage porosity was 
reduced from 79.23% to 17.87%. McElroy et al reported the formation of hydrogel 
contact lenses with different properties when the intiator percentage was increased 
(McElroy et al. 2014). When the percentage of diphenyl (2,4,6-trimethylbenzoyl)-
phosphine oxide (the initiator) was increased from 0.5% to 0.75% the percentage 
gel fraction increased from 90.35% to 93.68% and the water content percent 
reduced from 43.87% to 35.44%.  
As discussed previously two monomers of particular interests are HEMA 
and MPC. Combining both HEMA and MPC in an implant will have the potential of 
higher biocompatibility and less foreign body response compared to using HEMA 
alone. Homopolymers derived from MPC are brittle and difficult to fabricate into 
devices, however small amounts of MPC in co-polymers are sufficient to impart 
biocompatibility. Abraham et al reported that HEMA hydrogels made with 5-10 
mol% MPC have 64% less protein adsorption compared to HEMA hydrogels alone 
(Abraham et al. 2005). Contact lenses made from cross-linked HEMA and MPC are 
widely available and have higher biocompatibility and less biofilm formation in the 
eye compared to HEMA contact lenses (Selan et al. 2009; Goda & Ishihara 2006; 
Huang et al. 2007). 
When fabricating a hydrogel the relative proportion of the monomers used (in 
this case HEMA and MPC) will have an effect on the properties of the final hydrogel 
(Hiratani & Alvarez-Lorenzo 2004). Properties such as hydrogel morphology, water 
flow characteristics, swelling behaviour, water content, free to bound water ratio, 
mechanical strength, drug loading and drug release will be affected by both 
hydrogel fabrication process and composition differences (Wu et al. 2009). It is 
thought that water content can be controlled so that a hydrogel can be fabricated 
that has the ability to control aqueous flow. Refojo et al reported that the 
permeability of HEMA membranes with 53.8% water content is 1.05 × 10-17 
cm2/sec.dyne which is higher compared to the permeability of membranes with 
38.7% water content which is 8.4 × 10-18 cm2/sec.dyne (Refojo 1965).  
Medication is required with both GFS and GDDs and hydrogels are often 
investigated as drug delivery systems. If a GDD was fabricated from hydrogel, it 
could also be loaded with anti-inflammatory or anti-scarring agents to be used as 
combination device. In the clinic topical eye drops of corticosteroids are prescribed 
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after GDD implantation or GFS. DEX drops are used between 2-4 weeks after 
surgery. However, the use of eye drops has many disadvantages such as patient 
adherence to the treatment, irregular dosing and irritation to the already inflamed 
eye tissues due to the presence of preservatives. The disadvantages of eye drops 
may cause discomfort to the patient, reduce the therapeutic efficacy of the dose 
and the success rate of the surgery. If the hydrogel GDD was loaded with DEX it 
would eliminate the need to use DEX eye drops after implantation and reduce the 
side effects associated with eye drops.  
The same hydrogel material used for GDD could be used as a spacer after 
GFS to modulate wound healing process and reduce scarring for patients not able 
or who do not need to have a GDD. For example in corneal injury, it is sometimes 
necessary to inject a medicine into the subconjunctival space in an effort to control 
inflammation and angiogenesis. A drug loaded implant could be beneficial for these 
patients to ensure that a therapeutic level of drug is available while the cornea 
recovers from injury.  
Hypothesis and aims 
The flow control mechanisms used in current GDDs have limitations for controlling 
the IOP in glaucoma patients. Hydrogels are potentially good candidate materials 
for the development of new GDDs and other subconjunctival implants. Compared to 
polypropylene and silicone which is used in current GDDs, hydrogels may display 
better biocompatibility, so would elicit less foreign body response and inflammation. 
Additionally hydrogels would be expected to be permeable to water and have 
potential to extend the local residence time of a drug subconjunctival space. The 
GDD should have the following properties; i) mechanical strength to withstand 
implantation; ii) resist water flow enough through the hydrogel film to regulate the 
intraocular pressure; iii) higher free to bound water ratio to improve biocompatibility; 
iv) the ability to load and release drugs for local action in the subconjunctival space.   
 It was hypothesised that water can flow through a hydrogel matrix to control 
aqueous outflow from the eye. Aqueous flow could be controlled through the 
hydrogel by controlling the hydrogel permeability through formulation changes. By 
modifying the water content and water distribution, the permeability of a hydrogel 
could be modified to allow flow of aqueous humour through the hydrogel at a rate of 
2 µL/min (Figure 3:1).  
Controlling the flow at the rate of 2 µL/min may help in controlling the IOP in a 
more effective way. It is also hoped that the hydrogel could be developed that can 
be folded and used in such a way that only a small incision in the eye will be 
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required for implantation. If folding can be achieved, it is possible that a device can 
be developed that can be implanted requiring less surgical skill in a faster 
procedure that could be conducted in any ophthalmology clinic. Anti-inflammatory 
and anti-scarring agents could also be loaded into the hydrogel formulating a 
combination device. The hydrogel could also be used as a drug releasing spacer in 
the subconjunctival space to reduce scarring after GFS. The spacer could also 
mechanically separate the conjunctival and scleral tissues to prevent adhesion and 
local fibrosis after surgery. The suggested dimensions of both the device and 
spacer are 1 cm in diameter (the surface area will be 78.5 cm2) and 1 mm 
thickness.  
 
 
Figure 3:1 A suggested mechanism to control flow in GDD through hydrogels directly 
through diffusion into the hydrogel matrix. The aqueous will pass through the tube into the 
hydrogel matrix and when fully hydrated the aqueous will slowly diffuse at a slow rate 
through the hydrogel matrix to the surrounding subconjunctival space.  
Any modification in the monomer type, amount and cross-linker will have an 
impact on the properties of the fabricated hydrogel. The aim of work described in 
this chapter was to screen different formulations of biocompatible polymers (HEMA 
and MPC) to determine if a hydrogel based GDD is feasible. Water permeability 
and flow through the different formulations will be measured. Other characteristics 
of the fabricated hydrogels such as water content, water distribution, swelling 
behaviour, mechanical strength, morphology and the ability to load and release 
medication were also studied. The effect of the percentage of MPC incorporation on 
the above mentioned properties is also discussed to evaluate what might be the 
best formulation to be used to sustain the release of DEX within the subconjunctival 
space.   
Hydrogel 
GDD 
Water flow through 
the tube 
Water slowly diffuse 
through the spacer 
Water diffuse from the 
pores into the 
surrounding media  
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Results and discussion 
Effect of MPC content on general appearance of the prepared films 
The general properties of hydrogels are widely affected by the composition of the 
hydrogel. There is a need to understand the correlation between formulation and 
properties, in particular permeability and water content. Permeability and water 
content are important in developing GDD that control aqueous flow through the 
device. A range of hydrogel films were formulated with HEMA and increasing MPC 
stoichiometries ranging from 0% to 100% MPC. The monomers were cross-linked 
using PEGDA as cross-linker and AIBN as initiator by free radical polymerisation 
(Figure 3:2). MPC was used due to its zwitterionic nature which is responsible for its 
high biocompatibility. MPC is also a hydrophilic molecule that attracts large amount 
of water compared to HEMA which could modulate the water content and 
distribution of water within the hydrogel matrix.  
 
 
Figure 3:2 Chemical synthesis of HEMA-MPC hydrogel films by free radical polymerisation. 
The two monomers (HEMA and MPC) were mixed with cross-linker PEGDA to form clear 
solution. The initiator AIBN then added and placed in the oven at 70
o
C for 6 hours.  
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The percentage of MPC was increased in increments from 0-100% in the 
formulation to study the effect of MPC percentage on the properties of the prepared 
hydrogels. The term “Xerogel” is used to describe hydrogels in the fully dried state. 
Formulations labelled S1 to S7 (which represents 0% to 50% MPC) were hard and 
glassy in xerogel form. The hydrogel comprised of 100% MPC (S8) was jelly like in 
consistency and no hard film was formed (Figure 3:3).  
 
 
Figure 3:3 Formulations S1 to S8 (which represents 0% to 100% MPC) as xerogel and in 
fully hydrated state (hydrogel). At xerogel all the hydrogels, except 100% MPC, have the 
same dimensions. However, as hydrogels the dimensions (width, length and thickness) 
increased with increasing MPC percentage.     
Before hydration the thickness of all the xerogel films (S1 to S7) was 1.1 ± 
0.1 mm. The films were cleaned after removing the moulds and left to hydrate. 
When fully hydrated, formulations from S1 to S7 remained intact in film shape; 
however 50% MPC film (S7) were very fragile and could be easily broken (Figure 
1:2). The thickness of the hydrated hydrogel films increased with increasing MPC 
content. (Table 3:1). 
Table 3:1 Thickness of fully hydrated hydrogel films. The thickness of the hydrogel films 
increased with increasing MPC content.  
MPC% 0% 5% 10% 15% 20% 30% 50% 
Thickness 
mm 
1.13 ± 
0.01 
1.15 ± 
0.01 
1.19 ± 
0.01 
1.30 ± 
0.02 
1.35 ± 
0.01 
1.50 ± 
0.01 
1.80 ± 
0.02  
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Effect of MPC on film morphology  
Scanning electron microscopy (SEM) was used to examine the effect of MPC% on 
the morphology of the prepared films. The samples were freeze-dried prior to 
examination. Films with 0%, 10% and 30% MPC were analysed. The size and 
number of pores increased with increasing MPC% (Figure 3:4). 
 
 
Figure 3:4 The SEM images of 0%, 10% and 30% MPC films. The size and number of 
pores increased with increasing MPC percentage. The scale bar is 40 µm. 
It is thought that flow through the hydrogel could be adjusted at a desired 
rate by adjusting the porosity of the hydrogel. It was also thought that hydrogels 
with larger pores would allow more water to pass through and a higher percent of 
free water to be entrapped inside the films. Hydrogels with a larger pore size may 
allow entrapped materials (e.g. drugs) to be released quickly from the films. 
Formation of hydrogels with different pore sizes is possible by modifying MPC 
percentage.  
GDD flow design 
Aqueous humour in the eye is secreted and released at a rate of 2 µL/min. The 
balance between secretion rate and elimination rate control the pressure of the eye 
in the anterior chamber at around 15 mmHg. When the balance is disturbed by 
blocking the release, the pressure starts to build in the eye. GFS and GDD offer an 
alternative pathway for the flow of the aqueous humour to maintain the pressure 
around 12 mmHg. The main problem associated with GDDs is lack of control on 
flow and individual patient variability. As discussed previously the two mechanisms 
for control flow through current GDD with spacers are pressure controlled valve, 
and diffusion through fibrovascular capsule around the spacer. We are suggesting a 
new mechanism to control flow which is based on the permeability of hydrogels. It 
was thought that the aqueous humour could be adjusted to flow at a rate of 2 
µL/min under pressure through the hydrogel pores. 
40 µm 40 µm 40 µm 
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Measurement of hydrogel hydraulic conductivity (L) and permeability (K)  
To explore the possibility of using the hydrogel matrix for flow control, hydraulic 
conductivity (L) and permeability of the hydrogel films were studied. Hydraulic 
conductivity (L) is a term used to describe the fluid transport characteristics of a 
given membrane. It is the rate of fluid transported (m3/sec) per unit area of the 
membrane (m2) divided by the pressure (Pascal) that causes fluid flow and has 
units of m/sec/Pa. Since the rate of fluid transport is dependent on the thickness of 
the membrane, multiplying (L) by the thickness (T) gives the permeability (K) of the 
membrane. Thus permeability reflects the transport characteristics of the material 
comprising the membrane whereas the hydraulic conductivity describes the 
transport characteristics of a membrane of a given thickness.  
Hydraulic conductivities are usually measured using dynamic approach or 
fixed flow approach. In the dynamic method, a pressure head is applied to the 
membrane to instigate flow and the fall in pressure is followed as a function of time. 
Hydraulic conductivity is then determined mathematically as described in the 
appendix. This method has been used to determine the hydraulic conductivity of 
human Bruch’s membrane (Moore et al. 1995). In the fixed flow approach the flow 
of water is fixed at certain rate and the elevation in pressure is measured. Pressure 
is recorded at different time intervals and the change in pressure used to calculate 
the permeability. The permeability measurement for each sample was calculated 
using dynamic approach. The ideal permeability of a hydrogel film of 1 mm 
thickness that will allow the flow of aqueous humour at a rate of (2 µL/min) while 
maintaining the IOP at 10 mmHg was calculated to be (6 ×10-14 m2 s-1 pas-1). The 
permeability of 5%, 10%, 15% and 20% MPC films were measured (Table 3:2). 
Table 3:2 The permeability of different hydrogel samples using dynamic approach.  
Sample name 5% MPC 10% MPC 15% MPC 20% MPC 
Permeability m2 s-1 pas-1 
1.6x10-14 
 ± 0.2 
5.1×10-14 
± 0.9 
8.1x10-14 
± 0.8 
8.4x10-14  
± 1.2 
 
The results demonstrated that all the films were permeable at relatively 
similar rate which was unexpected and drew our attention to the problems 
encountered during the actual setting up of the experiment. During the experiment 
several problems arose with using the flow chamber with opening on the capping 
plate (open system). One of the problems was that these flow chambers are 
designed to measure hydraulic conductivity in human Bruch’s membrane. Bruch’s 
membrane is a few nanometres in diameter and once placed in the flow chamber 
the upper lid should fit into the chamber and seal the edges completely. The 
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hydrogel films thickness was significantly larger at 1 mm, which made it hard to 
completely seal the chamber as extra pressure may break the film around the edge 
and allow water to pass. 
 To overcome these problems and confirm that the results obtained are a 
true reflection of permeability a new chamber with a closed system was designed. 
The new chamber has a top that is completely sealable and an indentation allowing 
a better fit of the sample. Hydrogel films with 10% MPC was chosen for the 
comparison between the new and the old flow chamber. When the new chamber 
used the permeability of 10% MPC films measured reduced sharply to a value of 
(1.1×10-18 ± 0.7 m2 s-1 pas-1) which indicates that the previous measurement was 
due to evaporation from the incomplete closed edges of the open system 
chambers. The permeability measured is low and shows that the aqueous humour 
does not pass through the hydrogel films at low pressure. Therefore controlling the 
porosity of the hydrogel cannot be used as the pressure controlling mechanism in 
GDD.   
Creation of a pouch in a hydrogel film 
Permeability through the hydrogel films was very low. A suggested mechanism to 
increase the permeability is to create a pouch inside the hydrogel matrix. The pouch 
may exert extra pressure from inside the hydrogel to speed the flow rate through 
the hydrogel surfaces (Figure 3:5). The pouch will be deflated at low pressure and 
when the pressure increases, due to accumulation of aqueous inside the pouch, the 
pouch will expend (similar principle to balloons) and flow. Two approaches have 
been investigated to create a pouch; femtosecond laser and polymerising around a 
soluble matrix.  
Femtosecond lasers are used in cataract surgery. Cataracts are cloudy lens 
in the human eye and are treated by lens removal and replacement with a synthetic 
intraocular lens (IOL). In the surgery, an incision is created where the cornea and 
sclera meets to remove and insert the new IOL. Precise incisions could be 
produced by the use of femtosecond laser machines. The laser eliminates 
variability due to surgical skills and produces incisions without damage to 
surrounding tissues (Feizi 2011; Nagy 2014). Because of the precise incision 
capabilities of the laser without damaging the surroundings, it was thought that a 
pouch could be created inside a hydrogel without damaging the overall hydrogel 
matrix. The laser will be able to cut a full circle inside the hydrogel matrix without 
affecting the upper and the lower surfaces of the hydrogel films.   
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Figure 3:5 A suggested mechanism to control flow in GDD through a pouch followed by 
diffusion through the porous hydrogel matrix. The aqueous will accumulate in the pouch 
creating a pressure on the hydrogel matrix. The pressure will cause the aqueous to diffuse 
at a slow rate through the hydrogel matrix to the surrounding subconjunctival space.   
Three different designs were created for the pouch using HEMA-MPC 
hydrogel films. 15% MPC hydrogel film with 1.3 mm thickness was used to create a 
maximum pouch using different small circles to create larger inner space. Another 
15% MPC sample with the same thickness was used to create one small pouch 
(Figure 3:6). The femtosecond laser was able to create a pouch in the hydrogel 
matrix with different sizes without instant damage to the hydrogel surfaces. Before 
laser treatment hydrogels with 15% MPC could be bended several times without a 
crack. However, after laser treatment when the hydrogel film was bent around the 
large pouch area the surface starts to crack. The cracking indicates a loss of 
mechanical strength. It was thought that the larger the pouch in size, the thinner the 
surfaces will be which could cause breakage and cracking in the film.  
 
Figure 3:6 The pouch created in HEMA-MPC hydrogel films using femtosecond laser. 
Pouches created as single (A), triplet (B) and multi pouches (C).  
When only one circle or three circles were created no immediate cracking 
was observed during bending. However, after preserving the films in water for more 
than one week the films became more fragile and cracking was noticed.  
Hydrogel GDD 
with a pouch 
Water flow through 
the tube to the pouch 
Water diffuse from the 
pores into the 
surrounding media  
 
Water diffuse 
from pouch to 
edges 
A B C 
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Mechanical strength is an important criterion for an implant. It was concluded that 
the use of a femtosecond laser is not a good method for creating the pouch.  
Another approach to creating a pouch was investigated. It was thought that 
if the hydrogel solution was polymerised around a water soluble film or water 
soluble particles (such as PBS), the water soluble particles would dissolve and 
diffuse out of the hydrogel in water during the washing step creating a pouch. In an 
attempt to create a pouch in 10% MPC hydrogel film, the monomer mixture was 
used to fill half of the mould. PBS tablets were crushed into large particles, passed 
through a 40 mesh size sieve (which is equivalent to 500 µm) and placed as a solid 
sheet in the liquid monomer mixture. The mould was then filled with monomer 
mixture. Care must be taken to make sure that all the PBS particles were covered 
in the monomer mixture. After polymerisation the xerogel was hydrated in water, but 
the resulting hydrogel did not form a complete film. (Figure 3:7). To study whether 
the incomplete hydrogel film was a result of the presence of foreign particles and 
not the nature of PBS particles, the PBS particles were replaced with a thin film of 
polycaprolactone or filter paper and the hydrogel matrix was polymerised around 
the films. No complete film was also observed.  
It was thought that the presence of any foreign material (particles or films) in 
the monomer mixture, although they did not dissolve in the monomer mixture, 
affected the polymerisation process around the edges of the particles or films 
creating an irregular film surface.  
 
Figure 3:7 The polymerisation of 10% MPC around PBS particles. The hydrogel films 
formed were rough and irregular in shape.  
Another approach to create a pouch was investigated which is polymerising 
around a small metal spatula (0.5 mm thickness). The spatula was sandwiched 
between the polypropylene and silicone part of the mould and the end of the 
spatula was immersed in the monomer matrix inside the mould. It was thought that 
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after hydration of the polymerised xerogel the spatula could be easily removed 
leaving an empty space in the middle of the hydrogel film. However, when the gel 
was hydrated and the spatula removed, the hydrogel thickness was different around 
the spatula. The thickness of the surface below the spatula was thinner with a crack 
compared to the one above the spatula which was thick and intact. A possible 
explanation is that the spatula was unable to remain suspended in the middle of the 
monomer matrix and leaned towards the bottom of the monomer mixture due to 
gravitational forces. It was concluded that if a pouch was created in the hydrogel 
film the properties of the film (i.e mechanical strength and smoothness of the 
surface) will be affected.  
A new pressure control mechanism for a hydrogel GDD was suggested 
possible if hydrogel permeability to water flow could be controlled. However, when 
the permeability was measured it was very low compared to the required 
permeability at a flow rate of 2 µL/min. Although the pressure used for measuring 
the permeability was high (~30 mmHg) compared to the normal pressure of the eye 
(10-15 mmHg) the permeability was very low. The high pressure used and low 
permeability calculated suggested that the hydrogel matrix alone cannot be used to 
control flow in GDD.  
Although the HEMA-MPC hydrogel could not be used as a control 
mechanism it can still be used to fabricate a combination device. The hydrogel will 
be used as a material for a spacer synthesis that is attached to a tube and drug will 
be loaded in the spacer (Figure 3:8). The hydrogel could also be used as a spacer 
after GFS.  
   
Figure 3:8 The use of HEMA-MPC hydrogel as a material for fabrication of spacer in GDD. 
The spacer will be attached to a silicone tube and loaded with anti-inflammatory or anti-
scarring agents. Aqueous will flow through the tube only (blue arrow) and drug will be 
released by diffusion. 
After implantation 
Silicone tube 
Hydrogel 
spacer 
Drug 
molecule 
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Equilibrium water content percent (EWC%) and swelling ratio (SR) 
As mentioned previously, although HEMA-MPC hydrogels could not be used as 
pressure control mechanism they can still be utilized for drug delivery. 
Understanding water and swelling of HEMA-MPC hydrogels will help understanding 
drug loading and release from the hydrogel films. For a hydrogel to be used as drug 
delivery It was thought that the water content of the hydrogel may affect the rate of 
diffusion through the hydrogel; the more water; the better diffusion and the faster 
the release. The effect of MPC percentage on the EWC% of the formulation was 
measured. The EWC% of hydrogel formulations from S1 to S7 was calculated 
according to (Equation 1). The results are shown in (Figure 3:9A). The SR was also 
calculated for the same formulations using (Equation 2) (Figure 3:9B). 
 
 
Figure 3:9 A) The effect of MPC% on EWC% as measured using Equation 1; B) The effect 
of MPC% on SR as measured using Equation 2. As the relative proportion of MPC was 
increased, there was a significant increase (p<0.05) in both EWC% and SR.  
(A) 
(B) 
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As the relative proportion of MPC was increased, there was a significant 
increase (p<0.05) in both EWC% and SR. MPC is a hydrophilic molecule with a 
zwitterionic head group that attracts water. The water present is mostly in the free 
(bulk) form (Morisaku et al. 2008). Kazuhiko et al also noticed a dramatic increase 
in water content when MPC was copolymerised with n-butyl methacrylate to form a 
hydrogel (Kazuhiko Ishihara et al. 1990).  
When the MPC percentage was equal or exceeded the HEMA percentage, 
as in the S7 formulation (50% MPC), the water content in the formulations 
increased to the point where there was little mechanical strength in the films. The 
films were easily torn and broken. Several factors are responsible such as the 
arrangement of water molecules and polymer chains around each other, the 
solubility of the polymer chains in water and the total amount of water absorbed by 
the hydrogel. Although HEMA based polymer have the ability to absorb water, 
HEMA polymer cross-linked chains are insoluble in water, while MPC chains are, 
that is why HEMA hydrogels maintain a three dimensional shape in contrast to MPC 
hydrogels. Also MPC, compared to HEMA, has strong hydrophilic groups that 
attracts large amount of water. Water molecules tend to arrange themselves around 
the hydrophilic groups in the polymer chain and when the total amount of water 
increased and the relative polymer units remain the same they stretch the polymer 
chains and reduce the strength of the formed gels (Monti & Simonib 1992).  
Effect of MPC content on the distribution of water inside the hydrogel films 
Water in hydrogels is divided into three types; highly bound water, freely bound 
water and bulk water. It was thought that the higher water content, and larger pore 
size resulting from hydrogel formulations with higher percentages of MPC would 
have higher flow rates through the polymer matrix. It was also thought that the 
distribution of water inside the hydrogel may have an effect on the behaviour of the 
hydrogels regarding drug loading and release. To screen the different HEMA-MPC 
formulations the ratio between free and bound water was measured and calculated 
and the effect of increasing MPC percentage on the ratio was studied (Figure 3:10 
and Table 3:3).  
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Figure 3:10 Effect of MPC% on Wf and Wb. The ratio of free water compared to the bound 
water was increased when the percentage of MPC increased. The Wf is significantly 
different between the samples (p<0.05).  
Table 3:3 The ratio of bound water (Wb) to free water (Wf) in a hydrogel films based on 
MPC percentage. The ratio of free water increased with increasing MPC percentage.  
MPC% 0% 5% 10% 15% 20% 30% 50% 
Wb : Wf 1:0.3 1:1.2 1:1.8 1:2.5 1:3.2 1:4.1 1:6.8 
 
Increasing the relative percentage of MPC results in an increase in free 
water ratio compared to bound water. The MPC repeat units attract water 
molecules to form a layer of water associated around the pendant zwitterionic head 
groups. MPC units will form weak hydrogen bonds with water molecules so the 
layer of water surrounding them will remain mostly free and undisturbed (Shi et al., 
2012; Chen et al., 2010). On the other hand HEMA has the ability to form strong 
hydrogen bonds with water. As the percentage of MPC increased and HEMA is 
reduced more water molecules will be free or lightly bonded and can be frozen and 
detected by DSC.  
Effect of MPC on the mechanical strength of HEMA-MPC hydrogel films 
Hydrogels when completely swelled are semisolid materials and could be subjected 
to deformation when force applied into them. During GFS or implantation of GDD 
the surgeon will push the implant into the subconjunctival space using surgical 
instruments such as forceps and clamps. Implantable films need to have 
mechanical strength to withstand this stress during implantation. The films should 
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be able to stay intact during the surgery and be folded without break. The effect of 
MPC percentage on the mechanical strength of the prepared films was studied. The 
term mechanical strength reflects the ability of the films to stretch and to withstand 
force. Mechanical strength is required during implantation as force may rupture the 
hydrogel films.  
The term that is used for quantitative determination of mechanical strength 
(stiffness) is called young’s modulus or elastic modulus (E). A stress-strain curve is 
used for the determination of E value. Typical stress-strain curve has elastic and 
plastic regions (Figure 3:11). In the elastic region the material obeys Hooks law. 
Hooks law states that the force applied (stress) is proportional to the change in 
surface area (strain) of the material. The law states also that when no longer force 
is applied to the material, it returns to its original shape and size without 
deformation. In the stress strain curve the straight line represents Hooks behaviour 
of the material in the elastic region and the slope of the line is E. Materials which 
behave according to Hook’s Law are called elastic materials. If the material 
deformation is permanent under force it is called plastic material (Faridmehr et al. 
2014; Tranoudis & Efron 2004). An elastic behaviour is required for an implant or a 
device to withstand pressure during implantation without deforming.  
  
 
Figure 3:11 Stress strain curve demonstration the elastic and plastic regions. When the 
stress applied increase the strain increased in linear way (elastic region). The slop of the 
linear region used for the calculations of young’s modulus (Faridmehr et al. 2014). 
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The Young’s modulus (E) reflects the strength (stiffness) of films in general. 
The higher value for Young’s modulus indicates stronger films. The Young’s 
modulus of HEMA contact lenses was previously reported to be around 0.8 MPa 
and for proclear® contact lenses (which have 15% MPC) is 0.5 MPa (Young, 
Garofalo, Harmer, & Peters, 2010; Tranoudis & Efron, 2004). From (Figure 3:12) a 
decrease in Young’s modulus was observed with increasing MPC% which is 
consistent with the previously reported data by Monti. Monti has previously reported 
that when the bulk water of a hydrogel (in the form of contact lenses) increased the 
Young’s modulus reduced and becomes closer in value to Young’s modulus of 
human cornea (0.29 MPa) (Hamilton & Pye 2008; Monti & Simonib 1992). When 
the percentage of MPC increased the free water percentage also increased. Free 
water will impart softness to the films and reduce the mechanical strength. There 
was a significant difference between 0% MPC and all the other formulations 
regarding Young’s modulus (p<0.05).  
  
 
Figure 3:12 The effect of MPC% on Young’s modulus (E) values. When the MPC% 
increased the E value reduced which indicate a reduction in the mechanical strength of the 
prepared films. There was a significant difference between 0% MPC and all the other 
formulations regarding Young’s modulus (p<o.o5).  
Another approach to investigate the mechanical properties of the prepared 
hydrogels was used. An attempt to measure the softness of the hydrogel surface 
using surface contact angle was investigated. Softness of the surface is important 
due to the direct contact of the surface of the hydrogels with the tissues after 
implantation. However, there were difficulties and limitations in conducting the 
experiment. The HEMA-MPC hydrogels start drying quickly when removed from 
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water. Hydrogels need to be mounted on the device which requires time. By the 
time the experiment is ready the surface of the hydrogel starts to dry and loose its 
softness which will give the wrong estimation comparing the softness of the 
surfaces of different hydrogels. To compare the mechanical strength of the 
prepared hydrogels only young’s modulus was measured.   
Effect of MPC on hydrogel swelling ratio in different solvents  
Hydrogels have been investigated widely as drug delivery systems. Drug loading 
into a hydrogel is generally through two methods; soaking (imbibing) and in situ 
(mixing). In situ would not be a suitable method in this case, as the films require 
significant washing to remove unreacted monomers in the system and it is expected 
that a high percentage of the loaded drug will be released with the washed 
monomers. For the hydrogel formulation (HEMA-MPC), soaking is thought to be a 
better method for loading. 
 Loading of a drug into a hydrogel by soaking or imbibing depends on 
several factors such as the physicochemical properties of the drug (solubility) and 
the SR of the hydrogel in the loading solvent (Kim et al. 1992). If the drug is 
hydrophilic the loading medium will be water. However, if a hydrophobic drug needs 
to be loaded organic solvent should be used. Understanding loading from organic 
solvents requires an understanding of the behaviour of the prepared hydrogels in 
different solvents and the influence of MPC on that behaviour. Formulations with 
different percentages of MPC were studied to understand how MPC affects SR in 
solvents other than water. The SR was measured in methanol, ethanol, water: 
methanol (1:1) and water: ethanol (1:1) (Figure 3:13A). Pictures of the difference in 
SR between different solvents for 10% MPC hydrogels could be observed (Figure 
3:13B). 
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Figure 3:13 A) The effect of solvent used on SR of films with different percentages of MPC. 
When water alcohol mixture was used the SR increased with increasing MPC percentage; 
B) the SR of 10% MPC in different solvents.  
The swelling behaviour of films with different percentages of MPC in 
methanol was also studied. When the percentage of MPC increased from 0-30% in 
HEMA-MPC hydrogel films, no significant difference was observed in SR (p>0.05). 
However, at 50% the SR was significantly increased (p<0.05). When ethanol used 
as solvent, there was little change in SR even with MPC above 50%. Kiritosha et al 
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reported that poly MPC hydrogels (without HEMA) swell to a less extent and has 
low affinity to interact with methanol and ethanol, compared to water, which may 
explain why in spite of the increase in the percentage of MPC no change in SR in 
methanol and ethanol was observed (Kiritoshi & Ishihara, 2003). The results 
indicates that when alcohol was used as solvent the interactions between the 
solvent and HEMA polymer chains predominate while when water was used the 
MPC polymer interactions predominate and an increase in SR was observed with 
increasing MPC%. 
When a 1:1 mixture of methanol:water was used the SR increased with 
increasing MPC percentage. However, when a 1:1 mixture of water:ethanol was 
used this increase was only observed when MPC level increased above 20%. 
These findings can be explained by the difference in affinity of MPC to ethanol and 
methanol in which poly-MPC swells to a lesser extent in ethanol compared to 
methanol (Kiritoshi & Ishihara, 2002). 
Drug loading of HEMA-MPC hydrogel films 
After any surgery, a sequence of events takes place to heal the wound of the 
operation. The healing process is a series of complex events that starts with 
Inflammation and haemostasis and ends with tissue remodelling (scar formation) 
(Skuta & Parrish 1987). In the eye the scar formation is a problem as it may close 
the newly formed channel during GFS. Different methods and drugs, including the 
use anti-scarring agents in different dosage forms such as injections and 
implantable films, were investigated to modulate the wound healing process and 
reduce scar formation (Lockwood et al. 2013; Seibold et al. 2012). One of the 
methods explored was the use of a spacer at the incision site of the surgery (Hafez 
2015). Different materials could be used for the synthesis of the spacer including 
hydrogels.  
One of the advantages of fabricating a spacer from hydrogel, in addition to 
its biocompatibility, is the ability of hydrogels to load and release drugs. Since 
HEMA-MPC hydrogel films have low water permeability the loading and release of 
drugs will depend on drug solubility, hydrogel water content (especially the free 
water) and drug diffusion. To study the effect of free water on release of hydrophilic 
and hydrophobic drugs from HEMA-MPC films two drugs were used; pirfenidone as 
hydrophilic drug and dexamethasone (DEX) as hydrophobic drug.  
Pirfenidone was used because of its high solubility in water (~10 mg/mL), 
small MW (185.2 g/mole) and a potential anti-scarring agent in the eye. Pirfenidone 
is available in the clinic in the form of tablets for the treatment of idiopathic 
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pulmonary fibrosis which is characterised by scarring of the lung tissues (Jackson & 
Gomez-Marin 2011). Research has shown that it also has an effect in the reduction 
of scarring tissues after GFS when used (Figure 3:14) (Sun et al. 2011; Mora et al. 
2015; Gan et al. 2011). Topical corticosteroids such as DEX and prednisolone have 
been reported to effectively improve the outcomes of GFS by supressing the 
inflammation process. In the clinic topical eye drops of corticosteroids are 
prescribed after surgery.  
                     
 
Figure 3:14 The chemical structure of dexamethasone and pirfenidone. 
Drug loading into a hydrogel could be carried by two methods; in situ 
loading and soaking. For the HEMA-MPC formulations soaking was chosen as a 
method for loading. If the drug was loaded during polymerisation there is a 
possibility of losing a significant percentage of the loaded drug during washing of 
the hydrogel after polymerisation. Another problem is the effect of high temperature 
(70oC) used during polymerisation which may cause drug degradation. In addition 
to that the drug may interact with the cross-linker and the monomers and cross-
linked to the polymer matrix which may affect its release from the hydrogel. The 
soaking method was considered as the more convenient method for drug loading in 
this case. In the soaking method, the amount loaded and the loading efficiency of 
drugs in a hydrogel are affected by several factors such as EWC% of the hydrogel, 
swelling ratio, solubility of the drug, molecular weight of the drug and the 
concentration of the drug in the loading solution (Maulvi et al. 2014). 
Loading and release of a hydrophobic drug (dexamethasone)  
In drug releasing hydrogels there are several mechanisms involved in the release of 
loaded drug. These mechanisms (such as diffusion and erosion) are based on the 
type of hydrogel used, method of loading and the drug molecule itself (Colombo et 
al. 1996; Li & Mooney 2016). In conventional hydrogels diffusion of the drug from 
the loaded hydrogel is the driving force for the release (Satapathy et al. 2015). 
Pirfenidone Dexamethasone 
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Diffusion is related to the bulk water percentage in the hydrogel; the higher the bulk 
water content, the faster the release (Wu et al. 2016).  
To test that theory and screen the formulations DEX was loaded in films 
containing 0%, 10% and 30% MPC and the release from the three hydrogels was 
compared. For the loading of DEX the hydrogel dry disks were incubated in the 
loading solution for 24 hours, each 10% MPC disk is 1 mm in thickness and 1 cm in 
diameter. The dimensions of the discs used for release represents the actual 
dimensions intended for a GDD or a spacer. Once removed from the incubation 
solution the discs were washed with ethanol for 1 minute to remove the drug 
molecules attached to the surface of the discs. For a hydrophobic drug molecule 
the solubility plays an important role in loading and release. DEX has low solubility 
in water (0.1 mg/mL). If HEMA-MPC hydrogel discs were loaded from aqueous 
solution the amount loaded and loading efficiency will be low so a 1:1 ratio 
water:ethanol solvent mixture was used as the loading solution. By using organic 
solvent at this mixture the solubility of DEX in the loading solution will increase to (1 
mg/mL). DEX was loaded into a hydrogel disc (1 mm thickness, 1 cm diameter) 
from 1 mg/mL (1 mL) water:ethanol (1:1) loading solution. The loading of DEX was 
0.40 ± 0.03, 0.3 ± 0.1 and 0.19 ± 0.03 mg/disc for 0%, 10% and 30% respectively. 
The dry weight of each disc was 49.2 ± 1.3, 46.5 ± 1.2 and 22.7 ± 0.2 mg and the 
loading efficiency was 40%, 30% and 19% for 0%, 10% and 30% respectively. The 
difference in UV reading between the starting solution and the solution left after 
incubation was used to estimate the amount of drug loaded in each disc.  
To validate the method used for measuring loading samples DEX was 
extracted from hydrogel samples and the amount measured by extraction was 
compared to the amount measured by UV. 10% MPC hydrogels were used for the 
comparison. Methanol was used as extraction solvent because the discs swell to a 
higher extent in methanol compared to water or PBS. The results can be seen in 
(Table 3:4). There was no significant difference (p>0.05) between the two methods 
which indicated that UV method was a suitable method for loading estimation. 
Table 3:4 The amount loaded and loading efficiency of DEX in 10% MPC discs calculated 
using two different methods (UV and extraction). No significant difference (p>0.05) was 
observed in the amount loaded and loading efficiency between the two methods.  
Calculation method 
Amount loaded in 
mg/disc 
Loading efficiency% 
Based on UV readings 0.3 ± 0.1 30 % 
Based on extraction with methanol 0.39 ± 0.03 39 % 
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It was observed that the amount of drug loaded was decreased with 
increasing MPC percentage. Two factors affect the drug loading process; the 
affinity of the drug molecule to the polymer matrix and the amount of the drug 
soluble in the volume absorbed by the dry hydrogel matrix (the swelling of the 
hydrogel) (Kim et al. 1992). While the swelling of 30% MPC is higher than 0% MPC 
the affinity of DEX is thought to be less for 30% MPC polymer matrix. The low 
affinity could be due to the higher affinity of the PC head group to water molecule in 
favour of drug molecule. DEX has higher affinity to adsorb on hydrophobic surfaces 
(HEMA). When the level of HEMA reduced compared to MPC the DEX loading will 
be reduced. Guidi et al reported that the driving force of DEX loading into the 
hydrogel contact lenses is adsorption into the polymer matrix and DeX loading 
increased with increasing hydrophobicity of the lenses (Guidi et al. 2014). When 
HEMA was replaced with equal molar ratio of N,N-dimethylacrylamide (DMA) in the 
different formulations the amount of DEX loaded was higher in all DMA 
formulations. 
The release of DEX from the loaded hydrogels was studied using an eye 
flow chamber developed in our lab that resembles the flow in the subconjunctival 
space (2 µL/min). The discs were placed in the flow chambers and the samples 
were collected at different time intervals and analysed using HPLC. Faster release 
was observed from 30% MPC compared to 0% and 10% MPC (Figure 3:15). The 
half-life of DEX was 3.0 ± 12.6, 1.8 ± 8.9 and 1.0 ± 3.5 day for 0%, 10% and 30% 
MPC respectively. Mechanism of the drug release from HEMA-MPC hydrogels is 
diffusion which is affected by free water inside the hydrogel matrix. Since 30% MPC 
has higher free water compared to 0% and 10% MPC, the release of DEX was 
faster.   
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Figure 3:15 The cumulative release percent of DEX loaded in 0%, 10% and 30% MPC 
hydrogel films and concentration with time. The top panel is the percent of drug released 
and the bottom panel is the concentration of the drug released with time. The release from 
30% MPC film was faster than 0% and 10% MPC.  
Loading and release of a hydrophilic drug (pirfenidone)  
To compare loading and release of hydrophobic and hydrophilic drugs from 
different HEMA-MPC hydrogels, pirfenidone was loaded in hydrogel discs 
containing 0%, 10% and 30% MPC films and the release from the three hydrogels 
was compared. Using an aqueous loading solution concentration of 1 mg/mL (1 
mL), the amount loaded was 0.35 ± 0.02, 0.30 ± 0.01 and 0.25 ± 0.02 mg and the 
loading efficiency was 35%, 30% and 25% for 0%, 10% and 30% MPC respectively. 
The same pattern observed with DEX in loading (decreased loading with increasing 
MPC percentage) was observed with pirfenidone. Although pirfenidone is water 
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soluble the loading was reduced with higher water content hydrogels. The low 
loading could be due to the higher affinity of the PC head group to water molecule 
in favour of drug molecule. PC will attract the free water that will occupy the pores 
and displace the drug molecules.  
The release of pirfenidone was studied and the half-life of pirfenidone 
released was 1.2 ± 2.4, 0.7 ± 3.4 and 0.4 ± 2.1 day for 0%, 10% and 30% MPC 
respectively. More than 50% of the drug released within the first 24 h from 0% MPC 
and even higher percentage was released from 10% and 30% MPC (Figure 3:16). 
When 0.5 mg of the drug injected into the flow chamber without the hydrogel the 
drug was completely cleared within the first 24 hours and the half-life was 0.25 ± 
1.20 days. There was no difference in half-life when 30% MPC was used compared 
to free drug and a slight difference was observed when compared to 10% MPC 
hydrogels. The higher percentage of free water and the larger pore size observed 
with 30% MPC will help the drug to diffuse faster outside the hydrogel into the 
surroundings and shorter half-life will be observed with increasing MPC percentage 
(Wu et al. 2016).  
Although there was a small difference in the amount loaded into the 
hydrogel between DEX and pirfenidone, the release profile was different. The half-
life of DEX was 3.0 ± 12.6, 1.8 ± 8.9 and 1.0 ± 3.5 day for 0%, 10% and 30% 
respectively which was higher compared to pirfenidone. Because of the low 
solubility DEX in PBS (100 µg/mL) the drug will be deposited in the hydrogel and 
released slowly. The difference in release pattern indicates that the release is 
controlled by the free wtaer content of the hydrogel, hydrogel polymer matrix 
composition, the solubility of the drug in the loading solution and the affinity of the 
drug to the polymer matrix.      
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Figure 3:16 The cumulative release percent of pirfenidone loaded in 0%, 10% and 30% 
MPC hydrogel films and concentration with time. The top panel is the percent of drug 
released and the bottom panel is the concentration of the drug released with time. The 
release from 30% MPC film was faster than 0% and 10% MPC.  
Loading of a drug molecule into a hydrogel by imbibing depends on many 
factors, one of them being the swelling of the hydrogel used. It is thought that the 
higher the SR of the hydrogel in the loading solution, the higher the amount of the 
drug loaded. HEMA-MPC hydrogels swell to a large extent when a water/alcohol 
solvent mixture was used.  In order to increase the loading efficiency of pirfenidone 
water:ethanol (1:1) mixture was used as loading solvent. The SR of HEMA-MPC 
hydrogels is higher in water:ethanol mixture compared to water. It was assumed 
that the higher SR will allow more of the drug to be entrapped in the polymer matrix 
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of the hydrogel to achieve higher loading efficiency. However, the amount loaded 
was slightly lower compared to water. The amount loaded was 0.29 ± 0.02, 0.25 ± 
0.01 and 0.15 ± 0.02 for 0%, 10% and 30% respectively which was unexpected. 
The same pattern was also observed in which a reduction in loading was observed 
with increasing MPC percentage.  
For a hydrogel spacer, the balance between water content and mechanical 
strength is important. The presence of MPC will improve biocompatibility by 
increasing the free water percentage but at the same time will reduce the strength 
of the films. For 20 and 30% MPC films although the water content was high the 
mechanical strength was low. Low mechanical strength may cause problems during 
implantation such as rupture. Also any loaded drug will be released fast. Films 
made with 5% MPC have low amount of free water and low percentage of MPC 
which may not improve the biocompatibility of HEMA films (0% films). Although 
there was no significant difference in the EWC% and SR of 10 and 15 % MPC films, 
15% MPC films have significant amount of free water compared to bound water. 
The amount of free water affects the mechanical strength of 15% MPC as they 
have lower Young’s modulus compared to 10% MPC films. Based on these results 
10% MPC film was chosen as a material for development as drug releasing spacer 
for ophthalmic implantation. 
Effects of initiator and cross-linker on the water behaviour of 10% MPC films 
One parameter that is important to be considered in the synthesis of a drug 
releasing hydrogel implant is the ability to load and release drugs. That ability is 
directly affected by water distribution inside the hydrogel; the higher the free water,  
the faster the release. Hydrogels with 10% MPC were chosen as the best 
formulation for ophthalmic implantation compared to other MPC percentages. 
Hydrogels with 10% MPC have higher free water content compared to bound water 
(1.8:1). It was assumed that modifying the water content, distribution and free to 
bound water ratio could be achieved by modifying the percentage of cross-linker 
and initiator while the HEMA and MPC percentage remain constant in the 
formulation. Each initiator molecule will form a polymer chain that can be cross-
linked via the cross-linker molecule (eg PEGDA) to form the final polymer hydrogel 
structure. The higher the initiator amount, the smaller the number of chains formed 
and smaller the pores formed. A higher percentage of cross-linker can form 
hydrogels with smaller pore size. Modification of both the initiator and cross-linker 
was previously reported to affect the water content and distribution inside the 
hydrogels (Goda, Watanabe, Takai, & Ishihara, 2006; Kiritoshi & Ishihara, 2002).  
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For a 10% MPC formulation, the level of PEGDA was reduced from 0.56 % 
in the original formulation to 0.28 % and 0.14 % (which represents half and one 
quarter of the original amount of PEGDA respectively). The EWC% and SR were 
measured (Figure 3:17). No significant difference (P>0.05) was observed when the 
level of cross-linker was reduced to 0.28% and 0.14%. It is probably related to the 
fact that the level of MPC remains constant so the total amount of water molecules 
attracted to the zwitterionic head groups are the same. The same results were 
observed when the level of initiator (AIBN) was reduced from 0.74 % in the original 
formulation to 0.37 % and 0.185 % (which represents half and quarter the original 
amount of PEGDA respectively). 
 
 
Figure 3:17 The effect of cross-linker and initiator percentages on EWC% and SR of 10% 
MPC gels. No significant difference (P>0.05) was observed when the level of cross-linker 
and initiator was reduced.  
Although the EWC% was the same we investigated the possibility of 
changing the distribution of water inside the gels. The ratio of free to bound water 
was measured when the level of cross-linker and initiator changed. No significant 
difference (p>0.05) was observed with Wf% and Wb% when the level of cross-
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linker and initiator were reduced (Figure 3:18). Based on these results the original 
10 % MPC formulation with 0.56 % PEGDA and 0.74 % AIBN was found to offer the 
best balance between water content, mechanical strength and drug loading and 
release required for implantation.  
 
Figure 3:18 The effect of cross-linker and initiator percentage on Wf % and Wb %. There 
was no significant difference (P>0.05) was observed in the free and bound water ratio with 
decreasing cross-linker and initiator percentages.  
Extended release of DEX from 10% MPC  
Previous characterisation of the different HEMA-MPC formulations showed that 
10% MPC has the potential to be used as drug releasing spacer. One of the aims of 
this chapter is to sustain anti-inflammatory drugs in the HEMA-MPC hydrogels. For 
10% MPC hydrogel discs, the amount of DEX loaded in each disc was (~0.3 
mg/disc). The amount loaded was low and around 50% of the drug released within 
the first 48 hours accompanied with a burst release. DEX low solubility in water and 
water organic solvent combinations restricts the concentration of the starting 
solution which affects the amount loaded into the discs. To overcome the problem 
of low solubility in water methanol was used as solvent because of the high 
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solubility of DEX in methanol (30 mg/mL). Although DEX has high solubility in 
ethanol as well but the discs does not swell in ethanol. A solution of DEX in 
methanol 15 mg/mL (1 mL) was used for loading DEX into the gels. Although the 
loading efficiency was low when using methanol as solvent 13.7% compared to 
30% when water:ethanol was used, the amount loaded was 7 times higher when 
methanol was used. The amount loaded was 2.1 ± 0.5 mg/disc when methanol 
used compared to 0.30 ± 0.03 mg/disc when water:ethanol was used. When the 
release of the samples was studied the half-life of DEX in the discs increased from 
1.8 ± 8.9 days with water:ethanol to 4.5 ± 0.9 days when methanol was used 
(Figure 3:19).  
 
Figure 3:19 The release profile of DEX loaded into 10% MPC films from water:ethanol and 
methanol. The top panel is the percent of drug released and the bottom panel is the 
concentration of the drug released with time. The half-life of DEX was increased from 1.8 ± 
8.9 days to 4.5 ± 0.9 days when methanol was used. A burst release was observed in both 
samples.  
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When methanol was used as loading solvent a ‘burst release’ of DEX was 
also observed and the concentration was high compared to the therapeutic doses 
of DEX used in the eye tissues (Sharma et al. 2011). In order to reduce this burst 
release and help to extract methanol from the discs, water was used as a washing 
solvent. DEX has low solubility in water and once the methanol loaded discs and 
placed in water the DEX starts to precipitate inside the disc creating a depot for the 
drug (Figure 3:20). The precipitation of DEX indicates that there is no methanol to 
solubilize DEX in the hydrogel matrix and the methanol used for loading is slowly 
removed from the hydrogel matrix by diffusion into the surrounding water during 
washing due to the miscibility of water and methanol.  
 
 
Figure 3:20 The loading of DEX from methanol. When the DEX loaded discs transferred 
from methanol into water DEX starts to precipitate and form a depot. We can notice the 
discs appearance changed from transparent to opaque once placed in water.  
The depot formed will help to sustain the release of DEX from the discs. 
When the discs removed from incubation in methanol each disc was washed with 1 
mL of water for 4 hours. The amount of DEX lost during washing was 0.2 mg which 
is equivalent of 10% of the amount loaded. When the release was studied a 
reduction in the burst release and the concentration was observed and the half-life 
increased to 9.7 ± 1.9 days (Figure 3:21). Washing with water also helps to 
eliminate the extra free DEX present inside the hydrogel matrix which causes the 
reduction in burst release. Also the depot created with DEX helps to sustain the 
release for a longer period and in a more controlled manner. The release DEX from 
unwashed hydrogels was studied for only 10 days because it was preliminary study 
to examine whether using methanol has an effect on loading and release. However, 
the release of DEX from washed hydrogel was studied for a longer period of time to 
resemble the time DEX drops used in the clinic by patients.   
 
109 
 
 
 
Figure 3:21 The release profile of DEX loaded into 10% MPC films using methanol before 
and after washing with water. The top panel is the percent of drug released and the bottom 
panel is the concentration of the drug released with time. The burst release and 
concentration was reduced after washing with water.  
Loading a hydrogel with hydrophobic drug in sufficient amount is a 
challenging process due to the nature of hydrogels (filled with water). A 
hydrophobic drug (DEX) was successfully loaded into 10% MPC hydrogel discs in 
sufficient amount to sustain the release of DEX for 3 weeks.  
Storage and delivery of hydrogel films 
The intended use of the 10% MPC hydrogel film is a drug releasing spacer after 
glaucoma and trachoma surgery. One of the problems associated with hydrogels is 
the delivery in the clinic and how to maintain the hydrogel and the loaded drug 
stable during storage until used by the surgeon. Two possible ways of delivery, 
either stored in a storage solution (similar to contact lenses) to be used immediately 
during surgery or as dried hydrogels to be hydrated prior to use. Understanding the 
rate of swelling and deswelling will help to choose the best method for delivery of 
the hydrogel. The fully dried 10% MPC hydrogel requires at least 6 hours to reach 
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maximum hydration and 30 minutes to reach around 50% of hydration when placed 
in PBS at 25oC (Figure 3:22).  
 
Figure 3:22 The swelling and deswelling behaviour of 10% MPC hydrogel. Rapid swelling 
and deswelling was observed in the first hour compared followed by slow progression in 
both.  
Although storing a hydrogel in a storage solution will be more convenient to 
the surgeon, the stability of loaded drugs inside the hydrogel will be a problem. 
Some of the drug loaded will diffuse from the hydrogel matrix to the storage solution 
during storage and reduce the amount loaded. The loss of loaded drug during 
storage will be more significant with hydrophilic drugs. Also the stability of the drug, 
especially drugs subjected to hydrolysis, will be a problem. The best method is to 
deliver the hydrogel spacer in a dry xerogel-like form, with instructions to rehydrate 
them in 0.5 mL sterilised water for 1 hr prior to use. The hard glassy nature of dry 
hydrogels may cause irritation and discomfort if placed in dry form and rehydrating 
them for 1 hr will ensure at least 50% of swelling is achieved without drug loss. The 
remaining 50% of swelling will be completed after implantation by the flow of the 
aqueous humour. Complete swelling after implantation will have no effect on the 
dimensions of the device or spacer because once complete hydration is achieved 
the hydrogel return to its original intended dimensions of a GDD or a spacer. 
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Summary and conclusions 
The aim of this chapter was to formulate and characterise a HEMA-MPC hydrogel 
film that could be used for the development of GDD and a subconjunctival drug 
releasing implant after GFS. Different formulations with increasing stoichiometries 
of MPC from 0% to 100% were prepared. It was noticed that the SR and water 
content increased with increasing MPC percentage. When the percentage of MPC 
increased above 30% a film was not formed after hydration. The mechanical 
strength films were reduced with increasing MPC percentage. 
The hydraulic conductivity and permeability of the hydrogel films were too 
low to restrict aqueous outflow as a means to control the IOP after GDD 
implantation. The films were also impermeable to water passing through them. The 
flow rate of (1.12×10-18 m2 s-1 pas-1) for 10% MPC hydrogel was very low compared 
to the required flow rate in an ideal device (6 ×10-14 m2 s-1 pas-1). Creating a pouch 
by the use of a femtosecond laser or by polymerising around water soluble particles 
or films was also not successful for creating a hydrogel film capable of allowing 
aqueous outflow. While the HEMA-MPC hydrogels may not have the potential to 
control aqueous outflow; they were examine for potential use as a subconjunctival 
drug releasing implant.  
To choose an appropriate formulation for drug loading and release, hydrogel 
films were characterised regarding the swelling in different solvents and the ability 
to load and release hydrophobic and hydrophilic drugs. An increase in SR was 
observed with increasing percentage of MPC in (1:1) water:alcohol mixture. When 
pure alcohol (methanol or ethanol) were used as solvents the SR was not affected 
by an increase percentage of MPC for ethanol. An increase in SR was only 
observed when the percentage of MPC was above 30% for methanol.  
Formulations with 0%, 10% and 30% MPC were used for drug loading 
studies. The hydrogels were loaded with either a hydrophilic drug (pirfenidone) or 
hydrophobic drug (DEX) drug to examine the effect of MPC content (i.e. free water 
content) on loading and release. The drug loading was low and the release of the 
loaded drug was faster for hydrogels with 30% MPC for both drugs compared to 
hydrogels with 10% and 0% MPC.  
 Based on these findings hydrogels with 10% MPC offer the balance 
between water content, mechanical strength and drug loading and release. Since 
drug loading and release are related to free water, the level of cross-linker and 
initiator were varied to modify the ratio of free and bound water. However, there 
was no significant difference in free to bound water ratio when the cross-linker and 
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initiator percentages were reduced. Based on these results 10 % MPC formulation 
with 0.56 % PEGDA and 0.74 % AIBN was chosen as the best formulation for the 
synthesis of a hydrogel drug releasing spacer. 
To increase the loading efficiency and sustain DEX release from 10% MPC 
hydrogels, methanol was used as solvent for DEX loading. DEX was successfully 
loaded into a 10% MPC hydrogel film. The amount loaded increased from 0.3 mg 
into 1.9 mg/disc and the release was extended for more than 3 weeks. 
Although HEMA-MPC hydrogels were unable to show sufficient permeability 
and hydraulic conductivity to be of any use to control aqueous outflow to regulate 
pressure in a GDD, the hydrogel films offer a platform for development of drug 
releasing combination GDD and drug releasing spacer after GFS. 
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Chapter 4. Hydrogel implants for water soluble drugs 
Fibrosis that occurs due to treatment (e.g. GFS) or due to disease shares a similar 
mechanism and is the cause for much blinding disease (Hsu et al. 2000; Tovell 
2011; Bowman 1999). In the previous chapter HEMA-MPC hydrogel films were 
fabricated and characterised as a subconjunctival drug releasing spacer for GDD 
and after GFS to modulate wound healing. The HEMA-MPC hydrogels were 
characterised with the 10% MPC (which is 10% MPC, 88.7% HEMA, 0.56 % 
PEGDA and 0.74 % (w/w) AIBN) being selected as the optimal hydrogel formulation 
because it offers the best balance between water content, mechanical strength and 
drug loading and release. In addition to the problem of scarring caused by surgeries 
to lower the IOP in glaucoma, there is a condition known as trachoma where 
subconjunctival scarring is also the cause of blindness both due to the disease and 
also its surgical treatment which is widely used for recurring forms of the infection.  
Trachoma affects large populations of patients in developing countries and 
is a major ophthalmic health problem. It is considered an endemic disease that 
affects poor communities in Africa and Asia. It also affects a large population in 
Australia. It is estimated that 229 million people live in theses endemic areas and 
21 million people live with active trachoma (Taylor et al. 2014; Mariotti et al. 2009). 
Trachoma is a bacterial infection of the eyelid, conjunctiva and cornea that is 
caused by chlamydia trachomatis. The disease is spread directly through contact 
with the discharge from infected eyes or indirectly through poor sanitation and by 
flies (Kasi et al. 2004). Trachoma has different stages. In the early stages the 
infected eye suffers from symptoms of conjunctivitis symptoms including watery eye 
discharge, itching, redness, swelling and thickness of the upper eyelid (Darougar & 
Jones 1983). If diagnosed early, trachoma can be treated with antibiotics. In the 
early stages of trachoma infection antibiotics can be used. Oral azithromycin and 
topical tetracycline ointments are the drugs of choice (Solomon et al. 2004; 
Bowman et al. 2000). Other antibiotics have been studied to treat trachoma 
including doxycycline (Li et al. 2013).Recurrent infections will cause chronic 
inflammation of the eyelids which results in thickening and scarring of the upper 
eyelid ending with trichiasis (Gambhir & Basáñez 2007).  
Recurrent trachoma inflammation causes trichiasis. Trichiasis is a term used 
to describe the abnormal position or growth of the eyelashes towards the eye ball 
due to contraction of the eyelid as a result of scarring (Figure 4:1). The abnormal 
eyelashes movement will cause corneal opacification, due to scratching and 
scarring of the cornea, and eventually blindness if untreated (Mecaskey et al. 
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2003). There are several treatments available depending on the severity of the 
condition. Epilation is sometimes used for the removal of eyelashes either using 
forceps or scissors. Another procedure is the destruction of lash follicles. Epilation 
is effective for a short period and the eyelashes grow again (Rajak et al. 2012). 
 
 
Figure 4:1 The positioning of the eyelashes in normal and trachiasis eyes (HealthFixit 2016) 
A widely used treatment is the corrective surgery of the eyelid which is often 
referred to as the tarsal rotation procedure (Figure 4:2). The aim of the surgical 
procedure is to cut through the scarred tissues that cause contraction of the lid. The 
surgery involves rotating the marginal part of the eyelid outwards to prevent 
scratching of the cornea by the eyelids. A horizontal incision through the dense 
connective tissue located at the borders of lid margin is performed to separate it 
from the underlying submuscular tissues (Rajak et al. 2012). The incision will cut 
through the scared tissues followed by suturing of the tissue with the margin of the 
eyelids (Figure 4:2). The suture will be removed after two weeks and antibiotics are 
needed throughout the two weeks period to prevent infection. The problem with 
trachoma surgery is the recurrence of infection. The use of antibiotics after the 
surgery may reduce the risk of recurrence (Rajak et al. 2010; Burton et al. 2005). 
The problem again is limited patient adherence to the use of the antibiotics after 
surgery. Currently no treatment is available after trachoma surgery except the use 
of antibiotic ointments, such as tetracycline ointments (Bowman et al. 2002). 
Another problem to the surgery is the scarring that results from the surgery itself, 
which could be minimised if treated with an antifibrotic agent. MMC which is used 
for GFS and to implant GDDs cannot be used with trachoma surgery due to MMC 
toxicity.  
  
Scarred tissues 
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Figure 4:2  Posterior lamellar tarsal rotation. A) Horizontal incision through the tarsal plate 
and scarred tissues (orange). The blue line indicates the incision site; B) Separating the 
scarred tissues from the underlying submuscular tissues (green); C) Placing the sutures; D) 
Postoperative lid eversion. Adapted from (Rajak et al. 2012). 
The 10% MPC hydrogel implants could be used as drug releasing lid spacer 
after trachoma surgery. The films could be loaded with less toxic anti-scarring agent 
than MMC and be implanted at the incision site during trachoma surgery. However, 
trachoma is different from glaucoma in terms of the type of treatment needed after 
surgery. For GFS anti-inflammatory or anti-scarring agent is required; for trachoma 
an antibiotic is also required as the site of surgery is susceptible to infection and the 
origin of trachoma is bacterial and one of the causes of scarring is repeated 
bacterial infection (Khandekar et al. 2001; Li et al. 2013). The choice of drug that is 
both antibacterial and anti-scarring at the same time is important.  
Our lab is interested in developing anti-scarring therapeutics, dosage forms 
for drug delivery and exploring the possibility of using over the counter, currently 
used medications as new anti-scarring agents. One of the drugs that have shown 
promising results as anti-scarring agent is the known antibiotic doxycycline (DOXy) 
(Figure 4:3) (Sapadin & Fleischmajer 2006). It is a broad spectrum antibiotic of 
tetracycline family that has been used for the treatment of conditions caused by 
bacterial infections such as acne, urinary tract infections, intestinal infections, eye 
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Scarred tissues 
Separating the scarred 
tissues from the underlying 
submuscular tissues 
Postoperative lid eversion 
A B 
C D 
116 
 
infections, gonorrhea, chlamydia and periodontitis (gum infection) (Sloan & 
Scheinfeld 2008). DOXy is used in the clinic in several dosage forms including 
injection, suspension, capsules and tablets. It is also present in the form of hydrogel 
(Atridox®) for the treatment of periodontal disease (Do et al. 2014).  
 
Figure 4:3 The chemical structure of doxycycline free base.  
DOXy is present in three different forms; water soluble DOXy hydrochloride, 
water soluble DOXy hyclate and poorly water soluble DOXy monohydrate 
(Malmborg 1984; Joseph B Bogardus & Blackwood 1979). In addition to its 
antibacterial activity DOXy has also several biological activities, one of which is as 
an inhibitor of matrix metalloproteinases (MMPs) (Horwitz et al. 2014; Sapadin & 
Fleischmajer 2006; Stechmiller et al. 2010) MMPs are a group of enzymes that are 
capable of degrading the ECM components that are often present when there is 
fibrosis. MMPs depend on zinc for activation that is why they are called zinc 
dependant enzymes.  
During the wound healing process MMPs are overexpressed by the cells 
migrating to the wound. Overexpression of MMPs will result in dysregulation of the 
ECM and formation of scared tissues (Birkedal-Hansen et al. 1993). MMP inhibitors 
(MMPI) could be used to remodel the ECM and prevent excessive scarring. DOXy 
in the hyclate form was investigated as anti-scarring agent to modulate wound 
healing after GFS (Georgoulas et al. 2008). DOXy was also investigated as 
treatment before and after trachoma surgery to improve the success rate of the 
surgery (Li et al. 2013; Dawson & Schachter 1985). If 10% MPC hydrogel films 
were able to sustain DOXy hyclate for 2 weeks, such a dosage form would be a 
benefit for both glaucoma and trachoma.  
DOXy hyclate is water soluble (30 mg/mL). As described in Chapter 3, it is a 
challenge to prolong the release of a water soluble drug (pirfenidone) from a 
hydrogel. In an effort to slow the release of  DOXy hyclate and to achieve higher 
loading different methods employing cyclodextrin complexation will be evaluated 
using the 10% MPC hydrogel films to extend the release of DOXy hyclate.  
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Hypothesis and aims 
Hydrogel films with 10% MPC were fabricated as a potential material for GDDs or 
drug loaded subconjunctival spacer after GFS. It was hypothesised that a hydrogel 
implant could be used in other parts of the subconjunctiva such as the eyelid as a 
drug releasing implant after trachoma surgery. It was also hypothesised that a 
hydrophilic drug, doxycycline (DOXy), could be formulated in the hydrogel to display 
a sustained release profile. It was though possible that a diffusion barrier could be 
created through the hydrogel polymer matrix to delay doxycycline release. 
Hydrogels with 10% MPC were loaded with DOXy from different solvents 
and different concentrations to determine the best loading conditions. The films 
were also modified in an attempt to slow the diffusion of DOXy by introducing 
cyclodextrin as a DOXy complexation agent and potentially as a diffusion barrier 
within the hydrogel. The CD will be introduced using different approaches such as 
the formation of an IPN, semi-IPN network and embedding already cross-linked CD 
particles into the hydrogel matrix. The change in SR of the hydrogels after the 
addition of CD and the release of DOXy from CD modified films will be studied.  
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Results and discussion  
Loading and release of doxycycline in 10% MPC hydrogel films 
In the previous chapter hydrogels with the formulation (by weight percent) 10% 
MPC, 88.7% HEMA, 0.56 % PEGDA and 0.74 % (w/w) AIBN were found to be the 
most suitable for potential GDD and spacer development. The same formulation is 
intended as a starting point to develop a hydrogel formulation that could be 
considered for use after trachoma surgery. Delivering DOXy through 10% MPC 
hydrogels may improve the success rate after trachoma surgery. 
Water comprises a large part of the hydrogel matrix after hydration due to 
the ability of hydrogels to absorb and hold water in the hydrogel structure. 
Hydrogels can absorb up to one hundred times the dry weight during hydration 
(Vervoort et al. 1998; Kono & Fujita 2012; Appel et al. 2012). For a hydrogel it is 
thought that the loading efficiency of hydrophilic drugs will be high and accordingly 
the release of these drugs will be fast (Paradiso et al. 2014). Fast release was 
observed previously when pirfenidone was loaded into 0%, 10% and 30% MPC 
containing  hydrogel films. Pirfenidone is a hydrophilic drug, with high solubility in 
water (~10 mg/mL) and low MW (185.226 g/mol) (Richeldi et al. 2011). These 
findings are in agreement with the results reported by Hiraishi et al (Hiraishi et al. 
2008). The group reported that the release of another hydrophilic drug, 
chlorhexidine, in vitro from a methacrylated based resin with low water content was 
slower than the release from high water content resin.   
For a hydrophilic drug the amount of drug loaded and the loading efficiency 
depends on the concentration of the loading solution and the volume absorbed by 
the dry hydrogel. The amount loaded of timolol maleate was increased from 24.5 µg 
to 280 µg/lense when the loading solution concentration increased from 100 µg to 1 
mg/mL (Maulvi et al. 2014). Drug load can often depend on the degree of hydrogel 
swelling. Drug loading is usually estimated using Equation 8 where Vs is the 
absorbed volume by the dry gel, Wp is the weight of the dry gel and Co is the 
concentration of the loading solution (Kim et al. 1992)  
                          Lower amount loaded = (Vs/ Wp) X Co                                                           (8) 
To study the effect of swelling and concentration of loading solution on the 
amount of DOXy loaded into 10% MPC hydrogels, a soaking method was used. Dry 
xerogel (10% MPC) discs of 1cm diameter and 1mm thickness, and with 
approximate weights for each dry disc of 46.5 mg were used to analyse the amount 
of drug loading. One of the factors that affects loading is the concentration of the 
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loading solution. To estimate maximum loading and loading efficiency, each dried 
disc of 10% MPC hydrogel was placed in 1 mL of DOXy aqueous solutions with 
varying concentrations (6 mg/mL, 15 mg/mL and 30 mg/mL) for 24 hours. The 
amount loaded was estimated as the difference in UV absorbance between the 
loading solution before and after incubation. Each disc was removed from the 
loading solution and dried under vacuum for 24 hours.  
When the concentration of the loading solution was increased the amount of 
drug loaded was significantly increased (Table 4:1). Although the maximum amount 
loaded was 7.5 mg when loading from 30 mg/mL solution, 15 mg/mL was chosen 
as the optimum loading solution for further studies. It was reported that DOXy has 
the ability to supress cell contraction when used in a range of (100-400 µg) (H. Li et 
al., 2013). From the UV readings it was calculated that a loading solution of 15 
mg/mL will load 3.6 mg into each disc (weight of the dry disc is 48 mg) which is 
estimated to be enough for two weeks if the drug is released at a rate of 200 µg 
/day. 
Table 4:1 The amount loaded and loading efficiency of DOXy in 10% MPC discs. The 
solutions used for loading were (6 mg/ml, 15 mg/ml (3ml), 30 mg/ml; 1 ml).  
Loading solution in PBS 
Amount loaded 
mg/disc 
Loading efficiency % 
6 mg/mL (1 mL) 1.20 ± 0.08 24.10 ± 2.05 
15 mg/mL (1 mL) 3.60 ± 0.09 25.8 ± 0.8 
30 mg/mL (1 mL) 7.50 ± 0.09 25.0 ± 0.3 
 
Another factor that can affect loading is the volume absorbed by a dry 
hydrogel. According to equation 7 the higher volume absorbed will result in higher 
loading. The swelling ratio (SR) for HEMA hydrogels containing 10% MPC changes 
with different solvents. The SR of 10% MPC hydrogels in water and methanol was 
found to be 1.20 ± 0.02 and 1.20 ± 0.09 respectively. When a (1:1) water:alcohol 
mixture is used, the SR was increased to 2.80 ± 0.08 for water:methanol (1:1) and 
3.2 ± 0.1 for water:ethanol (1:1) mixture. A higher SR indicates a higher volume of 
the solvent is absorbed by the dry hydrogel matrix.  
It was assumed that by maximising the swelling of the films during the 
loading process the amount loaded would be increased. It was also assumed that 
using an alcohol:water (1:1) mixture for loading will result in a better entrapment of 
the drug. By swelling first in the alcohol:water mixture the drug will be loaded in 
higher amount compared to using water alone, and the volume absorbed by the 
hydrogel will be higher. After drying to remove the loading solvent the hydrogel will 
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re-swell again in PBS; however, it will swell to a lesser extent and less volume will 
be entrapped in the hydrogel matrix (Figure 4:4). This decrease in swelling may 
entrap the drug molecule deeper into the hydrogel matrix and will slow the release 
of the drug.  
 
 
 
 
 
Figure 4:4 The proposed mechanism for Improved loading and release from different 
solvent systems.1) The dried hydrogel disc placed in water: alcohol (1:1) mixture to achieve 
maximum swelling. The volume absorbed by the hydrogel is high which potentially load high 
amount of the drug; 2) After removal from incubation solution and drying, the drug is 
precipitated in the hydrogel matrix; 3) Less swelling will be observed when the loaded discs 
placed in the releasing buffer which may allow slow release of the loaded drug.   
Hydrogel discs with 10% MPC were loaded from different solvents and 
solvent combinations using a concentration of (15 mg/mL, 1 mL) and the release of 
DOXy from the loaded discs was studied. It was assumed that the amount loaded 
from water:alcohol mixture (1:1) will be high compared to water or methanol; 
however, there was no significant difference (p>0.05) in the amount loaded, and 
therefore the loading efficiency, when using different solvents and solvent 
combinations except where water:ethanol (1:1) was used (p<0.05). When 
water:ethanol (1:1) was used the amount loaded and loading efficiency was lower 
(Table 4:2). This may be due to the affinity of the drug for the hydrogel matrix. It is 
possible that when the loading solution is rich with alcohol, the alcohol will have a 
stronger interaction with the polymer matrix, displacing the drug and filling the 
internal volume of the hydrogel matrix, and any extra swelling and increase in size 
will be filled by alcohol not the drug.  
 
 
 
 
 
1 2 3 
Hydrogel discs 
incubated in 
water: alcohol 
drug solution 
Higher volume 
absorbed by 
the dry disc 
Dried hydrogel 
discs with 
loaded drug 
Less solvent 
absorbed 
during release 
(less swelling) 
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Table 4:2 The amount loaded, loading efficiency and half-life of DOXy in 10% MPC discs 
from 15 mg/mL 1 mL loading solution using different solvents.  
Loading solution 
Amount 
loaded mg 
SR 
Loading 
efficiency % 
Half-life 
days 
Water 3.7 ± 0.4 1.20 ± 0.02 24.6 ± 4.1 1.20 ± 0.01 
PBS 3.60 ± 0.09 1.20 ± 0.01 24.0 ± 0.8 -  
Water: Ethanol (1:1) 2.4 ± 1.8 3.2 ± 0.1 16.0 ± 2.8 0.9 ± 0.1 
Water: Methanol(1:1) 3.8 ± 1.8 2.80 ± 0.08 25.3 ± 9.4 0.9 ± 0.1 
Methanol 3.5 ± 5.5 1.20 ± 0.09 23.3 ± 8.4 1.1 ± 0.3 
 
The release of DOXy from the loaded discs was studied and the release 
profile was compared using the in vitro eye flow chamber. The release of DOXY 
from water or methanol loading was studied first for a week. The release was 
stopped when no more DOXy was detected from the collected samples using HPLC 
(Figure 4:5). However, only ~ 70% of the estimated loaded drug was released 
during that period. A possible explanation is that the amount of the drug loaded into 
the discs was overestimated and the real amount was lower. Another explanation is 
that the drug degraded through that period and the degradation products was 
entangled in the hydrogel matrix. 
Following the study of DOXy release from water and methanol, the release 
was studied from water:ethanol or water:methanol (1:1) loading. The release was 
faster compared to water and methanol. More than 80% of the loaded drug was 
released after 4 days compared to 60% using water or methanol (Figure 4:5). The 
experiment was ended after 4 days because the fast release of DOXy render the 
loading using water:ethanol or water:methanol (1:1) solution inappropriate for 
extended release. From the release experiment we concluded that the type of 
solvent used for loading has no effect on loading and release of DOXy from 10% 
MPC hydrogels.  
Based on the above observation DOXy was loaded and released from 10% 
MPC hydrogel discs. However, it was noticed from the release profile of DOXy 
(Figure 4:5) that the half-life of DOXy is 48 hours and there was burst release of the 
drug in the first 24 hours. In an effort to extend the half-life of DOXy in the films 
several modifications to the method were evaluated using the 10% MPC films. 
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Figure 4:5 The release profile of DOXy from 10% MPC discs loaded from 15 mg/mL 1.0 mL 
loading solution using different solvents. The top panel is the percent of drug released and 
the bottom panel is the concentration of the drug released with time. The solvents used are 
water, water:ethanol 1:1, water:methanol 1:1, ethanol and methanol. 
The use of beta-cyclodextrin (β-CD) in HEMA-MPC hydrogels 
The transport of molecules from loaded hydrogels to the surrounding medium is 
through the solubilisation of the drug in the water filled regions of the hydrogel 
matrix followed by drug transport through the polymer chains into the polymer 
surfaces (Amsden 1998). When the release of a molecule from a hydrogel is 
controlled by diffusion, the release rate is affected by the following factors; path 
length (l) and molecular diffusivity (D). The duration of release can be estimated by 
l2/D (Peng et al. 2010). The release profile can be increased by either increasing 
the path length (l) or decreasing diffusivity. Creating a diffusion barrier can prolong 
the path for the molecule to diffuse out of the polymer matrix (Hsu et al. 2014). Rad 
et al reported that the release of betamethasone from silicone based contact lenses 
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was reduced when vitamin E was used as hydrophobic diffusion barrier (Rad et al. 
2016). The release time of 90% of the loaded betamethasone (3.5 hours) from 
three commercial contact lenses was increased to (264-360) hours after using 
Vitamin E as diffusion barrier in the contact lens matrix. 
Molecular diffusivity is affected by the solubility of the material in the volume 
fraction of the hydrogel, the size of the molecule, the mobility of the polymer chains, 
the pore size of the hydrogel and drug polymer affinity (Amsden 1998; Korsmeyer 
et al. 1983; Nakamura et al. 2004). DOXy hyclate rapidly diffused from 10% MPC 
hydrogel discs. To slow the diffusion of DOXy from the polymer matrix, beta-
cyclodextrin (β-CD) was introduced. By incorporating β-CD into the polymer matrix, 
the affinity of DOXy to the hydrogel matrix could be increased and the release rate 
could be decreased.   
The concept of affinity based drug delivery has been investigated in recent 
years. In affinity based systems the drug will have higher affinity to the hydrogel 
matrix compared to the surrounding medium. The high affinity between the drug 
and the hydrogel matrix will help in modulating drug loading and release from the 
hydrogel matrix to increase loading and slow diffusion (Thatiparti et al. 2010; Vulic 
& Shoichet 2014; Wang & von Recum 2011). Jeon et al described the formation of 
affinity based heparin-alginate hydrogels for growth factor delivery (Jeon et al. 
2011). Due to the high affinity of growth factors to heparin, the heparin-alginate 
hydrogel was able to sustain the release of the growth factors in PBS for 3 weeks 
compared to 5 days using alginate hydrogel alone.   
CDs are cyclic oligosaccharides that are widely used in medicine as a 
complexing agent and there are several marketed products where CDs are used as 
excipients (Sharma & Baldi 2014; Rao et al. 2001; Szejtli 2005; Loftsson & Brewster 
2010). Through the formation of inclusion complexes the physicochemical 
properties of the drug molecules will be changed such as solubility, stability, 
permeability and toxic side effects (Davis & Brewster 2004; Concheiro & Alvarez-
Lorenzo 2013; Vilanova & Solans 2015). 
Jóhannsdóttir et al reported an increase in the solubility of cyclosporine A 
from 0.008 mg/mL to 0.5 mg/mL when 5% (w/v) of α-CD was used for the 
formulation of eye drop (Jóhannsdóttir et al. 2015). Moriwaki et al reported an 
increase in the solubility of albendazole from 13.62 µmol/L to 276 µmol/L when β-
CD was used in a concentration of 16.3 mmol/L (Moriwaki et al. 2008). Abdur Rouf 
et al reported that the solubility and dissolution rate of rapamycin was improved with 
complexting with CD (Abdur Rouf et al. 2011). In the dissolution test only 25% of 
the pure rapamycin was dissolved after one hour compared to 80% of the complex 
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when an equal amount of the drug was added. Kanjickal et al reported that 
alteration in the release of cyclosporine A from PEG hydrogels after sterilization 
could be avoided by using cyclosporine A-CD complex instead of the free drug in 
the hydrogel (Kanjickal et al. 2005).  
In the area of ophthalmic drug delivery CDs are widely used in formulation 
as an excepient, particularly in eye drops and several marketed products utilise 
CDs to increase drug solubility (Sharma & Baldi 2014; Cal & Centkowska 2008). 
Several commerical eye drops such as Voltaren Ophthalmic® and Clorocil® are 
available in the clinic in which CDs were used to improve the solubility of the poorly 
soluble drugs (Loftsson & Stefánsson 2002) .  
CDs can form inclusion complexes because they have an interior 
hydrophobic cavity that can accommodate hydrophobic drugs or hydrophobic parts 
of drug molecules that can fit in the cavity to form the complex (Del Valle 2004). 
Such a drug-CD inclusion complex can be more water soluble than drug alone due 
to the solubilising OH groups on the outer surface of CDs (Figure 4:6) (Pinho et al. 
2014). Moriwaki et al reported an increase in the solubility of albendazole from 
13.62 µmol/L to 276 µmol/L when β-CD was used in a concentration of 16.3 mmol/L 
(Moriwaki et al. 2008).  
 
 
Figure 4:6 Structure and arrangement of β–CD molecule that have 7 glucose units. The 
drug molecule is complexed with the inner cavity of the CD molecule. 
(http://watcut.uwaterloo.ca/webnotes/Pharmacology/deliveryCarriers.html) 
The drug-CD complex is formed by non-covalent interactions between the 
drug and CD, therefore the reaction is reversible. Formation and dissociation of the 
CD-drug complex depends on the stability of the complex formed (Bibby et al. 
2000). When a strong complex is formed the dissociation rate of the drug from the 
complex will be low (Stella et al. 1999). Corre et al reported that the decrease in 
intestinal absorption rate of diphenhydramine in rat model from two CD molecules 
Drug molecule 
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was related to the strength of the inclusion complex formed (Corre et al. 1998). The 
absorption rate was reduced by 36% when dimethyl-β-CD was used compared to 
only 8% when hydroxypropyl-β-CD was used because of the high stability of the 
complex formed with dimethyl-β-CD compared to hydroxypropyl-β-CD. The stability 
constant was 895 M-1 for dimethyl-β-CD compared to 494 M-1 for hydroxypropyl-β-
CD. 
CDs are available in three main forms α-, β- and γ-cyclodextrin which 
contain 6, 7 and 8 molecules of glucose respectively and derivatives of the three 
types are also available such as hydroxypropy-β-CD, hydroxypropyl-γ-CD, 
dimethyl-β-CD and sulphated-β-CD (Vyas et al. 2008; Crini 2014). The molecules 
differ in the size of the inner hydrophobic cavity and solubility in water. The 
difference in the properties allowed the formation of complexes with different 
properties and complexing wide range of drugs (Otero-espinar 2010; Lezcano et al. 
2002). Rodriguez-Aller et al reported different stability of latanoprost when 
complexed with different CD molecules as eye drops (Rodriguez-Aller et al. 2015). 
Latanoprost stability was not improved compared to the commercial eye drops 
when α-and γ-CD were used as complexing agents; however the stability was 
improved when β-CD derivatives were used. Only 33.5% of the initial latanoprost 
remained after 12 months in direct sunlight from the commercial eye drop 
compared to 81.9% and 79.6% for dimethyl-β-CD and propylamino-β-CD 
respectively. Bayomi et al reported that the improvement of photostability of 
nifedipine by complexation with CD was affected by the type of CD used (Bayomi et 
al. 2002). The degradation rate constant of nifedipine was smaller when dimethyl-β-
CD  and hydroxypropy-β-CD compared to β-CD which was 0.12, 0.29 and 0.47 for 
dimethyl-β-CD,  hydroxypropy-β-CD and β-CD respectively.  
CD hydrogels have been investigated as delivery systems to slow the 
release of loaded drugs (Concheiro & Alvarez-Lorenzo 2013; MacHín et al. 2012). 
Li et al reported that a supramolecular self-assembled hydrogel made of α-
cyclodextrin and a biodegradable poly(ethylene oxide)–poly[(R)-3-
hydroxybutyrate]–poly(ethylene oxide) (PEO–PHB–PEO) triblock copolymer was 
able to sustain the release of a model drug dextran-FITC (Li et al. 2006). The 
release of dextran in vitro was sustained for a month when the supramolecular 
hydrogel was used compared to using α-CD-PEO alone in which 100% of the 
loaded dextran was released in less than 5 days.  
CD Hydrogels could be made entirely from CD cross-linked molecules or the 
CD molecules introduced into the polymer matrix of the hydrogel (Concheiro & 
Alvarez-Lorenzo 2013). Drug-CD complex formation is governed by the rates of 
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association (Ka) and dissociation (Kd) (Bibby et al. 2000). When a drug is loaded 
into CD hydrogels, the rate of drug release will depend on two mechanisms; affinity 
of the drug to CD and diffusion from the hydrogel matrix. The loaded drug has to 
associate and dissociate through several CD molecules before diffusing outside the 
hydrogel (Figure 4:7). There are several approaches used to introduce CD into a 
hydrogel polymer matrix such as co polymerisation with CD, the use of CD grafted 
polymers and the formation of IPN with CD (Li et al. 2015; Rosa dos Santos et al. 
2009; Xu et al. 2010; Ribeiro et al. 2012).  
 
 
Figure 4:7 Schematic representation of drug release from hydrogels with CD molecule and 
hydrogels without CD. The drug molecule will have to complex and de-complex several CD 
molecules before release from the hydrogel while it diffuse without obstacles in CD free 
hydrogels. 
Moya-Ortega et al reported the formation of semi-IPN of γ-CD and 
polyacrylic acid for the sustained delivery of dexamethasone (Moya-Ortega et al. 
2010). Dexamethasone release was sustained for 1 week with the semi-IPN 
hydrogel compared to 1 day when using γ-CD hydrogel only. Mennini et al  reported 
Drug molecule 
Drug molecule 
Drug-CD complex 
CD molecule 
Diffusion 
Hydrogel matrix 
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that both the solubility and the release profile of hydrophobic drug 
dehydroepiandrosterone were improved when loaded in CD hydrogel for vaginal 
delivery (Mennini et al. 2016). The release of dehydroepiandrosterone from a 
combination hydrogel made with HP-β-CD and γ-CD was sustained for more than 8 
hours in vitro using dissolution apparatus. Kono and Teshirogi reported the 
formation of β -cyclodextrin-grafted carboxymethyl chitosan hydrogels (CD-g-
CMCs) as a controlled delivery system (Kono & Teshirogi 2015). The amount of 
acetyl salicylic acid absorbed into the (CD-g-CMCs) was 23.9 µmol/g compared to 
2.4 µmol/g for CMC hydrogels without CD. When in vitro release was studied the 
amount released from CMC hydrogels was 86% in the first 2 hours compared to 
41% using (CD-g-CMCs).  
Although CD has been used as complexing agent for hydrophobic drugs it 
has also been investigated as complexing agent for hydrophilic drugs to modulate 
the physicochemical properties of the complexed drugs (Ikeda et al. 2002; 
Mariangela de Burgos M de Azevedo et al. 2011). β–CD was used as complexing 
agent for DOXy monohydrate and hyclate to reduce photosensitivity and increase 
stability of DOXy (H. Zhang et al. 2013; Wang et al. 2013; He et al. 2011). Kogawa 
et al reported that DOXy hyclate has the ability to form inclusion complex with β–CD 
if they were mixed in equimolar ratios (Kogawa et al. 2014). Introducing β-CD into 
10% MPC hydrogel films may slow the diffusion and sustain the release of loaded 
DOXy.  
Formation of a complex of DOXy hyclate with β-CD was examined by 
dissolving the two molecules in equimolar amounts in 5 mL DW and sonicated for 
one hour then freeze dried to achieve the dry powder of the complex. There are 
several methods that could be used to confirm the formation of inclusion complex 
such as DSC, thermogravimetric analysis (TGA) and FTIR (Poorghorban et al. 
2015; Figueiras et al. 2015). A complex was confirmed when DSC was measured 
for the individual molecules, the physical mixture and the complex. The physical 
mixture was prepared by mixing CD and DOXy powders in equimolar ratios. The 
melting peak of DOXy at ~170oC disappeared when the complex was formed. The 
DOXy melting peak was present when physical mixture was formed (Figure 4:8). 
These results suggest that β-CD has the ability to form inclusion complex with 
DOXy. Similar DSC profile was reported by Kogawa et al when complexed DOXy 
with β-CD (Kogawa et al. 2014).   
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Figure 4:8 The DSC analyses of β-CD, DOXy and the physical mixture and complex of both 
β-CD and DOXy. In the DSC graph the melting peak of DOXy was not observed in the 
complex and was observed in the physical mixture which indicates the formation of inclusion 
complex.   
Formation of 10% MPC- 89.5% HEMA film with pendant CD 
Hydrogel films with 10% MPC-89.5% HEMA and pendant β-CD were prepared. 
Glycidyl methacrylate (GMA) was used as a monomer to conjugate CD into the 
hydrogels polymer chains. GMA was previously used as a monomer for the 
formulation of hydrogel soft contact lenses with pendant CD molecules as 
controlled drug delivery systems (Rosa dos Santos et al. 2009). GMA should be 
polymerised first with the hydrogel matrix as a co monomer followed by activation of 
the hydrogel for the conjugation of CD into GMA. GMA has an acrylate group at one 
end and epoxide at the other end. The acrylate group will help GMA to attach to the 
hydrogel network on one end and reacts with CD through the epoxy group on the 
other (Figure 4:9) (Ribeiro et al. 2012).  
Nava-Ortíz et al reported the functionalization of polyethylene and 
polypropylene films with β-CD using GMA (Nava-Ortíz et al. 2009). GMA was first 
grafted into the films. After grafting, the films were incubated for 24 hr with 
continuous stirring at 70oC in a mixture of DMF (2 mL) and 0.5 M NaCl (8 mL) with 
β-CD. 
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Figure 4:9 The chemical structure of GMA and the formation of pendant CD. GMA was 
attached through the acrylate group into the HEMA-MPC hydrogel film and conjugated to 
the CD through epoxide group through activation solution.   
Hydrogel films with 10% MPC and pendant CD were fabricated. The GMA 
was used as a co-monomer during the formulation of 10% MPC hydrogel. The CD 
was then conjugated by reaction of the epoxy group on the GMA. For the 
preparation of the hydrogels, to 1 mL of 10% MPC monomer solution mixture (that 
contains 88.7% HEMA, 10% MPC, 0.74% AIBN and 0.56% (w/w) PEGDA) different 
amounts of GMA (1%, 2.5%, 5% and 9% (w/v)) were added. The mixture was 
polymerised to synthesise hydrogels with GMA cross-linked in the polymer matrix. 
After polymerisation, the xerogels were left to hydrate in water and washed to 
remove the unreacted monomers. Hydrogels with higher percentages of GMA (5% 
and 9% (w/w)) did not hydrate when placed in water and remained in a hard and 
glassy xerogel form, due to the large percentage of GMA in the polymer mixture. 
Hydrogels with (1% and 2.5% (w/w)) was hydrated when placed in water for 
washing. To activate the epoxy group and conjugate β-CD to the polymer matrix, 
the GMA containing hydrogels need to be incubated in activation solution. The 
activation solution is composed of dimethyl formamide (DMF), sodium hydroxide 
(NaOH) and β-CD. Discs of 1 cm in diameter were cut from the hydrated films and 
placed in the activation solution at 80oC for 24 hr. In the presence of alkaline 
conditions (NaOH(aq)) and high temperatures the epoxy ring will open and form a 
covalent bond with the hydroxyl group of the β-CD (Figure 4:10).  
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Figure 4:10 The fabrication of 10% MPC hydrogel with GMA. Monomer mixture of 10% 
MPC was first polymerised with GMA. Followed the polymerisation and washing the 
hydrated hydrogel placed in activation solution at 80
o
C for 24 hours for the conjugation of β-
CD into the hydrogel. 
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β-CD molecules have several hydroxide groups (OH) and it is possible that 
more than one OH group may participate in the reaction and form a covalent bond 
with GMA, thereby two or more GMA molecules could be attached to the same β-
CD molecule. The multiple cross-linking of the same β-CD molecule may increase 
the cross-linking density of the hydrogel formed and potentially affect the properties 
of the hydrogel formed.  
When the discs were removed from the activation solution and washed with 
water for 3 days they were fragile and easy to break. The loss of mechanical 
strength is probably due to the presence of DMF which is a strong organic solvent. 
To examine the effects of DMF on the hydrogel the 10% MPC hydrated disc without 
GMA was placed in DMF for 24 h. When removed the disc was fragile and easily 
fragmented. Mechanical strength is an important parameter for a spacer or a device 
as it is intended for implantation for a long period of time. Reduction in the 
mechanical strength of the films after soaking in the activation solution, render them 
unusable for implantation. No further action was taken regarding the pendant β-CD 
using this activation method.  
In an effort to incorporate β-CD into the hydrogel without using DMF, the β-
CD solution was mixed with 10% MPC monomer solution and GMA, to create an in 
situ polymerisation method. Monomer solution of 10% MPC (1 mL) was mixed with 
1 ml β-CD solution and different amounts of GMA (0.5, 0.2 and 0.1 g). These are 
labelled formulations number 1, 2 and 3 respectively. The β-CD monomer solution 
is 20% (w/v) in 0.2 M NaOH solution (Figure 4:11). It was hoped GMA will be 
polymerised into the HEMA-MPC hydrogel matrix through the acrylate group and at 
the same time conjugated to β-CD through the epoxy group. 
 
 
Figure 4:11 The preparation of HEMA-MPC hydrogel films with pendant CD using GMA as 
conjugating agent in situ. The monomer mixture with CD placed at 80oC for 24 hours in the 
incubator.   
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Incomplete and brittle films were formed with formulations numbered 1, 2 
and 3 (Figure 4:12). A possible reason is the presence of large amount of β-CD in 
the mixture. β-CD only hydrogels are brittle and it is possible that the presence of 
high amount of β-CD in the formulations reduced the mechanical strength of the 
films. However, even when the volume of β-CD monomer solution used in the 
formulation was reduced to 0.5 mL in formulations numbered 4, 5 and 6 no proper 
film was formed (Figure 4:12). The hydrogel films formed were incomplete (filled 
with bubbles) and brittle around the edges. Since no proper film could be formed 
using in situ approach, a different approach was needed to incorporate β-CD into 
the hydrogel. 
 
 
Figure 4:12 Different formulations were prepared by varying the ratio of 10% MPC 
monomer solution with 20% β-CD monomer solution and GMA. Formulations numbered 1, 
2, 3 contain equal volumes of both monomer solutions and different amounts of GMA (0.5, 
0.2 and 0.1 g) respectively. Formulations numbered 4, 5, 6 contain (2:1) ratios of 10% MPC 
monomer solution: β-CD monomer solution  and varying amount of GMA (0.5, 0.2 and 0.1 
g) respectively. Complete films could not be formed by any of the formulations.    
Embedding CD cross-linked particles in 10% MPC-HEMA  films 
Preparation of films with pendant β-CD using GMA appeared to be unachievable in 
these MPC hydrogels. β-CD could be introduced as embedded particles in the 
hydrogel matrix. If β-CD were used as powder in the hydrogel mixture it will be 
washed with the unreacted monomers due to its solubility in water. Converting β-
CD into insoluble form would help to immobilise the particles within the hydrogel 
film. Chemically cross-linked CD particles (micro and nano) were previously 
reported and prepared to be used as sorbents and drug carriers for drugs (Trotta et 
al. 2012; Trotta 2011; Yamasaki et al. 2006; Torne et al. 2013; Trotta & Cavalli 
2009). Swaminathan et al reported the synthesis of β-CD nanosponges for the 
delivery of antitumor camptothecin (Swaminathan et al. 2010). During the release 
study in vitro only ~25% of the loaded camptothecin was released from the 
nanosponges after 24 hours.   
β–CD cross-linked hydrogel was used for the preparation of β–CD cross-
linked particles. The β–CD monomers were chemically cross-linked using 
1 2 3 4 6 5 
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poly(ethylene glycol) diglycidyl ether (PEGDE) as cross-linker for the formation of 
β–CD hydrogel (Figure 4:13). After polymerisation, the cross-linked hydrogel was 
crushed and passed through a sieve to create the microparticles. Understanding 
the properties and water behaviour of the β–CD hydrogels will help to choose the 
best formulation for the synthesis of the β–CD cross-linked particles.  
 
 
Figure 4:13 Formation of cross-linked β-CD hydrogels. The CD monomers mixed with 
polyethylene glycol diglycidyl ether (PEGDE) as cross-linker and polymerised at 50
o
C for 12 
hours at 150 RPM in 0.2 M NaOH. The epoxy group on the cross-linker interacts with the 
hydroxyl groups on the CD molecule through covalent bonding.    
To study the effect of the ratio of the cross-linker PEGDE to β–CD solution 
on the properties of the prepared hydrogels the level of cross-linker was varied (1:1, 
1:2, 2:1) with β–CD solution. β–CD was dissolved in 0.2 M NaOH at a concentration 
of 15% (w/v). The EWC% and SR of the formulations were measured (Table 4:3). 
There was only a slight difference in SR and EWC% observed between the 
hydrogels. However, when the level of PEGDE to β–CD solution was 2:1, the 
hydrogel formed was too hard to pass through the 40 mesh sieve. The softness 
could be increased by reducing the percentage of PEGDE compared to β–CD 
solution. The ratio of cross-linker chosen for the synthesis of the CD particles was 
(1:1) (Figure 4:14). This ratio will offer the advantage of a higher cross-linker 
density and the ability to pass through the 40 mesh sieve to produce the 
microparticles. The microparticles were freeze dried to be used for embedding in 
10% MPC hydrogels. 
   
50
o
C/12 hrs 
150 RPM 
β-CD 
PEGDE 
β-CD cross-linked hydrogel 
134 
 
 
 
Figure 4:14 The preparation of β–CD microparticles; A) The CD hydrogel was first formed 
the crushed and passed through 40 mesh sieve to create the particles; B) SEM image of the 
cross-linked CD particles with scale bar of 500 µm. 
 
Table 4:3 The EWC% and SR of CD hydrogels prepared with different ratios of cross-linker 
to monomer. The water content and SR was higher when the level of cross-linker was low.  
15% CD:PEGDE EWC% SR 
1:1 86.1% ± 0.7 5.9 ± 0.2 
2:1 90.6% ± 0.5 5.6 ± 0.3 
1:2 85.4% ± 0.5 9.7 ± 0.2 
 
Hydrogels with 10% MPC were polymerised around the cross-linked β-CD 
particles. Cross-linked β-CD particles are hydrogels so polymerising HEMA-MPC 
around the cross-linked β-CD particles could create a hydrogel inside a hydrogel 
and add an additional barrier to slow the release of loaded DOXy. The β-CD 
particles were added to 10% MPC monomer solution in two different concentrations 
1% and 2% (w/v). When the β-CD particles added to 10% MPC monomer solution, 
suspension was formed. A suspension made with 1% (w/v) β-CD particles was 
injectable through a 21G needle. A suspension made with 2% (w/v) was non 
injectable, even when the needle size was increased to 19G. 
β–CD hydrogel β–CD cross-linked particles 
A 
B 
500 µm 
135 
 
A hydrogel suspension of 10% MPC and 1% (w/v) was injected into the 
mould and placed in the oven for polymerisation. As a xerogel the film was opaque 
(compared to the clear 10% MPC) and after hydration the films were still opaque, 
confirming that the β-CD particles were embedded in the film and not washed out 
during the removal of unreacted monomers (Figure 4:15). Films with cross-linked β-
CD particles had similar strength to the films without β-CD particles which indicated 
that the presence of β-CD particles did not affect the mechanical properties of the 
original 10% MPC film. Qualitative determination was used to compare the strength 
of the hydrogels with and without crosslinked β-CD particles. Hydrogels made with 
10% MPC could be bended more than 20 times in one minute without breaking so 
as the 10% MPC hydrogels with crosslinked β-CD particles.    
 
Figure 4:15 10% MPC hydrogel made with embedded β-CD particles compared to standard 
10% MPC film. The film with β-CD is opaque compared to standard 10% MPC films.  
The EWC% and SR in different solvent systems were measured for 10% 
MPC hydrogels embedded with 1% (w/v) β-CD particles to study the effect of the 
presence of β-CD particles on 10% MPC behaviour. The EWC% of hydrogels with 
embedded β-CD particles was higher (65.4 ± 0.1) compared to 10% MPC hydrogels 
(55.1 ± 0.3). The increase in water content could be attributed to the hydroxyl 
groups present in the β-CD. When the ratio of free to bound water was measured 
for 10% MPC with embedded β-CD particles, the majority of water was free. The 
ratio of free to bound water was (2:1) for the 10% MPC with embedded β-CD 
particles compared to (1.8:1) in 10% MPC hydrogels. β-CD hydrogels have higher 
free water compared to bound water when examined. The ratio of free to bound 
water was (3.1:1). The SR in water was also increased in the presence of CD 
particles; however, there was no difference in SR in solvents other than water 
(Table 4:4). 
 
10% MPC  
hydrogel 
10% MPC hydrogel 
with embedded CD 
136 
 
Table 4:4 The effect of embedding CD particles on the SR of 10% MPC hydrogels in 
different solvents.  
 
Solvent used 
SR 
10% MPC 10% MPC with CD particles 
Water 1.20 ± 0.02 1.80 ± 0.09 
Methanol 1.20 ± 0.09 1.2 ± 0.2 
Water:Methanol (1:1) 2.80 ± 0.08 2.6 ± 0.3 
Water:Ethanol (1:1) 3.2 ± 0.1 3.7 ± 0.3 
Ethanol 0.20 ± 0.03 0.20 ± 0.01 
 
For the loading process a hydrogel disc of 1 cm diameter and 1 mm 
thickness was used. The loading of DOXy in each disc was increased from 3.7 ± 
0.4 mg in the 10% MPC films to 6.6 ± 0.4 mg when the hydrogel films were 
embedded with β-CD particles. Unfortunately, there was no significant difference in 
the release profile of DOXy from the β-CD embedded hydrogels compared to 10% 
MPC hydrogels (Figure 4:16). A possible explanation is that the affinity of DOXy for 
β-CD is low. The low affinity may have caused faster rate of dissociation compared 
to association between β-CD and DOXy. It is also possible that because of the high 
water solubility of DOXy the drug would prefer to be in solution form rather than the 
inner cavity of the β-CD molecule.  
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Figure 4:16 The release of DOXy from 10% MPC and 10% MPC hydrogels embedded with 
β-CD cross-linked particles. The top panel is the percent of drug released and the bottom 
panel is the concentration of the drug released with time. No difference in the release profile 
was observed.  
Formulation of an IPN derived from 10% MPC-HEMA and β-CD 
As described previously IPN and semi-IPN are terms used to describe hydrogels 
made by the polymerisation of two orthogonal monomer systems at the same time 
(IPN) or polymerisation of a monomer mixture around a polymer (semi-IPN). Each 
monomer system undergoes separate polymerisation with polymer chain addition 
(or growth) occurring simultaneously for each polymer. In principle, an IPN can 
result in an entangled mixture of two or more polymers that would be difficult to 
achieve by mixing alone. IPN and semi-IPN technique are usually used to impart 
strength to hydrogels or manipulate the physical and chemical properties such as 
swelling and mechanical strength (Lohani et al. 2014; Aminabhavi et al. 2015; 
Samanta & Ray 2014).  
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Full-IPN of cross-linked β-CD and 10% MPC was prepared using in situ 
approach. The two monomer mixture will be mixed in equal volume ratios. (Figure 
4:17). To ensure that each monomer system undergoes separate polymerisation, 
HEMA-MPC monomers were polymerised in the presence of PEGDE as a 
replacement of PEGDA and β-CD monomer mixture was polymerised in the 
presence of PEGDA as a replacement for PEGDE separately. Both mixtures 
remained liquid and did not polymerise to a hydrogel which indicates that the two 
systems can undergo separate polymerisation at the same time.  
 
 
Figure 4:17 The in situ polymerisation of IPN of β-CD and 10% MPC monomer solution. 
The two monomer mixtures are mixed together and polymerised at the same time. 
β-CD hydrogels are polymerised under different conditions than 10% MPC 
hydrogels (50oC/12 hours at 150 RPM). To ensure that 10% MPC could be 
polymerised in conditions similar to β-CD the monomer solution of 10% MPC was 
placed for polymerisation at (50oC/12 hours at 150 RPM). A xerogel was formed 
and there was no difference in appearance between hydrogels prepared at 70oC for 
12 hours and hydrogels prepared at (50oC/12 hours at 150 RPM).  
Three different formulations were prepared in which the β-CD monomer 
solution and 10% MPC monomer solution were mixed in equal volume ratios (1:1). 
The difference between the three formulations is the composition of β-CD monomer 
β-CD monomer 
mixture which 
contains β-CD in 
0.2 M NaOH and 
PEGDE 
10% MPC 
monomer solution 
which contains 
MPC, HEMA, 
PEGDA and AIBN 
Different ratios of 
the two mixtures 
were mixed 
In situ 
polymerisation at 
50
o
C for 12 at 150 
RPM  
Full-IPN of β-CD 
and HEMA-MPC 
hydrogels 
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solution used. Three different β-CD monomer solutions were prepared with varying 
percentages of β-CD (15%, 30%, 50% (w/v)) in 0.2 M NaOH. The amount of 
PEGDE as cross-linker in each β-CD solution was 50% (v/v). The percentage of β-
CD in the mixture was varied to identify the maximum amount of β-CD that could be 
applied into the monomer mixture and still maintain a film. The mixture then placed 
in the incubator at 50oC for 12 h at 150 RPM. Before incubation all the mixtures 
were white in colour. No complete film was formed and all the three films were 
broken and difficult to handle (Figure 4:18). 
 
 
Figure 4:18 IPN hydrogel films made by in situ polymerisation of two monomer solutions. β-
CD monomer solution and 10% MPC monomer solution were mixed in equal ratios (1:1). 
Three different β-CD monomer solutions were prepared with varying percentages of β-CD 
(15%, 30%, 50% (w/v)) in 0.2 M NaOH. The amount of PEGDE as cross-linker in each β-CD 
solution was 50% (v/v). For all the formulations prepared no proper film was formed. 
The closest film to the 10% MPC films superficially were the films made with 
30% β-CD monomer solution. To explore whether changing the ratio of β-CD 
monomer solution to 10% MPC monomer solution will have an impact of the 
formulation, different formulations with different ratios of 30% β-CD to 10% MPC 
monomers were prepared. The ratios in which the two monomer solutions were 
mixed were (1:1, 1:2, 2:1 30% β-CD:10% MPC). Varying the ratio between the two 
monomer solutions did not affect the properties of the films regarding the texture, 
the films prepared were brittle (Figure 4:19).  
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Figure 4:19 Hydrogel films with different ratios between 10% MPC-89.5% HEMA monomer 
solution : 30% CD monomer solution (1:1, 2:1, 1:2) were prepared. Formulation with 1:2 
ratio was not in the form of film and very brittle. The other two films were weak and the CD 
was not distributed uniformly through the film 
Since the formation of an IPN was not possible using an in situ approach, a 
sequential approach was investigated for the preparation of IPN of 10% MPC and 
β-CD. Sequential polymerisation is basically two steps polymerisation. The first step 
is to polymerise the first monomer mixture in the presence of the other mixture 
followed by polymerisation of the second monomer mixture (Figure 4:20). 
 
 
 
 
Figure 4:20 Sequential approach used for IPN synthesis. Polymerisation of the first 
monomer mixture in the presence of the second monomer mixture followed by 
polymerisation of the second monomer mixture to have an IPN hydrogel.  
The polymerisation of the 10% MPC monomer mixture first took place 
followed by the polymerisation of 30% β-CD monomer mixture. To avoid using the 
higher temperature required by AIBN (70°C), the initiator was replaced with 
TEMED/APS system. The TEMED/APS system is capable of starting the 
polymerisation process at room temperature eliminating the need of higher 
temperature. After 15 minutes of the addition of TEMED to start the polymerisation 
process, the mould was transferred to an incubator to start the polymerisation of β-
CD monomer solution. The films prepared were smooth similar to 10% MPC; 
however they were opaque which is a possible indication of the formation of an IPN 
(Figure 4:21). 
(1:1) (2:1) (1:2) 
First polymerisation 
for the synthesis of the 
first polymer network 
Second polymerisation 
for the synthesis IPN 
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Figure 4:21 IPN hydrogel film fabricated from sequential polymerisation of 10% MPC 
monomer solution and β-CD monomer solution. First TEMED/APS system was used for the 
polymerisation of 10% MPC followed by polymerisation of β-CD by placing the hydrogel in 
the incubator at 50
o
C for 12 hours at 150 RPM. A hydrogel film was formed. 
No difference was observed in SR when water, ethanol and methanol were 
used. There was an increase in SR when alcohol mixture was used in IPN 
formulations compared to standard 10% MPC films (Table 4:5). The loading of the 
IPN hydrogel was 5.9 ± 0.9 which was also significantly higher than the loading of 
the hydrogel without β-CD. Unfortunately, similar to using embedded β-CD particles 
no difference in DOXy release profile was observed between 10% MPC hydrogels 
and the IPN hydrogel discs (Figure 4:22). 
Table 4:5 The SR of IPN of β-CD and 10% MPC compared to 10% MPC hydrogels, no 
difference was observed in SR when water, ethanol and methanol were used. There was an 
increase in SR when alcohol mixture was used in IPN formulations compared to standard 
10% MPC.  
SR Water Ethanol Methanol 
Water:Ethanol 
(1:1) 
Water:Mthanol 
(1:1) 
IPN 
1.60  
± 0.04 
0.10 
 ± 0.03 
1.100 
 ± 0.004 
4.0  
± 0.1 
3.10 
 ± 0.09 
10% MPC 
1.20  
± 0.02 
0.20 
 ± 0.03 
1.20 
 ± 0.09 
3.2 
 ± 0.1 
2.80 
 ± 0.08 
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Figure 4:22 DOXy percent of drug release and concnetration from 10% MPC and IPN of 
10% MPC with CD. The drug follows similar profile in release from both hydrogels.  
 Different approaches were used for the incorporation of β-CD into 10% MPC 
polymer matrix. The β-CD was successfully incorporated into the hydrogel by using 
β-CD cross-linked particles or sequential IPN. However, there was no difference in 
release profile of DOXy in the presence of β-CD compared to standard 10% MPC. 
Another approach was considered for investigation which is the introduction 
of vitamin E (VE) as a diffusion barrier to slow the diffusion of DOXy from the 
hydrogel. VE is a large antioxidant hydrophobic molecule that is soluble in organic 
solvents and precipitate in the presence of aqueous environment. VE as diffusion 
barrier was studied to slow the release of water soluble drugs from hydrogel contact 
lenses (Peng et al. 2010). To create diffusion barrier inside a contact lens VE was 
loaded in the soluble form using organic solvent (typically ethanol). After loading the 
organic solvent was extracted with water which causes the VE molecules to 
aggregate and precipitate inside the lens creating the barrier. Longer time will be 
required for the drug molecules to diffuse from the lens and the release will be 
slowed (Figure 4:23).  
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Figure 4:23 VE as diffusion barrier with its chemical structure. VE was loaded using organic 
solvent then precipitated using water to create a barrier that prolong the diffusion pathway of 
the loaded drugs.  
Methanol was used to load 10% MPC hydrogel discs with VE. VE could 
possibly be loaded by three methods; first by loading the discs first with VE followed 
by DOXy, second by loading both VE and DOXy from the same solution and third 
by loading DOXy first followed by VE. Unfortunately each approach has its own 
limitation. For the first approach VE was successfully loaded into 10% MPC 
hydrogel discs. The dried discs were placed in methanol solution of VE (0.1 g/mL, 1 
mL) for 24 hours. After loading the discs were removed from the loading solution 
and placed in 2 mL DW for another 24 hours. The discs were clear after methanol 
loading and were opaque after soaking in water. This indicates that VE was 
precipitated in the hydrogel. However, soaking of VE loaded discs in DOXy solution 
for 24 hours (similar to 10% MPC hydrogel) for loading of DOXy was insufficient to 
load therapeutic dose of DOXy. Longer soaking times (e.g. weeks) will be required. 
DOXy is unstable molecule in aqueous solution and hydrolysed quickly which made 
the approach unsuitable for DOXy loading. 
Loading from the same solution was also considered by soaking dried discs 
of 10% MPC in DOXy and VE methanol solution. The limitation of this approach is 
the inability to calculate the loading of DOXy accurately into the discs. Both UV and 
HPLC cannot be used to estimate loading because the HPLC method for DOXy 
required aqueous buffer which will precipitate the VE inside the HPLC column and 
damage it. UV cannot be used because it cannot separate the readings of both 
VE molecule 
VE loaded in soluble form 
using organic solvent 
VE precipitated with water 
creating diffusion barrier  
Fast pathway for the 
release of loaded drugs  
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molecules. There is also the possibility that VE will occupy the whole space in the 
hydrogel reducing the amount loaded below the required therapeutic level.  
Theoretically loading of DOXy could be performed first followed by loading 
of VE. However, the limitation is that significant amount of the loaded DOXy could 
be lost during loading of VE from methanol solution by diffusing through the 
hydrogel or by the washing step to remove methanol. Due to the limitation of VE 
and the experimental conditions VE was not used as diffusion barrier.          
The aim of DOXy loaded hydrogel was to be used after trachoma surgery. 
The aim was to sustain the release of DOXy for 2 weeks and based on our current 
results the release was sustained for one week using the flow rate of ~2 µL/min, 
which is the aqueous flow in the subconjunctival space. However, the flow in the 
eyelid area is much slower than the subconjunctival space. When implanted in the 
eye lid the low flow will possibly cause slower diffusion of DOXy and slower release. 
It was difficult to measure the release at very low flow rates because of the flow 
chamber design. The space of the flow chamber is 400 µL designed to mimic the 
bleb after GFS and going to flow rate slower than 2 µL /min is going to slowly fill the 
inner space of the flow chamber. The slow filling of the chamber will allow most of 
the loaded drug to be released and gives the wrong estimation on burst effect and 
release profile of the drug. Up to our knowledge there is currently no treatment after 
trachoma surgery in the clinic or in development and the DOXy loaded film could be 
the proper solution to improve success rate after trachoma surgery. 
Summary and conclusions 
The aim of the work described in this chapter was to explore the possibility of using 
10% MPC-HEMA hydrogel films as drug releasing implant in the eyelid for potential 
use after trachoma surgery. DOXy hyclate has been identified as an excellent drug 
candidate to treat patients after trachoma surgery. It was anticipated that DOXy 
loading into the hydrogel would be challenging, but there is a great need to try to 
formulate DOXy for sustained local delivery to the eyelid. Different loading solutions 
and different loading solvents were used to load DOXy into a 1 cm hydrogel disc. 
Loading from DOXy (15 mg/mL) in 1 mL from PBS was found to be a satisfactory 
loading method compared to other concentrations and solvents. The amount loaded 
was 3.6 mg for each disc. Although the loading was high, the release was only 
maintained for less than a week at flow rate of 2 µL/min, which is better than would 
be expected by an injection. 
 β-CD was introduced as affinity barrier to slow the diffusion of DOXy from 
the hydrogel matrix. No compliant film could be formed using an in situ IPN of β-CD 
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and 10% MPC-89.5% HEMA was prepared, incomplete films were produced. 
Although a semi-IPN network could be fabricated using β-CD polymer, the apparent 
high average molecular weight of the polymer could cause batch-to-batch variability 
during synthesis. A hydrogel film with cross-linked β-CD particles embedded in the 
hydrogel matrix was also fabricated. The presence of β-CD particles did not affect 
the SR of the standard 10% MPC films. However, there was no difference in the 
release profile of DOXy with and without β-CD particles. This result implied the β-
CD particles were too densely cross-linked and were insoluble to allow for DOXy 
solubilisation. 
 A new approach was investigated for the synthesis of IPN of β-CD and 10% 
MPC by sequential polymerisation. A hydrogel film was formed and the cross-linked 
β-CD network did not affect the SR of the standard 10% MPC films. However, it 
was also observed that the presence of an IPN did not affect the release profile of 
DOXy from the hydrogel.  
 Currently there is no available treatment after trachoma surgery in the clinic. 
Although the hydrogel film sustained the release of DOXy for one week, the films 
could still be beneficial after trachoma surgery. Since the presence of β-CD did not 
affect the release of DOXy, hydrogel films with 10% MPC are a protential candidate 
for future development as a drug releasing spacer after trachoma surgery. The use 
of both DOXy hyclate for early release in combination with DOXy hydrate within the 
10% MPC-HEMA film may be warranted because the poorly soluble DOXy would 
be released over a sustained period after the acute phase which would be treated 
by the more fast release of the DOXy hyclate.    
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Chapter 5. Hydrogel formulation for the vitreous body 
The possibility of using a hydrogel as a drug implant to help control subconjunctival 
scarring on the eye after surgery was investigated in the work that is described in 
previous chapters. Most blinding eye conditions occur intraocularly at the back of 
the eye (posterior segment) (Bunce & Wormald, 2006; Jonas et al., 2014). Drug 
delivery to the posterior segment is challenging due to the physiological and 
anatomical barriers of the eye (Kang-Mieler et al. 2014). In an aging population, wet 
AMD is one of the main causes of visual impairment for the elderly population. The 
most common treatments available for AMD are anti-vascular endothelial growth 
factor (anti-VEGF) antibody based therapeutics. IVT injections of anti-VEGF 
medicines are often required every 4-8 weeks to slow the progression of wet AMD, 
and these injections may be required for many years or even decades (Ambati & 
Fowler 2012; Abedi et al. 2014; Peden et al. 2015). Multiple IVT injections are 
associated with complications such as inflammation, vitreous haemorrhage and 
retinal detachment. There is significant and real patient discomfort with undergoing 
IVT injections; including a financial burden placed on patients and healthcare 
systems (Falavarjani & Nguyen 2013). New formulations that can prolong the 
duration of action of an injected medicine that results in reduced dosing frequency 
are sought by patients, healthcare professionals and providers.  
Several approaches have been investigated to improve the duration of 
action of IVT injected proteins to better achieve sustained ophthalmic therapy that 
would decrease the number of injections required by patients. Strategies include 
protein PEGylation, and the use of particulates (micro and nanoparticles), gels and 
liposomes were used to increase the duration of action and reduce the frequency of 
dosing (Yu et al. 2014; Fletcher et al. 2016; Xie et al. 2015; Li et al. 2012; Pan et al. 
2011; Pisal et al. 2011). 
Rauck et al were able to sustain the delivery of bevacizumab after IVT 
injection into New Zealand white rabbit eyes using poly(ethylene glycol)-poly-
(serinol hexamethylene urethane) thermoresponsive gels over 9 weeks compared 
to bevacizumab bolus injection. Clinical examination of the rabbit eyes injected with 
the gel for inflammatory response showed no signs of inflammation and the 
intraocular pressure was maintained at baseline during the period of the study. 
Histological examination of the retinal tissues of the rabbit eyes after 10 weeks 
shows no distinguishable morphological differences between the gel injected eyes 
and the control (Rauck et al. 2013). 
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Abrishami et al reported the formation of liposome encapsulated 
bevacizumab for IVT injection. According to their results the concentration of 
bevacizumab on the rabbit eyes after liposome injection was three times higher 
than the therapeutic amount after 42 days and the clearance of the drug from the 
vitreous was slower compared to bevacizumab injection (Abrishami et al. 2009). 
Liposomes have long been studied in a range of applications, but there remain no 
protein based formulations that have been approved.  
Varshochian et al reported the synthesis of albumin-PLGA nanoparticles in 
an effort to extend the residence time of bevacizumab in the vitreous cavity. When 
the nanoparticles were injected into the vitreous of New Zealand albino rabbits the 
calculated half-life of bevacizumab from the nanoparticle was 8.4 days compared to 
5.2 days in the control rabbits that had received injected bevacizumab (Varshochian 
et al. 2015).  
Lovett et al reported that bevacizumab release was sustained for 3 months 
when injected in the vitreous of Dutch belted rabbits in the form of silk fibroin 
hydrogels. During the period of the study no obvious inflammatory or 
biocompatibility problem was observed in the animals. The level of bevacizumab in 
the vitreous after 3 months of gel injection was equivalent to the level detected after 
1 month of bevacizumab only injection which indicates sustained behaviour of the 
gel (Lovett et al. 2015). 
 Although the above discussed examples show promise as sustained 
formulations for protein delivery, there is a limitation regarding the methods used for 
release studies. The release was either studied using animal model (preferably 
rabbits) or in vitro release using test tubes. Animal eyes are anatomically and 
physiologically different from the human eye which may possibly give wrong 
estimation of the release of the protein. Using in vitro test tubes does not represent 
the actual volume of the vitreous or the actual fluid flow in the back of the eye.   
Extensive research has been described to develop methods for the 
sustained delivery of proteins; however no dosage form has been approved in the 
clinic for ocular delivery. One key limitation is the nature of the protein molecule (Fu 
et al. 2000). Proteins are challenging molecules to be formulated into extended 
release dosage forms because proteins must maintain their tertiary folded structure 
to be biologically active. Protein based medicines can also be immunogenic and 
display other toxicities, for example, increased susceptibility to infection as seen 
with anti-TNF antibodies (Ali 2013).  
Protein instability, during and after formulation, is a defining challenge. 
Protein therapeutics display relative long half-life when directly injected into the eye. 
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For example, the half-life of IVT ranibizumab (~40 kDa, 0.5 mg) and bevacizumab 
(~150 kDa, 1.25 mg) is approximately 6.7-10.0 days and 7-11 days in humans 
respectively (Krohne et al. 2008; Meyer et al. 2011; Zhu et al. 2008; Beer et al. 
2006; Krohne et al. 2012).   
Unfortunately IVT injection is still required every 4-6 weeks. Aflibercept 
(molecular weight 110 kDa) is a Fc fusion protein that is also targeted to VEGF. 
This medicine is given in a 2 mg dose which is approximately a 1.8 molar 
equivalent compared to the ranibizumab dose.  The increased amount of aflibercept 
in a 50 µL IVT injection allows this medicine to be given every 6-8 weeks whereas 
ranibizumab must be given monthly. Aflibercept is by far the most preferred IVT 
anti-VEGF because it can be dosed less frequently than ranibizumab. If a 
formulation for an anti-VEGF medicine could be developed that would allow dose 
once every 3 or 4 months, there would be much interest.  
Manufacturing processes are also important to preserve the activity of the 
proteins. Proteins are liable to unfolding and deactivation when subjected to organic 
solvents or harsh preparation conditions, which is often necessary when 
considering the formulation of proteins with some clinically used polymers, such as 
poly(lactic co glycolic) acid (PLGA) (Mohammadi-Samani & Taghipour 2014). Even 
successful loading of PLGA particles with proteins could be followed by phase 
separation due to the difference in solubility of PLGA (water insoluble) and the 
protein (water soluble). It is preferred to prepare protein dosage forms in aqueous 
environment to preserve the activity of the protein.  
Hydrogels have developed as an interesting field for the possible sustained 
delivery of proteins. Hydrogels are capable of imbibing a amount of high water 
content and are reported to be biocompatible. Many hydrogel systems that have 
been described do not require organic solvents during preparation (Shi et al. 2013; 
Stile et al. 1999; Vermonden et al. 2012). Proteins are also subjected to 
degradation by proteases and the entrapment of proteins inside a hydrogel network 
would be expected to protect the therapeutic protein from proteolytic degradation 
and while prolong its duration of action (van de Weert et al. 2005). It is also possible 
to consider hydrogels with a low cross-link density to allow formulation in the form 
of injectable solutions. If the composition of the hydrogel includes a stimuli 
responsive polymer that can collapse, it is possible to have an injectable solution 
that upon a stimulus would solidify to become an implant. Thermoresponsive 
hydrogels potentially offer the advantage of injectable implant to extend the release 
of a loaded protein (Klouda 2015).  
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Thermoresponsive hydrogels change their conformation with temperature, 
often collapsing from an open solubilised, water associated structure to a more 
dense, collapsed and insoluble form. The so called sol-to-gel transition changes the 
swelling and pore size of the hydrogel. In the soluble form, the hydrogel is soft, fully 
swollen with water and can pass freely through a small needle. At a temperature 
known as the volume phase transition temperature (VPTT), the polymer can 
deswell and collapse forming a viscoelastic implant (Huynh et al. 2011). The 
thermal responsiveness in these hydrogels is regulated by the balance between 
hydrophilic and hydrophobic interactions between the polymer chains and their 
surroundings (Stewart et al. 2011). 
One of the most widely investigated thermoresponsive polymers is poly(N-
isopropylacylamide) (NIPAAm) which can be made in the presence of a cross-linker 
to give a hydrogel. NIPAAm hydrogels are swollen in water below a VPTT of ~33oC. 
As the temperature rises about ~33oC many NIPAAm hydrogels then collapse and 
deswell pushing the water out of the hydrogel network (Stile et al. 1999; Lue et al. 
2011; Schild 1992). The preparation of NIPAAm hydrogels can be conducted in 
aqueous solution avoiding organic solvents, which is advantageous for protein 
delivery. The swollen hydrogel has a relatively large pore sizes which allow the drug 
to be released quickly at room temperature. Once injected and collapsed inside the 
human body the drug molecules will be entrapped inside the hydrogel structure 
potentially creating a depot and the pore size between polymer chains will be 
reduced which will slow protein diffusion from the hydrogel (Drapala et al. 2011). As 
previously discussed in Chapter 1 the characteristics and physical properties of 
NIPAAm hydrogels (e.g. VPTT) can be influenced by co-monomer, cross-linker type 
and the synthetic process (e.g. initiator and cross-linker stoichiometry) (Obeso-Vera 
et al. 2013; Yildiz et al. 2006). In the case of proteins, the use of a hydrophilic 
cross-linker could create a hydrophilic environment around the loaded protein that 
helps to preserve its stability and activity during formulation and use.  
Developing and comparing new formulations for IVT protein injections 
require a proper in vitro model that mimics the eye in terms of aqueous flow. One of 
the problems facing the preclinical development of ophthalmic IVT protein 
formulation is the lack of proper in vitro ocular flow model. The main route for 
elimination of a protein from the vitreous after injection is through aqueous outflow 
into the anterior chamber (Krohne et al. 2008; El Sanharawi et al. 2010). Proteins 
are large, charged molecules, so do not readily permeate through the retina as do 
low molecular weigh molecules such as steroids. In vitro models to study 
elimination of proteins through the anterior route are very limited and do not allow 
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proper examination of the clearance of proteins in a similar way to the human eye. 
Most research in preclinical development is conducted either through animal 
studies or other in vitro dissolution models. Animal studies are expensive.  Animal 
eyes are anatomically different from human eyes (in terms of volume of the vitreous 
and aqueous flow rates) and carry the risk of developing antidrug antibodies 
(ADAs). ADAs accelerate the clearance of the protein resulting in inaccurate 
estimations of clearance and half-life values in the vitreous (Shankar et al. 2006; 
Chirmule et al. 2012).  
Different in vitro techniques were described to evaluate IVT ophthalmic 
preparations including the use of computational modelling of the eye, permeation 
models and USP dissolution apparatus (Westebbe et al. 2013; Missel 2002; 
Durairaj et al. 2009). These models are rough and do not reflect the human eyes in 
terms of volume, scale and rate and direction of the aqueous flow. For example the 
USP dissolution apparatus used had a flow rate of 1.5 mL/min in a chamber of 8-19 
mL which is different from the flow rate of 2.0 µL/min and the vitreous volume which 
is 3.5-9 mL (Fotaki 2011). Another example is the use of single compartment non-
flow model to evaluate distribution in the vitreous by mimicking saccades eye 
movement (Repetto et al. 2005).     
To address these issues and to accelerate preclinical studies, our group has 
recently developed a 2-compartment, aqueous flow model called the PK-Eye to be 
used for ocular drug development. The model has been shown to estimate the 
human clearance times of proteins from the vitreous body (Awwad et al. 2015). The 
PK-Eye was used to study the release profile and half-life of injectable 
bevacizumab and injectable NIPAAm hydrogels loaded with bevacizumab and 
infliximab for comparison. 
Hypothesis and aims 
An ideal sustained delivery system for proteins in the vitreous should be (i) 
injectable, (ii) biocompatible, (iii) maintain both physical and chemical stability of the 
encapsulated protein during formulation and its stability over the period of the 
release, and (iv) maintain the level of the protein within the therapeutic 
concentration. Thermoresponsive injectable hydrogels could be used as a potential 
delivery system for proteins due to the properties related to biocompatibility, 
injectability and mild preparation conditions.  
It is hypothesised that the properties of a thermoresponsive NIPAAm 
hydrogel can be mediated by varying cross-linker stoichiometry and structure. The 
aim of this chapter was to examine formulations that could be the basis to develop 
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an injectable extended release thermoresponsive NIPAAm hydrogel for 
bevacizumab delivery. Three different hydrophilic, macromolecular cross-linkers of 
varying molecular weight (PEGDA, PC 3059 and acrylated HA) were examined. 
The use of macromolecular cross-linker may allow the formation of aqueous 
environment around the protein that may help in the mixing process and help with 
maintaining protein stability. Another possible advantage of using macromolecular 
cross-linker is creating an extra diffusion barrier to the protein encapsulated inside 
the hydrogel.   
The hydrogels were synthesised and then characterised in respect to VPTT, 
swelling ratio (SR), percentage water retention (WR%) and structure. The 
characterisation of the hydrogels formed the basis of a screening process to identify 
a possible formulation that will potentially extend the release of the protein in the 
vitreous. The release of bevacizumab was then studied using a specialised PK-Eye 
model that mimics protein clearance from the posterior segment.   
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Results and discussion  
Preparation of NIPAAm hydrogels using PEGDA-700 
NIPAAm hydrogels were prepared with different amounts of polyethylene glycol 
diacrylate PEGDA (Mn 700) by free radical polymerisation. Since these hydrogels 
are intended for protein delivery, it was important to create an aqueous environment 
surrounding the protein during synthesis and delivery. PEGDA was chosen as 
cross-linker because of its hydrophilic nature that attracts large amount of water 
molecules around the polymer chains creating an aqueous environment and human 
biocompatibility when cross-linked into hydrogels (Li et al. 2014). NIPAAm 
hydrogels made with PEGDA (Mn 575) was reported to have minimal effect on 
retinal function when administered as IVT injection in rats (Turturro et al. 2011).  
The high amount of water in the hydrogel matrix improves biocompatibility 
but also associated with burst release effect. Burst release can be of an advantage 
as initial loading dose; however the duration of release could be compromised and 
the possibility of dose related side effects could be increased. Optimisation of the 
formulation to have sufficient amount of water for biocompatibility and at the same 
time controlling release is important and could be achieved by controlling 
formulations parameters; in particular cross-linking density.   
Four different NIPAAM hydrogels were prepared with increasing PEGDA 
stoichiometries i.e. 2, 4, 8, 12 and 15 µL. The prepared hydrogels were screened to 
observe the effect of cross-linker on the physicochemical properties of the prepared 
hydrogels in order to identify the best formulation for protein delivery. Different 
mixtures of monomers were prepared by dissolving equal amounts of NIPAAm (40 
mg) monomers and ammonium persulfate (APS) (4 mg) with different amounts of 
PEGDA in 1 mL DW prior to polymerisation. Before the addition of TEMED (20 µL) 
the reaction mixture was in liquid form. Polymerisation was initiated by the addition 
of TEMED. Hydrogel formation was observed approximately after one minute. The 
mixture became viscous and no free movement was observed indicating the 
formation of the hydrogel (Figure 5:1). All or large percentage of the liquid monomer 
mixture was thought to be converted into a hydrogel since there was no free flowing 
liquid remained in the glass vial. The reaction mixture was allowed to polymerise at 
4oC for 24 hours. PEGDA amount below 4 µL displayed a free-flowing liquid even 
after the addition of TEMED. Therefore, 4 µL was the minimum amount of cross-
linker required for the formation of a hydrogel.  
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Figure 5:1 The chemical structure of the starting materials for NIPAAm hydrogel formulation 
and the hydrogels formed. NIPAAm hydrogels were prepared with different percentages of 
PEGDA as cross-linker by free radical polymerisation at 4
o
C for 24 hours. In the above 
picture the free flowing monomer mixture of PEGDA-700, NIPAAm and APS was converted 
into a viscous hydrogel by the addition of TEMED at room temperature.   
Hydrogels that were prepared with 4 and 8 µL of PEGDA were transparent 
in colour, whereas hydrogels with 12 and 15 µL were opaque. Increased cross-
linking density due to the addition of increasing PEGDA resulted in less soluble 
hydrogels, which was indicated by the reduction in transparency of the formed 
hydrogels (Figure 5:2A). SEM results displayed a more compact hydrogel structure 
with increased cross-linker percentage, which is consistent with the formation of 
denser hydrogels (Figure 5:2B). The cross-linker acts as junction point (cross-
linking point) that brings the polymer chains together and reduces the mobility of the 
polymer chains.  
 
NIPAAm 
PEGDA-700 
 
NIPAAm hydrogel 
TEMED 
APS 
TEMED 
Mixture of PEGDA-700, NIPAAm 
monomers, APS in water 
NIPAAm hydrogel 
(4oC/24 h) 
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Figure 5:2 A) Picture of the prepared NIPAAm hydrogels showing a decrease in 
transparency with increasing cross-linker amounts. Hydrogels made with 12 and 15 µL 
PEGDA were opaque compared to transparent hydrogels made with 4 and 8 µL; B) SEM 
images of NIPAAm hydrogels prepared with different amounts of PEGDA cross-linker. More 
compact structure was observed with increasing cross-linker amount. The scale bar is 100 
µm. 
An important criterion to consider for IVT injections is the ability of a 
hydrogel to pass easily through a small needle without undue back pressure. The 
injectability of each hydrogel was qualitatively evaluated by passing the contents 
through a 23G needle (Table 5:1). The hydrogel was loaded into a 2.5 mL syringe 
by first removing the plunger of the syringe and placing the hydrogel inside the 
syringe with a spatula. After loading of the hydrogel into the syringe body the 
plunger returned into the syringe. Hydrogels made with 4 µL and 8 µL of the 
PEGDA cross-linker were easily injectable. Hydrogels with 12 µL of the cross-linker 
could be injected only with extra pressure while 15 µL hydrogels were not 
injectable. Passing the hydrogel through a small needle did not break the hydrogel 
and the hydrogel remain intact after injection. Hydrogels with 4 and 8 µL PEGDA 
allowed higher mobility of the polymer chains, which are similar to fluids and 
allowed them to be freely injected through small needle. 
 
 
(B) 
(A) 
100 µm 100 µm 100 µm 
4 µL 8 µL 12 µL 15 µL 
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Table 5:1 The qualitative determination of injectability of NIPAAm hydrogels formulated with 
different amounts of PEGDA using 23G needle.   
PEGDA amount Injectability 
4 µL Easy 
8 µL Easy 
12 µL Difficult 
15 µL Non-injectable 
 
Measuring the viscosity of the prepared hydrogels was considered to relate 
the viscosity and injectability of the hydrogels. However, there were difficulties to do 
the experiment in the facilities available at UCL School of Pharmacy. In order for 
the hydrogel to be examined by the rheometer available, the hydrogel needs to be 
completely soluble in water. NIPAAm hydrogels cannot be dissolved in water so the 
hydrogels cannot be tested using the available rheometer.       
Hydrogel characterisation 
There was a need to determine the effect of cross-link density on the 
thermoresponsiveness of the hydrogels. Drapala et al reported an increase in VPTT 
and SR at 25oC of NIPAAm hydrogels with increased amounts of PEGDA (Mn 575) 
(Drapala et al. 2011). The VPTT, SR and WR% were determined for the 4 prepared 
hydrogels to better understand the effects of the different cross-link densities. Three 
batches (n=3) for each type of cross-linker were prepared for the characterisation of 
the hydrogels.  
Effects of different percent incorporation of cross-linker on VPTT 
An important factor for biomedical thermoresponsive hydrogels is that the VPTT is 
often desired to be lower than the physiological body temperature (~37oC). The 
VPTT was determined by DSC to correlate changes with cross-link density. 
Hydrophilic interactions predominate at temperatures below the VPTT due to the 
formation of more strong non-covalent interactions such as hydrogen bonds 
between water and the hydrogel polymer matrix. The collective interactions of 
polymer and water are greater than polymer-polymer interactions, so the polymer 
remains in solution. When the temperature is increased above the VPTT, non-
covalent hydrophobic interactions dominate between polymer chains. Water-
polymer interactions, in particular hydrogen bonds, become less dominant so the 
polymer becomes less soluble. At the VPTT, the hydrophobic interactions of the 
isopropyl pendant groups of NIPAAm cross-linked chains become stronger than the 
hydrogen bonds between the amide pendant groups and the surrounding water 
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molecules (Zhang et al. 2003). The internal volume of the polymer decreases as the 
polymer begins to collapse onto itself. Polymer-polymer chain interactions will 
continue to increase until the polymer precipitates and the hydrogel is transitioned 
from a swollen to deswollen (collapsed) form resulting in a reduced internal volume 
(Yıldız et al. 2002; Sato Matsuo & Tanaka 1988).  
It was previously reported that the VPTT of NIPAAm hydrogels is ~33oC 
(Schild 1992). The onset temperature of the DSC endothermic peak was 
considered as the VPTT. The endothermic peak increased to a slightly higher 
temperature with an increasing amount of cross-linker (Figure 5:3). The VPTTs 
were 34.3 ± 0.1, 35.5 ± 0.1, 35.6 ± 0.4, and 36.2 ± 0.2oC as the PEGDA cross-linker 
was increased from 4 to 15 µL respectively. The sharpness of the endothermic 
peak was reduced with increasing amounts of cross-linker indicating a reduction in 
the thermal responsiveness of the hydrogel. 
 
Figure 5:3 DSC graph representing volume phase transition temperature (VPTT) of 
NIPAAm hydrogels with varying PEGDA concentrations. The onset temperature of the DSC 
endothermic peak was considered as the VPTT. It was observed that there was a shift in 
endothermic peak to a higher value with increasing amount of cross-linker. The VPTT were 
34.3 ± 0.1, 35.5 ± 0.1, 35.6 ± 0.4, and 36.2 ± 0.2
o
C for 4, 8, 12 and 15 µL respectively.  
 
 
 
 
36.2oC 
Onset temperature 
34.3oC 
35.5oC 
35.6oC 
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The mechanism of VPTT can also be explained thermodynamically by 
Gibbs energy of the system in which ΔG represents the change in free energy, ΔH 
represents the change in enthalpy, ΔS represents the change in entropy at T 
temperature. 
ΔG=ΔH−TΔS 
 
At temperatures below VPTT there is large number of hydrogen bonds that 
helps in keeping the polymer matrix in the dissolved (swelled) form favouring the 
enthalpy of dissolution. When the temperature increases the enthalpy of the system 
will be reduced and the entropy will be increased. The hydrogen bonds becomes 
weak and phase separation occur which is characterised by the collapsing of the 
hydrogel (Alarcón et al. 2005). Alteration of the number of hydrogen bonds in the 
polymer matrix can shift the VPTT (Lutz, J. F. 2008). PEGDA is a moderately large 
molecular weight cross-linker that is hydrophilic. PEGDA has an oxygen molecule in 
each repeat unit, so PEGDA can form hydrogen bonds with water molecules. 
Higher energy will be required to thermodynamically disturb the system when 
higher level of PEGDA present in the formulation which explains the increase in 
VPTT when the PEGDA level increased. 
Cross-linker effects on hydrogel swelling ratio (SR) and water content  
The SR is used to describe the swelling capacity of a hydrogel when at equilibrium 
within the surrounding media. An increase in weight of the hydrogel is observed due 
to water imbibing into the dry hydrogel matrix. It can also be used to estimate the 
water content in a fully swollen (room temperature) and deswollen 
thermoresponsive hydrogel (body temperature) (Park & Hoffman 1994). The SRs of 
the NIPAAm-PEGDA cross-linked hydrogels prepared were measured at 25, 37 
and 48oC (Table 5:2). There was a significant decrease (p<0.05) in the SR for all 
the hydrogels when the temperature was increased from 25 to 37oC. 
Table 5:2 The SR of NIPAAm hydrogels prepared with different percentages of PEGDA as 
cross-linker at three different temperatures (25, 37 and 48
o
C).  
 
Temperature 
SR 
4 µL 8 µL 12 µL 15 µL 
25oC 47.8 ± 11.6 34 ± 2 24.8 ± 0.1 14.9 ± 1.1 
37oC 1.4 ± 0.5 3.2 ± 0.8 7.5 ± 0.7 9.6 ± 1.6 
48oC 0.8 ± 0.3 1.1 ± 0.3 1.9 ± 0.2 3.7 ± 0.4 
 
When the SR is measured at a temperature below the VPTT (25°C), the 
hydrogel is more soluble with more internal water due to the hydrogen bonds 
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between the hydrophilic groups on the polymer chains and water. A hydration shell 
is formed around the hydrophobic groups further leading to more water uptake. All 
of the NIPAAM hydrogels retain a larger amount of water at 25oC compared to 
37oC. At 25oC, the SR was the highest with 4 µL cross-linker and dropped with 
increased amounts of PEGDA. With higher cross-link density, the mobility of the 
polymer chains forming the hydrogel matrix will be reduced and hydrogels with 
small pore size and compact structure will be formed. Increased cross-link density 
causes a reduction in hydrogel swelling with increased cross-linker percentage. 
PEGDA amount of 4 µL was not significantly different from 8 µL (p>0.05); however 
it was significantly different (p<0.05) from 12 and 15 µL hydrogels (Figure 5:4A). 
When the temperature increased above the VPTT (37oC), all the collapsed polymer 
hydrogels displayed a much lower SR (Table 5:2). When a hydrogel collapsed, 
large amount of the water inside the hydrogel was pushed out and small amount of 
water remained entrapped inside the hydrogel.    
Drapala et al reported that the SR of different NIPAAm hydrogels with 
different amounts of PEGDA (Mn 575) at 37oC was independant on the cross-linker 
amount (Drapala et al. 2011). Based on that it was thought that the SR at 37 and 
48oC would not be affected by the increase in the amount of cross-linker used and 
all the hydrogels will behave in the same manner above the VPTT of the hydrogel; 
however when the temperature was increased above VPTT, the SR increased with 
increasing cross-linker amount (Figure 5:4A). Although all the hydrogels prepared 
were able to collapse and deswell when the temperature increased from 25oC to 
37oC the degree of collapse was different and dependant on the cross-linker 
amount. At 37oC and 48oC there was no significant difference (p>0.05) in SR 
between 4 and 8 µL, but there was a significant difference between 4, 12 and 15 µL 
(p<0.05). In contrast to what Drapala et al reported it was found that in our system 
PEGDA when present in a higher amount (12 and 15 µL) would reduce the 
thermoresponsiveness and the ability of the hydrogel to collapse. The incomplete 
collapse of the hydrogels will allow more water to be entrapped compared to 
hydrogels made with 4 and 8 µL, which may influence the release of the entrapped 
protein. The visual difference in swelling of the hydrogels at 25 and 37oC is 
presented in (Figure 5:4B).where the hydrogels appeared transparent at 25oC and 
opaque at 37oC.   
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Figure 5:4 A) A graph representing the SR of NIPAAm hydrogels prepared with different 
percentages of PEGDA as cross-linker at three different temperatures (25, 37 and 48
o
C). At 
25
o
C the SR of 4 µL hydrogel was not significantly different from 8 µL (p>0.05); however it 
was significantly different (p<0.05) from 12 and 15 µL. At 37
o
C and 48
o
C there was no 
significant difference (p>0.05) in SR between 4 and 8 µL, but there was a significant 
difference between 4, 12 and 15 µL (p<0.05); B) Pictures of the hydrogels showing the 
visual difference in swelling of the hydrogels at 25 and 37
o
C. Hydrogels at 25
o
C were 
transparent but turned opaque when the temperature increased to 37
o
C.  
 
 
(A) 
(B) 
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Effect of percentage cross-linker on water retention percent (WR%)  
WR is the weight of water retained inside a hydrogel above the VPTT versus the 
weight of the initially absorbed water before hydrogel collapse. The WR% gives an 
indication of how much water will be entrapped inside the hydrogel after collapse. 
Water retention characterises the change in volume and the time required to 
achieve that change when the temperature increases above the VPTT of the 
hydrogel. Hydrogels that take a longer time to collapse will allow some of the 
encapsulated drug to diffused into the surroundings and reduce the amount of drug 
entrapped during collapse. Also the degree of collapse of a hydrogel is important. 
Hydrogels that completely collapse and retain small amount of water in the 
collapsed inner structure risk losing large amount of the entrapped drug. The drug 
will be expelled with the expelled water resulting in a low entrapment and high initial 
burst release, which will affect the release profile of the encapsulated drug.  
The effect of increasing the amount of cross-linker on WR% was measured 
(Figure 5:5). The thermal responsiveness of the lowest cross-linked NIPAAM 
hydrogels (4 µL PEGDA) was faster compared to more highly cross-linked 
hydrogels (8-15 µL PEGDA). With increased amounts of PEGDA, the NIPAAM 
hydrogels became less responsive to temperature changes while encapsulating a 
higher amount of water in after collapse. A significant difference in WR% was seen 
between the lowest cross-linked hydrogel (4 µL PEGDA) compared to the higher 
two cross-linked hydrogels (12 and 15 µL PEGDA). There was no significant 
difference in WR% (p>0.05) between the two lower cross-linked dense hydrogels (4 
and 8 µL PEGDA). The difference in WR% between the hydrogels suggests that 
hydrogels with lower percentage of cross-linker may control the diffusion of the drug 
from the collapsed hydrogel in a more controlled manner compared to hydrogels 
with higher percentages of cross-linker.  
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Figure 5:5 A graph representing the water retention percent (WR%) of NIPAAm hydrogels 
prepared with various percentages of PEGDA as cross-linker. There was no significant 
difference in WR% (p>0.05) between 4 and 8 µL hydrogels; however here was a significant 
difference (p<0.05) when 4 µL was compared to 12 and 15 µL hydrogels.  
In thermoresponsive hydrogels drug diffusion is a two stage process; initial 
burst release followed by a slow extended release of encapsulated drugs. During a 
collapse of a thermoresponsive hydrogel, large amounts of water will be expelled 
causing the initial burst release and reducing the inner volume of the hydrogel. The 
initial burst release results in a proportion of entrapped drug into the collapsed 
hydrogel matrix creating a depot surrounded by a skin like layer at the interface 
between the hydrogel surfaces. The surrounding media that acts as a controlling 
mechanism for the release of the remained drug (Schild 1992). The entrapped drug 
will diffuse slowly through the interface. Several factors will control the diffusion of 
encapsulated drug in a thermoresponsive hydrogels; volume of water entrapped, 
the solubility of the drug in water and the MW of the drug (Varshosaz & Hajian 
2004). Proteins are soluble in water so it was suggested that when high amount of 
water entrapped in the hydrogel matrix after collapse, the fraction of protein soluble 
will increase and faster release will be observed.  
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In vitro release of antibody from NIPAAm hydrogels using the PK-Eye  
Protein loading into a hydrogel could be achieved through several methods such as 
soaking (imbibing), cross-linking, two phase partitioning and in situ polymerisation,  
(Bromberg & Ron 1998; Kim et al. 1992). Proteins, such as bevacizumab with a 
molecular weight of 150 KDa, are large molecules and simple imbibing of the dry 
hydrogel into the protein solution for loading may result in low loading effeciency 
(He et al. 2016). When the loading of ovalbumin into dextran hydrogel by imbibng 
was studied, only 9% (w/w) of the protein from the loading solution was loaded into 
the hydrogel (Gehrke et al. 1998). Theortically, the problem of low loading 
effeciency could be avoided by repeated cycles of swelling and drying of the 
hydrogel in the loading solution; however the approach is difficult with proteins 
because of the possibility of protein denaturation and aggregation by repeated 
drying (Frokjaer & Otzen 2005).   
Cross-linking of a polymer in the presence of the protein could also be used 
for protein loading. The protein need to be thouroughly mixed with the polymer 
before cross-linking; however it is difficult to achieve homogenous mixing with 
macromolecules and there is a possibility that the cross-linker used could interact 
with the protein itself instead of the polymer (Bromberg & Ron 1998). 
Two phase partitioning involves the partitioning of the protein from polymer 
solution into the hydrogel. The protein should have low solubility in the polymer 
solution compared to the hydrogel matrix (Bromberg & Ron 1998). High loading of 
dextran gels with BSA was achieved by partitioning of BSA from PEG polymer 
solution (low affinity with BSA) into the dextran gel phase (High affinity with BSA)   
(Gehrke et al. 1991). 
In situ polymerisation is preferred for efficient protein loading compared to 
other methods. Polymerising the protein in the presence of monomers and cross-
linker allows the entrapment of the protein within the hydrogel matrix and could 
result in higher protein encapsulation. The polymerisation proces can result in 
better entanglement of the protein within the polymer matrix due to proper mixing of 
the protein with the small monomers (Leach & Schmidt 2005). When using in situ 
polymerisation it is important to consider polymerisation processes that would not 
be detrimental to the stability of protein. For our work, it is hypothesised that the 
combination of NIPAAm polymerisation in aqueous enviroment and at 4oC will 
maintain the stability of protein.  
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Both methods of imbibing and polymerising in the presence of bevacizumab 
were used and compared for NIPAAm hydrogel loading. In the imbibing method, 8 
µL PEGDA hydrogel was formulated. After the polymerisation, the hydrogel was 
freeze-dried for 3 days. The freeze-dried NIPAAm hydrogel was soaked in 1 mL of 
bevacizumab solution (12.5 mg/mL in PBS). The hydrogel was incubated for 48 hr 
at 4oC (Figure 5:6). After incubation, the hydrogels were removed from the 
incubation solution and then rinsed gently 5 times, 4 mL each time in PBS; each 
wash was 15 minutes long. Each wash fraction was analysed by HPLC to calculate 
how much of the protein was lost during the wash; it was calculated to be ~28% 
(~3.5 mg). The drug loading was the difference between the starting solution and 
the amount lost during washing. Bevacizumab final loading was 72.3 ± 6.6% (~9 
mg). In the in situ method, the polymerisation reaction of the hydrogel was 
performed in 1 mL protein solution (25 mg/mL) instead of 1 mL DW. The 
encapsulation was 100%. A hydrogel was formed similar to the one made without 
the protein with no signs of heterogeneity or precipitation.  
 
 
 
 
 
 
Figure 5:6 Schematic representation of the preparation of bevacizumab loaded NIPAAm 
hydrogels through imbibing and mixing methods. Through imbibing a portion of the protein is 
loaded into the hydrogel matrix while using mixing all the protein in the mixture entrapped in 
the hydrogel.  
The release of bevacizumab from the hydrogels was compared to its 
injection form: (i) 100 µL of NIPAAM hydrogel prepared by mixing, (ii) 250 µL of 
NIPAAm hydrogels prepared by imbibing and (iii) 100 µL injection (all equivalent to 
2.5 mg bevacizumab). All the formulations were injected into the posterior part of 
the PK-Eye model at 37oC (Figure 5:7). The release profile of bevacizumab from 
the NIPAAm hydrogel prepared by imbibing was similar to its injection form; there 
was no significant difference (p>0.05) in the half-life which was 1.9 ± 0.3 days and 
2.3 ± 0.8 for the hydrogel and the injection respectively. However, the hydrogel 
Mixing Imbibing 
Bevacizumab PEGDA 
NIPAAm 
monomer 
NIPAAm 
Hydrogel 
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prepared by in situ polymerising showed an extended release profile. The half-life of 
bevacizumab was 3.7 ± 1.2 days. The large size of the protein allowed better 
entanglement during polymerisation compared to the imbibing method.  
The in situ method was used to prepare hydrogels with different PEGDA 
stochiometries i.e. 4, 8 and 12 µL. The clinical dose of bevacizumab is (1.25 mg, 50 
µL). In previous work with the PK-Eye model, the in vitro half-life of bevacizumab 
(1.25 mg, 50 µL) was reported to be 1.2 ± 0.1 days and the half-life of 2.5 mg of 
bevacizumab in PBS was 2.3 ± 0.8 days (Awwad et al. 2015). The PK-Eye was 
used to study the release of the four prepared samples of bevacizumab loaded 
hydrogels. The injection of bevacizumab solution (2.5 mg, 100 µL) and 
bevacizumab loaded hydrogels (4 µL. 8 µL and 12 µL) (2.5 mg, 100 µL) were 
investigated after injection in the posterior cavity of the model. After polymerisation, 
no effort was made to remove the unreacted monomer by washing as it was 
important to first determine if there was an extended release profile compared to 
bevacizumab alone.  
 
 
Figure 5:7 A graph representing the release of bevacizumab after injecting 100 µL of 
NIPAAM hydrogel prepared by mixing, 250 µL of NIPAAm hydrogels prepared by imbibing 
and 100 µL injection (all equivalent to 2.5 mg bevacizumab) into the PK-Eye. There was no 
significant difference (p>0.05) in the half-life of bevacizumab from the injection and imbibing 
method, the half-life was 1.9 ± 0.3 days.  
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A half-life of 2.0 ± 0.01, 3.7 ± 1.2 and 2.60 ± 0.03 days was observed with 4, 
8 and 12 µL PEGDA respectively with a protein release of ~74%, ~87% and 95% 
respectively after a month (Table 5:3). The release of bevacizumab was studied for 
one month to compare it with the monthly injection administered in the clinic. After 
10 days ~61.9 ± 3.6%, 63.2 ± 8.3% and 75.0 ± 1.9% of bevacizumab was released 
from 4, 8 and 12 μL PEGDA respectively and this is in contrast with the injection of 
the free antibody which was nearly cleared within 10 days with about 95.1% ± 3.1 of 
the injected dose having been released. There was no significant difference in 
release (p>0.05) between 4 and 8 µL PEGDA but there was a significant difference 
when compared to 12 µL PEGDA (p<0.05). Bevacizumab was released faster from 
12 µL PEGDA hydrogels. 
Table 5:3 Summary of in vitro bevacizumab release from the PK-Eye. Bevacizumab (2.5 
mg, 100 µL) injection and NIPAAm hydrogels of bevacizumab (2.5 mg, 100 µL) made with 
PEGDA (4 µL. 8 µL and 12 µL) were injected via the injection port of PK-Eye model.  
Bevacizumab 
Rate constant 
(d1) 
Half-life 
(days) 
Drug released (%) 
after one month 
(2.5 mg, 100 µL) injection 0.32 ± 0.09 2.3 ± 0.8 95.1 ± 3.1 
(2.5 mg, 100 µL) 4 µL 0.350 ± 0.002 2.0 ± 0.01 74.2 ± 0.3 
(2.5 mg, 100 µL) 8 µL 0.20 ± 0.06 3.7 ± 1.2 87.6 ± 6.4 
(2.5 mg, 100 µL) 12 µL 0.270 ± 0.003 2.60 ± 0.03 95.8 ± 2.2 
     Abbreviations: k: rate constant. 
 
The release of bevacizumab followed a bimodal display profile from the 
NIPAAM hydrogels (Figure 5:8A), whereas the free antibody followed a first order 
kinetic profile. All three hydrogels showed a burst release after a week followed by 
a decrease in protein concentration with time. The burst release is thought to be a 
result of the immediate collapse of the hydrogel at 37oC. After a week, the profile 
was close to zero-order kinetics, which is characterised by a constant release with 
time (Figure 5:8B).  
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Figure 5:8 The release profile of Bevacizumab (2.5 mg) injection and NIPAAm hydrogels 
made with different amounts of PEGDA (4, 8 and 12 µL) in PBS, pH 7.4 with half-life values 
of 2.01 ± 0.01 days, 3.66 ± 1.21 days and 2.55 ± 0.03 days respectively for (4, 8 and 12 µL) 
respectively.   
Protein release rate is controlled by (i) the initial burst release during 
collapsing of the hydrogel above VPTT, (ii) the pore size of the hydrogel formed 
after collapse and (iii) the amount of water retained in the hydrogel structure after 
collapse. Antibody release which occurs upon hydrogel collapse will cause a burst 
release. Once the hydrogel collapses, the pore size within the hydrogel would be 
expected to be less than when the hydrogel is swollen with water. The remaining 
protein would then be expected to be entrapped within the collapsed hydrogel 
resulting in a more sustained release profile. There will also be less entrapped 
water with a higher relative amount of bound water which could further slow the 
diffusion of the protein through the hydrogel. Increased cross-link density appeared 
to give a higher burst with little difference in the rate of release for the entrapped 
fraction (Figure 5.8). Burst release is expected with thermoresponsive hydrogels 
due to the expulsion of water during collapsing at VPTT. Derwent and Mieler 
reported an immediate burst release of BSA and IgG from NIPAAm hydrogels made 
with different amounts of PEGDA-575 as cross-linker. The different amounts of 
cross-linker used had no effect on the burst release (Kang Derwent & Mieler 2008).  
(A) 
(B) 
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NIPAAm hydrogels made with 4 and 8 μL PEGDA showed similar 
characteristics, behaviour and sustained the release of protein to the same extent in 
vitro. At 25oC the SR of 4 µL is higher than 8 µL, which may cause the loss of 
higher percentage of the protein during washing. Washing is required to remove the 
unreacted monomers from the hydrogel before injection. Also hydrogels made with 
4 µL is very soft and difficult to handle. Based on these observations 8 µL PEGDA 
was chosen as the best formulation to sustain the release of bevacizumab in the 
posterior segment.  
Effect of protein on the physical properties of the loaded hydrogels 
Encapsulating or entangling a large molecule during the polymerisation process 
when formulating a hydrogel may affect the physical properties of the prepared 
hydrogels. A more macroporous and hetrogenous network structure of cross-linked 
NIPAAm hydrogel is expected when the hydrogel is prepared in the presence of a 
large molecule to be entrapped. Zhang et al reported that a macroporous NIPAAm 
hydrogel was prepared when polymerised in the presence of PEG. SEM images 
demonstrated larger pores in the hydrogel matrix when the MW of PEG increased 
from 300 to 2000 and the SR at 25oC was also increased (Zhang et al. 2001).  
The physical properties of the 8 µL PEGDA cross-linked NIPAAm hydrogels 
polymerised in the presence of bevacizumab were evaluated. The protein loaded 
hydrogels were characterised regarding VPTT, SR and WR%. VPTT shifted from 
35.5 ± 0.1oC for the empty hydrogel to a lower value of 34.2 ± 0.5oC for the 
bevacizumab loaded hydrogels, which was still well below the physiological 
temperature (Figure 5:9). Proteins will compete with water molecules to occupy the 
internal volume of a hydrogel and less water will be entrapped resulting in reduced 
formation of hydrophilic bonds. Less energy (which indicates lower VPTT) will be 
required for the hydrophobic interactions to predominate over the hydrophilic ones. 
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Figure 5:9 DSC graph on the effect of the protein on VPTT of 8 µL NIPAAm hydrogel. The 
VPTT shifted from 35.5 ± 0.1
o
C for the unloaded hydrogel to 34.2 ± 0.5
o
C when 
bevacizumab was loaded.  
The SR of bevacizumab loaded hydrogels were 34.13 ± 2.05, 3.2 ± 0.8 and 
1.1 ± 0.3 at 25, 37 and 48oC respectively. There was a significant difference in SR 
at 25oC (p<0.05) between the bevacizumab loaded and unloaded hydrogel. 
However, there was no significant difference in the SR at 37 and 48oC (p>0.05) 
(Figure 5:10A). Hydrogels polymerised in the presence of bevacizumab at 25oC 
were denser and opaque compared to empty hydrogels; however, when they 
collapsed at 37oC they were both opaque and white in colour.  
The difference in swelling at 25oC could be related to the MW of 
bevacizumab. Bevacizumab is a large molecule and when incorporated inside the 
hydrogel during the polymerisation process will be entangled into the polymer 
matrix. The entangled protein will restrict the movement of the polymer chains and 
occupy the space that is usually occupied by the free water. This will restrict the 
swelling of the hydrogel at 25oC. At 37oC even the presence of a large molecule did 
not have an impact on SR and did not alter the behaviour of the hydrogel.  
Since proteins are hydrophilic in nature they will not have an impact on 
hydrophobic bonds formation. Therefore, the deswelling of NIPAAM hydrogels will 
not be affected by the presence of protein. This was also confirmed by the results of 
WR%, which showed no significant difference for both loaded and unloaded 
hydrogels because (p>0.05) (Figure 5:10B). The SEM images showed a relatively 
denser and more compact structure with the protein loaded hydrogels as compared 
to unloaded hydrogels at 25oC (Figure 5:10C). 
Onset temperature 
35.5oC 
34.2oC 
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Figure 5:10 A) A graph demonstrating the effect of loaded bevacizumab on SR of 8 µL 
NIPAAm hydrogel. A significant difference in SR at 25
o
C (p<0.05) was observed between 
bevacizumab loaded and unloaded hydrogel, no significant difference was observed at 37 
and 48
o
C (p>0.05); B) A graph demonstrating the WR% of loaded and unloaded hydrogels. 
There was no significant difference observed in WR% (p>0.05) in hydrogels with and 
without the protein; C) Scanning electron microscopy (SEM) images of NIPAAm hydrogels 
with and without protein made with 8 µL PEGDA. The structure of the loaded hydrogels was 
relatively denser and more compact compared to unloaded hydrogels at 25oC. The scale 
bar is 40 µm.  
(A) 
(B) 
(C) 
40 µm 40 µm 
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Washing the hydrogel by some process would be an important step to 
remove unreacted monomers, which can be toxic if tested in vivo. Contact lenses 
are washed after fabrication to remove monomeric and oligomeric material. In the 
case of an antibody-loaded hydrogel, it was expected that some of the antibody 
would be lost during the wash step.  
To study the effects of washing the hydrogels on the release profile and 
percentage of protein lost during washing, bevacizumab NIPAAm hydrogels were 
prepared using 8 μL PEGDA. After polymerisation, the hydrogels were rinsed gently 
5 times, 4.0 mL each time in PBS. Each wash was 15 minutes long. Each wash 
fraction was analysed by HPLC to calculate how much of the antibody was lost 
during the wash. It was calculated to be ~28% (~18.4 mg remaining). In a 100 μL 
volume, the final concentration of bevacizumab after washing was ~1.84 mg/100 
μL. To compare washed and unwashed hydrogels, approximately 125 μL of the 
washed gel (equivalent to ~2.3 mg of bevacizumab) was injected into the posterior 
cavity of the model with PBS. A half-life of 3.1 ± 1.3 days in PBS was observed with 
the washed hydrogel, which was not significantly different (p>0.05) from the 
unwashed hydrogel i.e. 3.7 ± 1.2 days (Figure 5:11).  
 
 
Figure 5:11 The release profile of unwashed and washed bevacizumab 8 µL NIPAAm 
hydrogels in PBS, pH 7.4. The half-life of unwashed and washed hydrogels was 3.7 ± 1.2 
and 3.13 ± 1.3 days respectively. No significant difference (p>0.05) was observed in the 
half-life between washed and unwashed hydrogels.  
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The release profiles of bevacizumab from washed and unwashed hydrogels 
were similar. However, the concentration of bevacizumab measured during the first 
3 days was lower in washed hydrogels compared to the unwashed ones. During 
polymerisation some of the protein will be entrapped close to the surface and they 
will be washed when the monomers were washed. Removal of the protein close to 
the surface will reduce the initial burst release associated with the hydrogel (Figure 
5:11).  
Incorporation of phosphorylcholine PC into NIPAAm hydrogels  
One of the advantages of using PEGDA as the cross-linker to make the NIPAAm 
hydrogels is the biocompatibility of the PEG structure. The biocompatibility of the 
NIPAAM hydrogel as currently made is important because these hydrogels would 
be expected to be nondegradable in the body remaining in contact with tissues for a 
long period. As discussed in chapter 1, phosphorylcholine (PC) containing 
hydrogels have the advantage of increased biocompatibility due to the presence of 
zwitterionic pendant chain that resembles cell membranes.  
Chang et al reported that NIPAAm hydrogels made by copolymerisation of 
NIPAAm and zwitterionic sulfobetaine methacrylate (SBMA) shows improved 
biocompatibility over standard NIPAAm hydrogels. When the absorption of three 
major plasma proteins (γ-globulin, fibrinogen, and human serum albumin) was 
compared between NIPAAm hydrogels and NIPAAm-co-SBMA hydrogels, the 
relative protein adsorption on the surface was reduced below 12% for the 
copolymer hydrogel. Also blood platelet activated and adhered on the NIPAAm 
hydrogel surface was considerably reduced in the presence of zwitterionic groups 
compared to NIPAAm hydrogels with no zwitterionic groups (Chang et al. 2010).  
MPC (similar to sulfobetaine) belongs to the family of zwitterionic monomers. 
To explore the possibility of copolymerisation of MPC with NIPAAm for the 
synthesis of MPC-co-NIPAAm thermoresponsive hydrogel, NIPAAm formulation 
was prepared with 8 µL PEGDA and 5 mg of MPC was added to the formulation 
mixture before polymerisation. After polymerisation a transparent hydrogel was 
formed; however when the VPTT was measured no thermoresponsiveness was 
observed. When the amount of MPC was reduced to 1 mg there was a slight 
response to temperature changes (Figure 5:12). Although there was a thermal 
responsiveness when 1 mg MPC was used, it was very weak and the VPTT was 
36.3 ± 0.3 oC, which was very close to body temperature. It was concluded that this 
formulation was not thermally responsive. A possible explanation is that a 
combination of PEGDA and MPC form strong hydrogen bonds with water. The 
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increased number of hydrophilic interactions on the polymer chains will require 
higher temperatures to disturb the hydrophilic lipophilic balance causing the 
hydrogel to collapse.   
 
Figure 5:12 DSC graph representing the VPTT of 8 µL hydrogels prepared with 5 mg or 1 
mg MPC compared to NIPAAm without MPC. There was no thermal responsiveness when 5 
mg MPC was added and the VPTT was 36.3 ± 0.3 when 1 mg MPC was added compared 
to 35.5 ± 0.09; however the VPTT was close to body temperature and the onset of 
temperature changes was not sharp.  
In order to add PC zwitterionic group into the NIPAAm hydrogels and 
maintain the thermal responsiveness, PEGDA was replaced with PC bearing cross-
linker. PC cross-linker is described in the literature and used to improve the 
properties of hydrogels (Kiritoshi & Ishihara 2004). US patent application number by 
Michael Driver also describes the synthesis of different acrylated PC molecules for 
various applications (Driver 2013).  
A proprietary PC cross-linker (PC 3059) was supplied by Vertellus 
biomaterial (UK) for use in this work. 8 µL PEGDA as cross-linker in NIPAAm 
hydrogels was replaced with equivalent weight of PC as cross-linker. When PEGDA 
was replaced with equivalent weight of PC (9 mg which is equivalent to 13% (w/w)) 
no hydrogel was formed. The mixture solution remained as free flowing liquid after 
the addition of TEMED. The reaction mixture remained liquid even when the 
amount of PC increased to 15 mg (equivalent to 20% (w/w)). A hydrogel was only 
formed when the amount of PC added was 20 mg (equivalent to 25% (w/w)).   
Onset temperature 
35.5o
36.3o
C 
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Effect of cross-linker change on the behaviour of NIPAAm hydrogel 
It is expected that many important properties of NIPAAm hydrogel would be 
affected by the dramatic change of cross-linker from PEGDA to a PC derived 
macromolecular cross-linker. To study whether replacing PEGDA with a PC derived 
cross-linker would have an impact; hydrogels made with 8 µL PEGDA and 20 mg 
PC (equivalent to 25% (w/w)) were prepared and compared in respect to VPTT, 
SR, WR% and in vitro release. To eliminate the effect of any other factors, except 
the cross-linker type, on the behaviour of the hydrogels prepared the two hydrogels 
were prepared in the exact same conditions. A 1 mL bevacizumab solution (25 
mg/mL) was used to prepare bevacizumab loaded PC hydrogels, which is 
equivalent to the loading for bevacizumab loaded PEGDA hydrogels.  
Both monomer mixtures for the hydrogels polymerised after 1 minute of 
TEMED addition. In both cases, the hydrogels were transparent and easily 
injectable through a 23G needle. With PC, the VPTT shifted to a slightly lower value 
(33.8 ± 0.1oC) compared to PEGDA-NIPAAm hydrogels (35.5 ± 0.1oC) (Table 5:4). 
The PC cross-linker was expected to attract more water than PEGDA. The 
presence of the zwitterionic pendant chain in the PC repeat unit in its structure can 
either be free or lightly bound water, which requires less energy to break and lower 
the VPTT. This could be a contributing factor to the sharp decrease in WR% after 5 
minutes when PC was used as compared to PEGDA (Figure 5:13). However, the 
overall behaviour is the same and they both respond by deswelling with an increase 
in temperature. There was no significant difference (p>0.05) in SR between PEGDA 
and PC hydrogels in all the temperatures tested (25, 37, 48oC). 
Table 5:4 Volume phase transition temperature (VPTT) and swelling ratio (SR) at 25, 37 
and 48
o
C of NIPAAm hydrogels made either with 8 µL PEGDA or 20 mg PC 3059. With PC, 
the VPTT shifted to a slightly lower value (33.8 ± 0.1
o
C) compared to PEGDA-NIPAAm 
hydrogels (35.5 ± 0.09
o
C) There was no significant difference (p>0.05) in SR between 
PEGDA and PC hydrogels in all the temperatures tested.  
Cross-linker type SR VPTT Injectability 
 25oC 37oC 48oC   
8 µL PEGDA 34 ± 2 3.2 ± 0.8 1.1 ± 0.3 35.5 ± 0.1 Easy 
20 mg PC 3059 37.6 ± 3.2 3.8 ± 1.9 1.4 ± 0.3 33.8 ± 0.1 Easy 
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Figure 5:13 The water retention (WR%) of hydrogels synthesised with 12 µL PEGDA and 
20 mg PC. A sharp decrease in WR% after 5 minutes when PC was used as compared to 
PEGDA; however, the overall behaviour is the same (no difference was observed in WR%).  
No significant difference (p>0.05) was observed in the release of 
bevacizumab from both hydrogels (Figure 5:14). The release of hydrogel loaded 
protein is thought to be affected by the amount of water entrapped in the hydrogel 
structure after collapsing. Both hydrogels swell to the same extent and entrap 
similar amounts of water at 37oC, which provides the basis for a similar release 
profile of bevacizumab to occur. 
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Figure 5:14 The release of bevacizumab from NIPAAm hydrogels made with 20 mg PC 
cross-linker compared with 8 µL PEGDA cross-linker. No significant difference (p>0.05) was 
observed in percent of drug released and concentration between the two hydrogels. 
Effect of bevacizumab on the physical properties of the PC cross-linked 
hydrogel 
From previous experiments it was noted that the presence of the antibody during 
the polymerisation process had no effect on the physical characteristics of the 
PEGDA cross-linked NIPAAm hydrogels. The same was observed with PC cross-
linked hydrogels.  A VPTT of 33.8 ± 0.1oC and 33.3 ± 0.3oC was observed for the 
empty and bevacizumab loaded hydrogels respectively, which were not significantly 
difference (p>0.05) (Figure 5:15A). The SR of bevacizumab loaded hydrogels was 
25.4 ± 1.4, 3.1 ± 1.3 and 1.0 ± 0.2 at 25, 37 and 48oC respectively. There was a 
significant difference is SR at 25oC (p<0.05) between bevacizumab loaded and 
unloaded PC cross-linked hydrogel but no significant difference (p>0.05) was 
observed at 37 and 48oC (Figure 5:15B). A more compact structure was observed 
in SEM when the PC cross-linked hydrogel was loaded with bevacizumab (Figure 
5:15C). 
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Figure 5:15 The effect of the protein on the physical characterisation of 20 mg PC NIPAAm 
hydrogel; A) VPTT shifted from 33.8 ± 0.1
o
C for the unloaded hydrogel to 33.3 ± 0.3
o
C for 
the bevacizumab loaded hydrogels; B) A significant difference in SR at 25
o
C (p<0.05) was 
observed between loaded and unloaded hydrogel, no significant difference was observed at 
37 and 48
o
C (p>0.05); C) A more compact structure was observed with loaded hydrogels 
compared to empty ones. The scale bar is 100 µm.  
(A) 
(B) 
(C) 
Onset 
temperature 
33.8o
C 
33.3oC 
100 µm 100 µm 
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Effect of increased PC cross-linker on NIPAAm hydrogels 
NIPAAm hydrogels formulated with 8 µL PEGDA and 20 mg PC displayed similar 
behaviour and release characteristics of bevacizumab. When increasing the 
stoichiometry of PEGDA from 4 to 12 µL the resulting NIPAAm hydrogels became 
non-injectable. In analogous fashion, the amount of PC cross-linker was increased 
from 20 mg to 30 mg (equivalent to 33.5% (w/w)). For the preparation of the 
hydrogels, NIPAAm monomers and APS were dissolved in 1 mL of DW with 
increasing stoichiometries of PC i.e 20, 25 and 30 mg (equivalent to 25%, 30%, 
33.5% (w/w) respectively). The mixture was free flowing liquid in the vial. All the 
hydrogels transparent and converted to a gel after the addition of TEMED (Figure 
5:16A). SEM showed a more compact structure with increased amounts of PC 
(Figure 5:16B).  
 
 
 
 
 
Figure 5:16 A) Picture of the prepared NIPAAm hydrogels using PC 3059 as cross-linker. 
Gels made with 20, 25 and 30 mg cross-linker are all transparent; B) SEM images of 
NIPAAm hydrogels shows no difference in structure when the cross-linker percentage 
increased. The scale bar is 40 µm. 
The injectability of each PC hydrogel was also determined qualitatively with 
a 23G needle (Table 5:5). The hydrogel was injectable with a PC amount up to 30% 
(w/w), however the gel was difficult to inject above 33.5% (w/w). 
(A) 
(B) 
40 um 40 um 40 um 
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Table 5:5 The qualitative determination of injectability of NIPAAm hydrogels synthesised 
different amounts of PC 3059 using 23G needle.  
PC 3059  Injectability 
20 mg Easy 
25 mg Easy 
30 mg Difficult 
 
A successful thermoresponsive hydrogel should have a VPTT below the 
physiological pH. The VPTT for the PC cross-linked hydrogels was ~34˚C and there 
was no significant difference (p>0.05) in the VPTT between the hydrogels made 
with the different amounts of PC (Figure 5:17). The endothermic peak remained 
sharp when the percentage of PC increased which indicates that a higher 
percentage of PC as cross-linker didn’t reduce the thermal responsiveness of the 
prepared gels.    
 
Figure 5:17 Volume phase transition temperature (VPTT) of NIPAAM hydrogels with 
varying PC 3059 concentrations determined by DSC. The VPTT was 33.8 ± 0.1, 34.3 ± 0.05 
and 34.4 ± 0.1 for 20, 25 and 30 mg PC respectively.  
The swelling ratio of NIPAAm hydrogels prepared was measured at 25, 37 
and 48oC. Similar to PEGDA, there was a significant decrease (p<0.05) in SR for all 
hydrogels when the temperature increased from 25 to 37oC (Table 5:6).   
 
 
 
 
Onset 
temperature 
33.8oC 
34.3oC 
34.4oC 
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Table 5:6 The SR of NIPAAm hydrogels prepared with different amounts of PC 3059 as 
cross-linker at three different temperatures (25, 37 and 48
o
C).  
 
Temperature 
SR 
20 mg 25 mg 30 mg 
25oC 37.6 ± 3.2 26.5 ± 4.7 23.0 ± 2.0 
37oC 3.8 ± 1.9 5.2 ± 1.8 5.1 ± 0.5 
48oC 1.4 ± 0.3 2.4 ± 1.3 2.8 ± 1.3 
 
At 25oC there was a significant difference (p<0.05) in the SR between the 20 
mg, and 25 and 30 mg PC cross-linked hydrogels. No significant difference was 
observed (p>0.05) between 25 and 30 mg PC hydrogels. This is consistent with the 
results observed when PEGDA. Higher cross-linking density is associated with less 
swelling in the surrounding medium. At 37 and 48oC, no significant difference was 
observed in any of the hydrogels (p>0.05) (Figure 5:18A). The behaviour of the PC 
cross-linked hydrogels is different compared to PEGDA cross-linked hydrogels at 
37oC. This is probably related to the nature of the cross-linkers and the interaction 
between the cross-linker and water. While it is known that PEGDA can form 
hydrogen bonds with water, PC groups attract free water around the PC polymer 
chains. The visual difference in swelling of the hydrogels at 25 and 37oC is 
presented in (Figure 5:18B).  
The effect of PC on WR% was also measured. Higher amounts of PC 
results in higher water entrapment inside the hydrogel (Figure 5:18C) due to the 
presence of PC head group. The same pattern was also noticed with PEGDA. This 
indicates that hydrogels made with a hydrophilic cross-linker behave the same way 
regarding water content and swelling.    
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Figure 5:18 A) The swelling ratio SR of NIPAAm hydrogels prepared with various amounts 
of PC 0598 as cross-linker. The SR was measured at three different temperatures (25, 37 
and 48
o
C); B) Pictures of the hydrogels at 25 and 37
o
C; C) The WR% of PNIPAAm 
hydrogels prepared with various amounts of PC 3059 as cross-linker.  
(A) 
(B) 
(C) 
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NIPAAm hydrogels made with 20, 25 and 30 mg (equivalent to 25, 30 and 
33.5% (w/w) respectively) PC were screened regarding physical properties of the 
formulated hydrogels and the effect of PC cross-linker on the general behaviour of 
NIPAAm hydrogels. Although the NIPAAm hydrogel made with 33.5% (w/w) PC 
was thermoresponsive, it was difficult to inject this hydrogel. Hydrogels made with 
25% and 30% (w/w) PC showed similar characteristics and thermal behaviour when 
compared to PEGDA.  
Acrylated hyaluronic acid (Ac-HA) cross-linker in NIPAAm hydrogel synthesis 
Most of the non-biodegradable delivery systems for posterior segment require 
removal after the drug is fully released. There are some exceptions where there is 
no need to remove the delivery system when the drug is fully released, for example 
Iluvien®. Iluvien® is a small, non-biodegradable, injectable polymer drug matrix that 
release fluocinolone acetonide in the vitreous up to 3 years for the treatment of 
diabetic macular edema (Kane et al. 2008).  
 NIPAAm hydrogels made with PEGDA-700 or PC 3059 displayed a 
sustained release of bevacizumab for more than a month; however they are non-
biodegradable. Turturro et al reported that only a small transient effect was 
observed in the retinal functions during the first few days after injection of NIPAAm 
hydrogel and the data returned to normal base line after one week of injection 
(Turturro et al. 2011). Surgery may be required to remove the empty hydrogels 
when several injections are used and the empty hydrogels starts to accumulate in 
the vitreous and affect the ocular tissues. To avoid surgery in these cases, the use 
of biodegradable cross-linker for NIPAAm hydrogel synthesis could be an option. 
Biodegradable NIPAAm hydrogels were reported to be synthesised by incorporating 
a biodegradable monomer unit into the polymer backbone structure or cross-linker 
(Fujimoto et al. 2009; Zheng et al. 2015; Huang & Lowe 2005). Lee and Cheng 
reported the synthesis of biodegradable NIPAAm hydrogels using biodegradable 
polycaprolactone diacrylate as cross-linker (Wang & Li 2011). To study the 
possibility of using a biodegradable cross-linker and its effect on the physical and 
chemical properties of the hydrogel, NIPAAm hydrogel with hyaluronic acid (HA) as 
cross-linker was prepared and analysed.   
Hyaluronic acid (HA) is natural polysaccharide polymer with repeating units 
of D-glucuronic acid and N-acetyl-D-glucosamine disaccharide. It is a common 
component in many parts of the human body such as extracellular matrix, synovial 
fluid and the vitreous humour. It has the ability to absorb thousand times its dry 
weight of water (Kogan et al. 2007; Mero & Campisi 2014). It is a widely 
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investigated and used component for drug delivery due to its biodegradability and 
biocompatibility (Figure 5:19A). The commercially available form of HA is called 
sodium hyaluronate and it is used for the synthesis of eye drops, eye gels and 
injections (Pavelka & Uebelhart 2011; Widjaja et al. 2014; Mayol et al. 2008).  
 In our lab an acrylated HA (Ac-HA 50 kDa) molecule was synthesised to be 
used as biodegradable hydrophilic cross-linker for NIPAAm hydrogel synthesis. The 
same method and percentages of monomers used for the preparation of PEGDA 
and PC NIPAAm hydrogels was used for the synthesis of Ac-HA NIPAAm 
hydrogels. Different amounts of Ac-HA were used for the hydrogel synthesis (2, 4, 7 
and 10 mg which represents 3.2%, 6.3%, 10.5% and 14.4% (w/w) respectively). 
The monomer mixtures start to gel approximately one minute after the addition of 
TEMED (Figure 5:19B).  
 
 
 
 
 
Figure 5:19 A) The chemical structure of hyaluronic acid (HA), B) the starting materials for 
NIPAAm hydrogel formulation and the hydrogels formed. NIPAAm hydrogels were prepared 
with different percentages of Ac-HA as cross-linker by free radical polymerisation.  
 
Hyaluronic acid (HA) 
(A) 
(B) 
APS 
TEMED 
Acrylated hyaluronic acid 
(Ac-HA) 
NIPAAm hydrogels 
NIPAAm  
+ (4oC/24 h) 
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The injectability of the hydrogels was determined using a 23G needle. 
Hydrogels with 7 and 10 mg Ac-HA were very hard to inject and displayed VPTT 
values very close to body temperature with no significant difference in SR (from 
25oC to 37oC). Similar trend to PEGDA and PC3059 in SR at 25oC was observed; 
when the cross-linker amount increased the SR reduced which can be observed by 
the SEM images of the freeze dried hydrogels (Figure 5:20A). Hydrogels with 2 and 
4 mg showed thermal responsiveness and both were injectable (Figure 5:20B and 
Table 5:7).  
 
 
 
 
Figure 5:20 A) SEM images of NIPAAm hydrogels made with different amounts of Ac-HA. 
Denser hydrogels were prepared with increasing Ac-HA amount. Scale bar is 100; B) 
Pictures of the hydrogels at 25 and 37
o
C. The hydrogels at 25 are transparent and became 
opaque at 37
o
C. 
(A) 
(B) 
100 µm 
100 µm 100 µm 
100 µm 
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Table 5:7 Different physical properties of NIPAAm hydrogels made with different amounts of 
Ac-HA. All data presented was done in triplicate (n=3) and presented as mean and standard 
deviation (± STD) except for VPTT (one experiment). 
Ac-HA mg VPTT oC 
SR 
25oC              37oC 
Injectability 
2 33.7 165.4 ± 2.9 102 ± 8 Easy 
4 34.5 105.1 ± 8.4 94.1 ± 5.9 Easy 
7 36.4 79.8 ± 2.9 78.2 ± 3.4 Difficult 
10 36.9 62.5 ± 4.8 60.2 ± 0.7 Non-injectable 
         
NIPAAm hydrogels made with 2 and 4 mg Ac-HA were loaded with 
infliximab to study the release of the protein. Infliximab was used instead of 
bevacizumab because of the lack of resources for bevacizumab (Infliximab and 
bevacizumab have the same MW 150 kDa). The aim was to prepare Ac-HA 
NIPAAm hydrogel with 10 mg infliximab by dissolving AC-HA, NIPAAm and APS in 
1 mL of protein solution (9.4 mg/mL); however the AC-HA was hard to dissolve and 
properly mixed with the protein solution. The reduction in solubility of HA could be 
attributed to the addition of acrylate groups in the HA structure. OH groups were 
replaced with acrylate which possibly affected the solubility by reducing the groups 
available for hydrogen bond formation. Proper mixing between the monomers and 
the protein is important to achieve uniform distribution and proper entangling of the 
protein. To help in the mixing process Ac-HA, NIPAAm and APS were first 
dissolved in 200 µL of PBS. When a clear solution was formed 1 mL of protein 
solution was added taking the total volume into 1.2 mL. A hydrogel was formed 
after addition of TEMED with a concentration of protein 7.8 mg/mL. The same 
washing process used for PEGDA NIPAAm hydrogel was used for washing Ac-HA 
NIPAAm hydrogels.    
 During washing the amount of drug lost was quantified. After washing, 
hydrogels with 2 and 4 mg lost 2.5 mg ± 0.2 (~26.7%) and 1.8 mg ± 0.2 (~19.5%) of 
the loaded protein respectively. The final concentration of protein in the hydrogels 
was 5.8 mg/mL and 6.3 mg/mL for 2 mg and 4 mg AC-HA NIPAAm hydrogels 
respectively. The amount of protein lost during washing of 4 mg hydrogels was 
significantly lower than the amount lost during washing 2 mg hydrogels. This was 
expected because the SR of hydrogels made with 2 mg was significantly higher 
than the SR of 4 mg hydrogels. Based on these findings hydrogel with 4 mg cross-
linker was further characterised for release studies. 
The release of 4 mg AC-HA NIPAAm hydrogels from the PK-Eye model was 
studied and compared with bevacizumab. The amount of infliximab injected was 1.1 
mg (170 µL) of the hydrogel and after 10 days only ~25% of the drug was released 
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compared to ~60% from 8 µL PEGDA and PC NIPAAm hydrogels (Figure 5:21). 
The large MW of the HA provided a proper entangling to the protein and created 
another barrier for the diffusion of the protein from the collapsed hydrogel. 
 
Figure 5:21 A graph comparing the release of bevacizumab and infliximab from NIPAAm 
hydrogels made with different cross-linkers. After 10 days only ~25% of the drug was 
released from NIPAAm hydrogels made with Ac-HA compared to ~60% from 8 µL PEGDA 
and PC NIPAAm hydrogels.   
In hydrogels made with PC and PEGDA the presence of protein did not 
have a major effect on the overall physicochemical properties of the hydrogels 
except for swelling at 25oC, it was significantly lower in the presence of protein. 
With AC-HA as cross-linker the hydrogel was still injectable after loading with the 
protein and the VPTT was 35.5oC compared to 34.5oC for the empty hydrogel. 
However, with Ac-HA there was a significant difference is SR not only at 25oC but 
also at 37oC (Table 5:8). HA is a viscous material that is used to increase viscosity 
of solutions. When used as cross-linker the viscosity of the hydrogel will increase 
reducing the SR significantly at 25oC. At 37oC the higher viscosity of HA may also 
prevent complete collapse of the hydrogel.      
Table 5:8 Different physical properties of NIPAAm hydrogels with and without infliximab.  
Ac-HA NIPAAm hydrogel VPTT oC 
SR 
25oC              37oC 
Injectability 
Empty hydrogel 34.5 105.1 ± 8.4 94.1 ± 5.9 Easy 
Infliximab loaded hydrogel 35.5 33 ± 6 20.3 ± 3 Easy 
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When comparing SR of hydrogels made with PEGDA or PC 3059 vs 
hydrogels made with Ac-HA at 25oC and 37oC, a significant difference was 
observed (Table 5:9). The structure of HA molecule is dominated by the presence 
of OH groups that are capable of forming hydrogel bonds with water. The combined 
effect of large MW of Ac-HA (50 kDa) and the abundance of OH group will attract 
large amount of water and increase the swelling of the hydrogel compared with 
PEGDA and PC (PEGDA Mn is 700 Da).  
Table 5:9 The SR of NIPAAm hydrogels prepared with different hydrophilic cross-linkers.  
Cross-linker type 
SR 
       25oC                    37oC 
8 µL PEGDA 34 ± 2 3.2 ± 0.8 
20 mg PC 3059 37.6 ± 3.2 3.8 ± 1.9 
4 mg Ac-HA 105.1 ± 8.4 94.1 ± 5.9 
 
 
NIPAAm hydrogels made with 2, 4, 7 and 10 mg Ac-HA were screened 
regarding physical properties of the prepared hydrogels and the effect of cross-
linker amount on the general behaviour of NIPAAm hydrogels. Hydrogels made with 
7 and 10 mg Ac-HA were non injectable and non thermoresponsive. Although 
hydrogel made with 2 and 4 mg Ac-HA were injectable and thermoresponsive, only 
4 mg hydrogels were used for release studies. Higher percentage of the loaded 
protein lost during the washing of unreacted monomers from 2 mg hydrogels 
compared to 4 mg. Only ~25% of the loaded protein was released after 10 days. 
NIPAAm hydrogels made with 4 mg Ac-HA are good candidates for developing 
sustained formulation for protein delivery. 
Summary and conclusions 
NIPAAm thermoresponsive hydrogels were prepared by free radical polymerisation 
using different macromolecular hydrophilic cross-linkers i.e. PEGDA, PC 3059 and 
Ac-HA. The in vitro release of an antibody was studied in the PK-Eye model. This in 
vitro model that mimics the aqueous flow of the human eye provides a good 
estimate of antibody clearance from the vitreous body. NIPAAm hydrogels (derived 
from 40 mg of NIPAAm monomer) containing 4, 8, 12 and 15 µL PEGDA were 
prepared and characterised regarding their physical properties. With larger amounts 
of PEGDA, the hydrogels were less thermoresponsive and retained larger amounts 
of water in at 37oC. In addition, the injectability of these hydrogels also reduced. No 
significant difference was observed between 4 and 8 µL cross-linker regarding SR, 
VPTT and WR%.  
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In vitro studies in the PK-Eye showed a bimodal release profile 
characterised by an initial burst followed by a zero-order release after a week for 
one month. No significant difference was observed with the different cross-linker 
stochiometries. The presence of protein during polymerisation did not appear to 
affect the physical properties of the prepared hydrogels (i.e. VPTT, injectability and 
SR at 37oC).  
To prepare hydrogels with potentially improved biocompatibility and to 
examine the effect of changing the cross-linker type on the properties of the 
hydrogel, 4 µL PEGDA was replaced with 20 mg of a preparatory molecule (PC 
3059) as a cross-linker with 40 mg NIPAAm. Changing the cross-linker had no 
significant difference in the behaviour of the prepared hydrogels regarding their 
properties such as VPTT, SR, WR% and the release of loaded bevacizumab. Three 
different amounts of PC 3059 was investigated i.e. 20, 25 and 30 mg. No significant 
difference in VPTT and SR were observed with increased amounts of cross-linker. 
The presence of protein during the polymerisation process again, surprisingly, did 
not alter the physical properties of the prepared hydrogels. Hydrogels made with 20 
mg PC2059 retained less water in their structure and were further investigated for 
their release properties. Both hydrogels are potential candidates for further study to 
be the basis for an extended release formulation for intravitreal protein delivery.   
Another hydrophilic cross-linker was examined for the synthesis of NIPAAm 
hydrogels. Different NIPAAm hydrogels with increasing stoichiometries of Ac-HA 
(50 kDa) were prepared (2, 4, 7 and 10 mg). When the amount of Ac-HA ws 
increased, the thermal responsiveness was reduced and the SR was alsoreduced 
at 25oC. This hydrogel behaves in similar way to PEGDA-NIPAAm cross-linked 
hydrogels. Preliminary release studies of Ac-HA loaded hydrogels demonstrated 
better control of the loaded protein compared to PEGDA and PC NIPAAm 
hydrogels with the release of 25% only of the encapsulated protein from Ac-HA 
hydrogels compared to 60% from PEGDA and PC hydrogels in 10 days. 
NIPAAm hydrogels with different properties were prepared by using different 
types of hydrophilic macromolecular cross-linkers. The type and percentage of 
cross-linker in the formulation significantly affects the characteristics of the hydrogel 
to sustain the release of the encapsulated antibody.    
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Chapter 6. General discussion and conclusion 
Blinding eye diseases are considered a major economic and social problem in 
developed and developing countries, generally affecting aging populations. Most 
blindness and severe visual impairment are caused by conditions that cause 
damage in the back of the eye; such as glaucoma and AMD (Bunce & Wormald 
2006). 
People suffering from glaucoma is estimated to be 60.5 million in 2010 and 
the number is estimated to increase to 111.8 million in 2040 (Tham et al. 2014; 
Quigley & Broman 2006). The only proven treatment for glaucoma is to lower the 
intraocular pressure (IOP) in the eyeball. Current treatments have a variable long-
term success rate (Manickavasagam & Oyewumi 2013). Eye drops require lifelong 
use, are costly and are associated with local side effects. Compliance remains a 
major problem with eye drops with no solution to compliance emerging (Tsai 2009; 
Sleath et al. 2006). Laser treatment to open the drainage meshwork can lower 
pressure, but local fibrosis can occur (Wise 1987). Both the use of eye drops and 
laser treatments often fail to achieve long term reduction in IOP required to slow 
disease progression.  
The lowest IOP can be achieved by creating a new drainage channel that 
allows aqueous to flow out of the eye into the subconjunctival tissues. Aqueous 
drainage can be achieved be trabeculectomy (or glaucoma filtering surgery-GFS)  
or by surgically implanting a glaucoma drainage device (GDD) (Schwartz et al. 
2006; Chiselita 2001). There are many GDDs that have been developed, but 
limitations remain. Successful surgery is associated with a better clinical outcome 
and quality of life with lower healthcare costs compared to standard long term 
medical therapy. Unfortunately surgery has not become the primary treatment 
option because of its complexity and the post-surgical treatments that are often 
needed due to localised fibrosis (Skuta & Parrish 1987). Complications such as 
accurately control aqueous outflow due to blockage caused by local fibrosis results 
surgical failure with a return to higher IOP and disease progression.  
GDDs are increasingly being used as first line treatment when surgery is 
called for. There are two key problems with current GDDs; (i) lack of control on 
aqueous outflow in the first few weeks before the fibrous capsule formation which 
may cause hypotony, (ii) lack of long term and consistent control of IOP among 
wide range of patients, (iii) formation of a thick fibrous capsule around the implant 
due to excessive scarring and foreign body response which may cause blockage of 
the tube and elevated IOP. The material used for the fabrication of implantable 
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devices, including GDDs plays an important role in the long-term success of the 
device. If the material used is highly biocompatible, less foreign body response is 
expected and a thin, less dense fibrous capsule may be formed around the implant. 
GDDs with spacer plates typically control aqueous outflow through a pressure 
controlled valve or use of a suture through the drainage tube with diffusion through 
the fibrous capsule formed around the implant. Consideration of new mechanisms 
for flow control based on different principles may help to developing new GDDs with 
higher success rate compared to the current GDDs.  
An ideal GDD should; (i) have minimal foreign body response, (ii) be able to 
control the IOP to 10-12 mmHg over a wide range of patients for a prolonged period 
of time, (iii) be easily implanted and (iv) be affordable for patients around the world. 
It is thought that a GDD made from a hydrogel may offer a solution to the problems 
associated with the current devices available in the clinic.    
Hydrogels are widely used in biomedical research because they are known 
to be biocompatible materials due to their tissue like properties (flexibility, softness 
and high water content). Hydrogels are polymer networks that allow the transport of 
gases, liquids and dissolved substrates (Hoare & Kohane 2008; Devi & Nautiyal 
2014; Buwalda et al. 2014). Example applications where hydrogels are widely used 
and investigated include tissue engineering, 3D cell culture, wound dressing, 
medical adhesives and drug delivery systems (Yang et al. 2011; Huynh et al. 2011; 
Appel et al. 2012). 
Initially it was hypothesised that a biocompatible hydrogel material could be 
used as a flow restrictor in a GDD. It was thought that the flow through a hydrogel 
material could be adjusted based on the characteristics of the hydrogel to allow 
aqueous flow. It was hoped that cross-link density and polymer properties could be 
found that allowed the flow of water at approximately 2 µL/min with a pressure 
resistance of 10 mmHg. It was hypothesised that hydrogel properties would allow 
aqueous flow to be impeded by resistance through the hydrogel network that would 
result in pressure control for a GDD.   
It was further hoped that with an appropriate hydrogel material could be 
used to moderate the lower foreign body response to reduce the chance of a 
fibrous capsule forming around the device. Avoiding capsule formation is important 
to ensure unmanageable IOP increases do not occur over time. Long-term 
implantable devices into the subconjunctiva (including GDDs) currently require the 
administration of an anti-inflammatory and/or anti-fibrotic agent to reduce the 
foreign body response to the device after the trauma of surgery and implantation. 
Anti-inflammatory or anti-scarring agents could be loaded to the hydrogel to 
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formulate a combination device that would further reduce the foreign body 
response.   
HEMA and MPC based co-polymers were selected as hydrogel components 
to control aqueous outflow as a means to regulate pressure because of these 
polymers are widely used in the eye (contact and intraocular lens). Much is known 
about the use of hydrogel materials in the manufacture of and coating of lens. It 
was not clear at the outset of this research what was the permeability and the 
capacity of water to actually flow through a hydrogel, it was necessary to evaluate 
gels derived comprised of different relative amounts of MPC to HEMA. A small 
library of hydrogel films ranging from 0 to 100 % (w/w) MPC were prepared and 
characterised in respect to appearance, water permeability and water content. From 
the outset it appeared that as the relative amount of MPC increased within the 
hydrogel films, the total water content and network pore size increased.  
The critical properties needed for aqueous flow to control pressure were 
water permeability and the hydraulic conductivity of the hydrogel. These properties 
are not usually measured for hydrogels used in drug delivery but sometimes 
measured in ophthalmic lens development. In the case of contact lens, oxygen 
permeability is the key parameter that must be optimised. Water permeability and 
hydraulic conductivity of 10% MPC-HEMA hydrogels was measured under pressure 
by dynamic approach. Hydrogels fabricated with 10% MPC was chosen as a 
representation of the HEMA-MPC formulation. It was thought that if sufficient water 
flow through the 10% MPC hydrogel matrix, the formulation could be manipulated. 
Unfortunately, the fabricated hydrogel film displayed low permeability. The 
permeability and water flow was low at high pressure (~30 mmHg) which indicates 
that the films cannot be used as flow control mechanism for GDD.  
Low water permeability was unexpected. One thought was that the low 
permeability was related to how water was distributed inside the hydrogel network 
where the ratio of bound water could be high compared to free water due to the 
presence of hydrophilic monomers such as MPC and HEMA. However, when the 
bound water ratio was measured the ratio of free water was high compared to 
bound water. The results suggest that for this particular HEMA-MPC formulation the 
water type has no effect on permeability.   
Another rationale for the low permeability to water flow may be due to gel 
blocking. Water flow and water transport may be two different processes. Clearly 
when hydrated films were placed on a bench, the water quickly evaporated, much 
as what happens in a contact lens.  Likewise the xerogel becomes hydrated. These 
observations indicate there is water transport. However this transfer of water 
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appears to differ from transfer due to flow.  In this case it is possible that under the 
pressure of flow, hydrogel chain conformations change resulting in polymer chains 
actually blocking flow (Höhne & Tauer 2014; Wack & Ulbricht 2007; Berg et al. 
1994). 
To avoid aqueous flow through an entire hydrogel film, the incorporation of a 
chamber or pouch was considered. The pouch may exert extra pressure from inside 
the hydrogel to speed the flow rate through the hydrogel surfaces. The pouch will 
be deflated at low pressure and when the pressure increases, due to accumulation 
of aqueous inside the pouch, the pouch will expand (similar principle to balloons) 
and the aqueous will flow. Two approaches were examined to create a pouch; (i) 
femtosecond laser and (ii) gel film fabrication around a water soluble positive 
mould. A femtosecond laser was used to create a pouch in a fully hydrated 
hydrogel. Unfortunately, after the laser treatment the film surface became fragile 
and cracked. This preliminary experiment suggested that ablation of the internal 
volume of the hydrogel would be difficult to achieve. One reason for this may be 
due to the chaotic nature of the hydrogel, or because upon vaporisation by the laser 
there was a high localised increase in pressure/heat that caused the cracking. 
Since the femtosecond laser was not useful to create an internal cavity 
within the hydrogel pouch, A PBS tablet was crashed and placed in the mould 
before conducting the polymerisation to fabricate the hydrogel. It was thought that 
by polymerising around a soluble material, the material could be dissolved during 
the washing process of the hydrogel to leave an empty pouch. No candidate 
hydrogel films worthy of further study were fabricated when polymerising around 
particles. The presence of the particles affected the polymerisation process in the 
surrounding area producing an irregular thickness to the film around the particles. 
 To further confirm that the polymerisation process is affected by the 
presence of foreign material during the polymerisation and not the nature of the 
PBS tablet itself, the polymerisation of 10% MPC monomer mixture was conducted 
in the presence of a metal spatula, filter paper and polycaprolactone film. No proper 
film was formed with each of the materials used. A pouch or a continuous internal 
volume could not be created. After much experimentation, it was determined that 
HEMA-MPC hydrogel films could not be used to restrict flow as a means to control 
pressure. The concept of using flow through hydrogels as a mean to control flow 
through GDD could still be investigated in future work by using different polymers 
and monomers for the GDD fabrication. A different concept for the hydrogel could 
also be investigated such as the synthesis of macroporous hydrogels.       
Although we were unable to use a hydrogel as a flow-restricting barrier to 
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control outflow pressure, it was still possible to consider a hydrogel-derived spacer 
that could be used in a conventional GDD. The hydrogel material would be 
expected to have a lower propensity for causing a severe foreign body response.  
Additionally since GDDs do need co-administration of an anti-fibrotic agent, a 
hydrogel GDD spacer could be used also to release an appropriate drug within the 
subconjunctival space after GFS.  
Hydrogel formulations were examined in terms of mechanical strength, drug 
loading and drug release. Young’s modulus (E) of the fabricated films was 
measured as an indication of mechanical strength. As the strength of films 
increases, the modulus also tends to increase. The modulus inversely varied with 
the amount of MPC.  
The drugs DEX (hydrophobic) and pirfenidone (hydrophilic) were loaded into 
MPC discs to study the effect of water content on drug release. The discs were 1 
cm in diameter and 1 mm thickness in fully hydrated state. Fully dried discs were 
used for loading. The MPC was varied from 0-30% in the discs that were evaluated. 
For pirfenidone, the amount loaded was 0.35 ± 0.02, 0.30 ± 0.01 and 0.25 ± 0.02 
mg/disc for 0%, 10% and 30% MPC respectively. For dexamethasone, the amount 
loaded was 0.40 ± 0.03, 0.3 ± 0.1 and 0.19 ± 0.03 mg/disc for 0%, 10% and 30% 
respectively. Initially it was thought that the loading would be increased with 
increasing MPC percentage because the swelling of the hydrogel increased with 
increasing MPC percentage. It came as a surprise that the loading decreased with 
the increasing MPC percentage for both drugs. The affinity between the drug 
molecule and the polymer matrix could explain the results. DEX has higher affinity 
to adsorb on hydrophobic polymer chain surfaces (HEMA). When the level of 
HEMA was reduced compared to MPC (highly hydrophilic), DEX loading was 
reduced. 
The release of both drugs was studied using an eye flow chamber that 
mimics the aqueous flow in the subconjunctival space at a rate of 2 µL/min. Both 
drugs were released faster from the 30% MPC compared to 0% and 10% MPC 
hydrogels. The half-life of DEX was 3 ± 12, 1.8 ± 8.9 and 1 ± 3 day and the half-life 
of pirfenidone was 1.2 ± 2.4, 0.7 ± 3.4 and 0.4 ± 2.1 day for 0%, 10% and 30% 
MPC respectively. In non-stimuli responsive non-biodegradable hydrogels diffusion 
of the drug from the loaded hydrogel is the driving force for the release (Satapathy 
et al. 2015). Diffusion is also related to the percentage of free water in the hydrogel, 
where it is thought that the higher the bulk water content the faster the release (Wu 
et al. 2016). Since 30% MPC hydrogels have higher free water compared to 0% 
and 10% MPC hydrogel, the diffusion was faster from 30% MPC.  
193 
 
A GDD spacer must have sufficient mechanical strength to be implanted 
and sufficient water content to ensure biocompatibility. The presence of MPC will 
increase the water content, which potentially may improve biocompatibility but at 
the same time will reduce the strength of the films and cause faster release of the 
loaded drug. Hydrogels with 20% and 30% MPC have low mechanical strength with 
high free water. The half-life of both DEX and pirfenidone was short when released 
from 30% MPC compared to 0% and 10% MPC. Hydrogels with 5% MPC have 
higher relative mechanical strength and less free water but they have low 
percentage of MPC compared to the other formulations which could impact 
biocompatibility long-term. Hydrogels with 10% and 15% MPC showed similar 
characteristics regarding water content; however, hydrogels with 10% MPC are 
mechanically stronger and have larger fraction of free water compared to 15% 
MPC. Hydrogels made with 10% MPC were chosen as the best formulation for the 
fabrication of a drug releasing subconjunctival spacer after GFS. The 10% MPC 
hydrogels offer the best balance between water content, mechanical strength, drug 
loading and drug release. 
Both drugs (DEX and pirfenidone) still did not have an optimal release 
profile from 10% MPC hydrogel discs. As discussed previously, the high ratio of 
free water facilitates the diffusion of loaded drugs in hydrogels. It was thought that 
by modifying the ratio of cross-linker and initiator in the 10% MPC formulation, the 
free to bound water ratio could be modified. It was previously reported that 
modification of both initiator and cross-linker have an effect on water content and 
distribution inside the hydrogels (Goda, Watanabe, Takai, & Ishihara, 2006; 
Kiritoshi & Ishihara, 2002). It was thought that by increasing the ratio of bound to 
free water in the formulation, the loaded drugs would more slowly diffuse to prolong 
its release.  
To modify the water amount and distribution the percentage of cross-linker 
(PEGDA) was reduced from 0.56% to 0.28% and 0.14% while keeping the 10% 
MPC formulation mixture constant (88.7% HEMA, 10% MPC, 0.74% (w/w) AIBN). 
The initiator was also modified. The percentage of AIBN was reduced from 0.74% 
to 0.37% and 0.18% while keeping the 10% MPC formulation mixture constant 
(88.7% HEMA, 10% MPC, 0.56% (w/w) PEGDA). There was no significant 
difference in the free to bound water ratio when either the cross-linker or initiator 
was decreased. Based on the experiments that were conducted, the 10 % MPC 
formulation with 88.7% HEMA, 0.56 % PEGDA and 0.74 % (w/w) AIBN was chosen 
as the best formulation to fabricate a hydrogel derived drug releasing GDD spacer. 
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When a GDD implanted or a patient undergoes GFS, medication is required 
for a period of 4-8 weeks after surgery with non-steroidal anti-inflammatory drops 
often being prescribed. DEX eye drops are often used to reduce local ocular 
inflammation. Loading the hydrogel spacer with DEX to sustain its local could 
eliminate the side effects associated with using eye drops such as low efficacy, low 
patient adherence to treatment and increased sensitivity of an already inflamed eye 
tissue due to the presence of preservatives (Ghate & Edelhauser 2008; Noecker 
2001).  
DEX loading was 0.3 mg/disc and the half-life for release was 1.8 ± 8.9 days 
when water:ethanol (1:1) was used as the loading solvent for 10% MPC. 
Water:ethanol (1:1) was replaced with methanol as solvent for loading in an effort to 
maximise hydrogel loading by mediating gel swelling and increasing drug 
concentration in the soluble phase during loading. The maximum solubility of DEX 
in water alcohol mixture is limited. However, if ethanol or methanol were used alone 
a solution of 15 mg/mL of DEX could be prepared. Ethanol could not be used 
because 10% MPC hydrogels have low SR in ethanol (0.20 ± 0.03). On the other 
hand, the SR of the hydrogel is similar between water and methanol (1.20 ± 0.02 
and 1.20 ± 0.09 for methanol and water respectively). The toxicity of methanol was 
a factor to be considered. To extract methanol from the loaded hydrogel and to 
create a depot of DEX inside the hydrogel matrix, the loaded discs were washed 
with 2 mL of water for 4 hours followed by vacuum drying for 24 hours. The loading 
increased from 0.3 mg to 1.9 mg/disc and the half-life increased from 1.9 days to 
9.7 days.  
For future work release could be studied using hydrogel discs with different 
dimensions and study the effect of thickness, surface area and shape on the 
release of loaded drugs. There is a wide range of drugs that could be used as anti-
inflammatory or anti-scarring after GFS (such as ilomastat) and the loading and 
release of different drugs from HEMA-MPC hydrogel could be further investigated. 
There is also the potential for loading more than one drug on the same hydrogel to 
have synergistic effect. Two or more drugs could be loaded either from the same 
solution or loading one drug first followed by drying of the hydrogel and loading the 
other drug molecule.     
Currently there are no GDDs in the clinic that possess a drug eluting spacer. 
In the case of GFS, there are also no clinically approved drug eluting spacers that 
could be used after trabeculectomy. A drug eluting spacer could offer a solution to 
the major problem of foreign body response that is associated with GDDs. Large-
scale production, efficacy, ensuring sterility and minimising costs are important 
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parameters to be considered. The same techniques used for contact lens 
fabrication and sterilisation could be modified for the fabrication of a GDD and drug 
eluting spacer.  
As discussed previously scarring of the subconjunctival tissues is a common 
complication after GDD implantation and GFS. An effort was made to load anti-
scarring drug into the 10% MPC hydrogel discs fabricated. One of the drugs that 
show promising results as anti-scarring agent is the known antibiotic doxycycline 
(DOXy) (Li et al. 2013; Dawson & Schachter 1985). Another advantage of 
fabricating a DOXy releasing hydrogel spacer is the possibility of utilising the spacer 
for other subconjunctival scarring conditions (e.g.  trachoma).     
Trachoma is the number one cause of blindness caused by an infection, 
often occurring in resource limited regions of the world. The cause of blindness is 
due to subconjunctival scarring in the eyelid resulting in lid contracting and turning 
inwards so when the eye blinks, the eye lashes scratch the cornea causing 
blindness. Trachoma surgery often fails because the eyelid contracts due to 
scarring resulting in blindness. Ideally topical antibiotics (e.g. tetracyclines) should 
be used for two weeks after surgery; however, patient adherence in many resource 
limited regions to topical treatments is very low and currently there is no available 
treatment after trachoma surgery. The 10% MPC hydrogel films could be used as a 
solution to the problem of trachoma surgery. The hydrogel film could be loaded with 
an anti-scarring agent and implanted at the incision site during the surgery. 
DOXy, in the hycale form, is highly soluble in water (~30 mg/mL). When a 
hydrophilic drug (pirfenidone) was previously loaded into 10% MPC hydrogel disc 
and the release was studied using eye flow chamber, the half-life was less than one 
day (0.7 days). For a hydrophilic drug the amount of drug loaded and the loading 
efficiency depends on the concentration of the loading solution and the volume 
absorbed by the dry hydrogel (Kim et al. 1992). Both parameters (drug loading 
concentration and volume absorbed by the hydrogel) were examined regarding the 
effect on amount loaded and release profile.   
DOXy loading solutions with varying concentrations (6 mg/mL, 15 mg/mL 
and 30 mg/mL) were used. The amount loaded was 1.20 ± 0.08, 3.60 ± 0.09 and 
7.50 ± 0.09 mg/disc for 6 mg/mL, 15 mg/mL and 30 mg/mL respectively. The 
loading increased with increasing concentration. Although the maximum amount 
loaded was 7.5 mg when loading from 30 mg/mL solution, 15 mg/mL was chosen 
as the optimum loading solution for further studies. It was reported that DOXy has 
the ability to supress cell contraction when used in a range of (100-400 µg) (H. Li et 
al., 2013). If loading solution concentration used was 15 mg/mL, the amount loaded 
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in each disc will be 3.6 mg which is estimated to be enough for two weeks if the 
drug is released at a rate of 200 µg /day. 
 The 10% MPC hydrogel swell to a different extent in different solvents. The 
amount of solvent absorbed into the dry hydrogel may affect the loading and 
release profile of DOXy. Different solvents and solvent combinations were 
evaluated to optimise DOXy release. The loading efficiency of DOXy into a 10% 
MPC hydrogel disc was 24.6 ± 4.1, 24 ± 0.8, 16 ± 2.8, 25.3 ± 9.4 and 24.3 ± 8.4% 
for water, PBS, water:ethanol (1:1), water:methanol (1:1) and methanol 
respectively. Although high loading efficiency was achieved, the release of the 
DOXy was fast with 50% of the loaded drug released within 24 hours. The half-life 
of DOXy was 1.2 ± 0.01, 0.9 ± 0.1, 0.9 ± 0.1 and 1.1 ± 0.3 for water, water:ethanol 
(1:1), water:methanol (1:1) and methanol respectively. 
The release of DOXy was studied in the eye flow rig that mimic the 
subconjunctival flow. Usually the flow rate of 2 µL/min is only in the subconjunctival 
space at the GFS site while the flow rate in the subconjunctival space in the eyelid 
is much smaller. Keeping that in mind, the release of DOXy from 10% MPC films is 
expected to be slower in the eyelid and the half-life is expected to be longer. Ideally 
the release of DOXy should have been studied at flow rate lower than 2 µL/min; 
however the flow rate from the peristaltic pump can go down only to 1 µL/min. Even 
if the flow rate was reduced, the inside volume of the flow rigs will cause a problem 
in estimation of half-life. The volume of the flow chamber is 400 µL (similar to the 
bleb created by the GFS) which will allow longer contact time of the fluid with the 
hydrogel and faster release (as seen in our results). For a future work a design of 
new flow chamber with low internal volume (100 µL instead of 400 µL of the current 
version) will be required. The new flow chamber with a flow rate of 0.2 µL /min 
instead of 2 µL /min will result in a more accurate estimation to the flow in the 
trachomatous eye lid.  
While DOXy loaded hydrogels have the potential to be used after trachoma 
surgery, slower release is required if they are to be used after GFS. In an attempt to 
slow the diffusion of DOXy from 10% MPC hydrogels, a diffusion barrier was 
created inside the hydrogel. β-cyclodextrin (β-CD) was incorporated into the 
hydrogel matrix to create an affinity drug releasing system. By incorporating β-CD 
into the polymer matrix, the affinity of DOXy to the hydrogel matrix could potentially 
be increased and the release rate could be decreased. DOXy has the ability to form 
inclusion complex with β-CD and the multiple association and dissociation between 
β-CD and DOXy in the hydrogel matrix may slow the release of DOXy. Different 
approaches were investigated to conjugate β-CD including formation of a film with 
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pendant β-CD, embedding of cross-linked β-CD particles into the polymer matrix 
and formation of IPN of 10% MPC and β-CD. 
For the preparation of 10% MPC hydrogel with glycidyl methacrylate (GMA) 
in the polymer matrix, GMA was mixed with 10% MPC monomer solution before 
polymerisation. The ratio of GMA used in the formulation was (1%, 2.5%, 5% and 
9% (w/w). After polymerisation and washing to remove leachables, the films were 
incubated for 24 hr with continuous stirring at 70oC in a mixture of DMF and 0.5 M 
NaCl with β-CD. The activation solution will activate the epoxy group in GMA to 
start the conjugation reaction with β-CD. However, this approach was infeasible. 
Films fabricated with 5% and 9% (w/w) GMA were unable to hydrate and remained 
glassy even after incubation in water for more than a week. Although films 
fabricated with 1% and 2.5% (w/w) GMA were hydrated in water, the films started to 
break apart after incubation in the activation solution.  
In an effort to incorporate β-CD into the hydrogel without using an activation 
solution, the β-CD solution was mixed with 10% MPC monomer solution and GMA 
to be polymerised at the same time (in situ polymerisation). A monomer solution of 
10% MPC was mixed in equal volumes with β-CD solution and increasing amounts 
of GMA (0.5, 0.2 and 0.1 g/mL). It was hoped GMA could be polymerised into the 
HEMA-MPC hydrogel matrix through the acrylate group and at the same time 
conjugated to β-CD through the epoxy group. Unfortunately no compliant film was 
formed after polymerisation. Even when the volume of 10% MPC monomer solution 
used was double the volume of β-CD solution, no proper film was formed. β-CD 
molecules have several hydroxide groups (OH) and it is possible that more than 
one OH group may participate in the reaction to form a covalent bond with GMA, 
and two or more GMA molecules could be attached to the same β-CD molecule. 
The multiple cross-linking of the same β-CD molecule may increase the cross-
linking density of the hydrogel formed and potentially affect the properties of the 
hydrogel formed. 
Preparation of films with pendant β-CD using GMA appeared to be 
unachievable in these MPC hydrogels. β-CD could be introduced as embedded 
particles in the hydrogel matrix. If β-CD were used as embedded particulate in the 
hydrogel mixture it could be washed with the unreacted monomers due to its 
solubility in water. Converting β-CD into insoluble form would help to immobilise the 
particles within the hydrogel film.  
For the preparation of 10% MPC hydrogels with embedded β-CD cross-
linked particles, β-CD hydrogel was first prepared. The β-CD hydrogel was then 
passed through a 40 mesh sieve to create microparticles and the particles were 
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freeze dried to be used in the 10% MPC film. Different β-CD cross-linked 
microparticles were prepared with different ratios of cross-linker (PEGDE) to β–CD 
solution (1:1, 1:2, 2:1). When the level of PEGDE to β–CD solution was 2:1, the 
hydrogel formed was very hard to pass through the 40 mesh sieve. The softness 
increased by reducing the percentage of PEGDE compared to β–CD solution. The 
ratio of cross-linker to β–CD solution chosen for the synthesis of the cross-linked 
CD particles was 1:1. The ratio offered the advantage of higher cross-linker density 
and the ability to pass through the 40 mesh sieve to produce the microparticles. 
A monomer solution of 10% MPC was prepared and β-CD cross-linked 
particles were added into the monomer solution in two different concentrations (1% 
and 2% (w/v)). The combination used for polymerisation was 10% MPC with 10% 
(w/v) β-CD particles. Formulation with 20% (w/v) of β-CD cross-linked particles in 
10% MPC monomer solution was non-injectable into the mould through 21G 
needle. Even when the needle size changed to 19G, suspension made with 2% 
(w/v) was still non injectable. The ability to inject the formulation into the mould is 
important to avoid air bubbles and to ensure uniform distribution of the formulation 
mixture through the mould.  
After polymerisation of the monomer mixture with 1% (w/v) β-CD cross-
linked particles a film was formed. The presence of the particles slightly increased 
the SR, free water ratio and water content in the hydrogel films. The EWC% was 
(65.4 ± 0.1) and (55 ± 0.3), the free to bound water ratio was (2:1) and (1.8:1) and 
the SR was 1.8 ± 0.1 and 1.2 ± 0.1 for 10% MPC with and without embedded β-CD 
particles respectively. The increase in water content could be attributed to the 
hydroxyl groups present in the β-CD structure that attracts water molecules. It is 
worth mentioning that when the ratio of free water to bound water was measured for 
cross-linked CD particles, the ratio of free to bound water was high (3.1:1). The 
hydrogel discs were then used for drug loading and release studies using eye flow 
rig. 
Although the amount of DOXy loaded increased from 3.7 ± 0.1 mg/disc for 
non β-CD embedded hydrogels to 6.6 ± 0.1 mg/disc for β-CD embedded hydrogels, 
the release profile was the same. A possible explanation is that the affinity of DOXy 
for cross-linked β-CD is low. The low affinity may have caused faster rate of 
dissociation compared to association between β-CD and DOXy. It is also possible 
that because of the high water solubility of DOXy the drug would preferentially 
partitioned too much into solution rather than the inner cavity of the β-CD molecule. 
A new approach was investigated for the incorporation of β-CD into the 
polymer matrix. An IPN of 10% MPC and β-CD hydrogels was prepared by in situ 
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polymerisation. It was thought that by using an IPN the hydrogel would have 
different properties compared to 10% MPC hydrogel alone or cross-linked β-CD 
hydrogels alone. Hydrogel formulations were prepared in which the β-CD monomer 
solution and 10% MPC monomer solution were mixed in equal volume ratios (1:1) 
and polymerised into a hydrogel. Various percentages of β-CD (15%, 30%, 50% 
(w/v)) were used for the formulations. The percentage of β-CD in the mixture was 
varied to identify the maximum amount of β-CD that could be applied into the 
monomer mixture and still maintain a film. After polymerisation the films were brittle.  
Since formation of IPN was not possible using in situ approach, sequential 
approach was investigated. In the sequential approach the 10% MPC monomer 
solution was polymerised first, in the presence of 30% (w/v) β-CD monomer 
solution, followed by polymerisation of the β-CD monomer solution. Equal volumes 
of both monomer solutions were used for the IPN preparation. When the 
polymerisation process completed, a hydrogel film was formed. Unfortunately, no 
difference in release profile was observed with DOXy. 
Further work with DOXy is still possible since this active drug substance is 
widely used and is known to have anti-bacterial, inflammatory and anti-fibrotic 
effects. The concept of utilizing a complexing agent in the hydrogel matrix as 
complexation or diffusion barrier could still be investigated in future work. One 
possible aspect is formation of polyelectrolyte complex with DOXy. DOXy is a weak 
base and if a weak acid polymer or monomer (such as acrylic acid) incorporated in 
the hydrogel matrix a complex could be formed. The complex may slow the release 
of the loaded DOXy. The possibility of using the concept of microparticulates for 
DOXy delivery could also be investigated. For example PLGA coated microparticles 
could be embedded in the hydrogel matrix to slow the release of DOXy.      
Another possible approach to increase the duration of action of DOXY is the 
use  of DOXy monohydrate rather than DOXy hyclate. DOXy monohydrate is less 
soluble than the hyclate form and work conducted with an MSc student at the end 
of this PhD project has shown potential to utilise CD as an affinity agent within a 
hydrogel for DOXy when the monohydrate form was used. Much work remains 
however to better understand DOXy affinity and rebinding effects to CD. 
Maintaining DOXy stability also remains an issue.   
As discussed previously, much blindness and visual impairment worldwide 
are related to glaucoma and AMD. While hydrogels could be considered to 
overcome some of the current treatment problems associated with current GDDs 
and GFS for glaucoma, it was also thought that hydrogels could be investigated to 
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overcome problems with current AMD treatments. There are many other conditions 
that require direct administration of medicines to the vitreous cavity.  
IVT injections of antibody based medicines are the first line treatment for 
AMD. IVT injections can have complications such as inflammation, vitreous 
haemorrhage, retinal detachment, patient discomfort and place a financial burden 
on patients and healthcare systems when IVT injections are required repeatedly 
over a long period (Falavarjani & Nguyen 2013). Sustained release protein 
formulations designed for the back of the eye have the potential to reduce the 
frequency of IVT injections. Solid implants for sustained drug delivery to the 
vitreous are available in the clinic; however implants are only used for the delivery 
of low molecular weight, poorly soluble drugs such as steroids. Proteins are hard to 
formulate as solid implants because it is difficult to maintain tertiary structure of 
proteins. Protein stability is difficult to maintain because proteins are susceptible to 
unfolding and aggregation. Protein therapeutics such as antibodies are currently not 
formulated as implants or even as formulations that can be incorporated into a 
pump, such as some insulin formulations. Formulations that can reduce the 
frequency of administration and can maintain the stability of the protein during 
storage and release are desperately needed in the clinic.     
Hydrogels with 10% MPC that were considered for use in the 
subconjunctival space could not be considered for use in the vitreous cavity 
because of the need for implantation. From the outset, use of a hydrogel for the 
back of the eye would require that the hydrogel formulation be injectable. 
Implantation of a hydrogel device would require a surgical procedure which long 
term would be expensive and limit patient access. Also it would be expected that 
the polymerisation conditions used for the HEMA-MPC hydrogels, e.g. relatively 
high temperature or UV initiation conditions would be difficult to achieve while 
maintaining protein stability. It was clear that an in situ approach is necessary to 
consider a hydrogel strategy using a protein as the active drug substance since.  
Mixing a large molecule such as a protein into a pre-formed hydrogel was 
considered not to be feasible.  
Another type of hydrogel was investigated as a potential injectable 
formulation for therapeutic proteins destined for the vitreous cavity. 
Thermoresponsive injectable hydrogels were considered as a potential formulation 
strategy for the intraocular use of therapeutic proteins. Biocompatibility, injectability 
and mild preparation conditions render thermoresponsive hydrogels as possible 
candidates for development of depot protein formulations. Thermoresponsive 
hydrogels that are in principle designed to be swollen and able to flow at room 
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temperature could then collapse into a semisolid implant once the surrounding 
temperature increased above hydrogel VPTT. Clearly issues related to the potential 
burst release of protein upon gel collapse and the need to consider the ultimate fate 
of the hydrogel are important, non-trivial issues that require effort to solve. However 
it was felt that first it was important to determine what could be achieved to prolong 
the duration of action for a protein from an injectable thermoresponsive hydrogel.   
NIPAAm derived thermoresponsive polymers are widely examined for 
biomedical applications, including as the basis of extended release formulations. 
NIPAAm thermoresponsive hydrogels are frequently made with small molecular 
weight cross-linkers to allow the complete collapse of the hydrogel at physiological 
temperature. It was thought that if a large molecular weight hydrophilic cross-linker 
was used, a thermoresponsive hydrogel could still be formed. The hydrophilic 
cross-linker was considered to be able to provide a more favourable to maintain the 
stability of the protein within the hydrogel during formulation, collapse and release. 
The type and relative incorporation of the cross-linker was expected to affect the 
properties of the hydrogel formed. PEGDA with a Mn of 700 was chosen as cross-
linker because of its hydrophilic nature and its reported biocompatibility in the 
human body (Li et al. 2014; Turturro et al. 2011). 
NIPAAm hydrogels with increasing relative amounts of PEGDA (4, 8, 12 and 
15 µL) were prepared both in the presence and absence of protein (bevacizumab or 
infliximab). These hydrogels were prepared in water with a mild initiating system 
that have the ability to start the polymerisation reaction at ambient temperatures 
and continue the polymerisation reaction at 4oC (TEMAD/APS system) in an effort 
to avoid loss of protein stability. The antibody loaded NIPAAm hydrogels were 
characterised and compared regarding physicochemical properties in particular 
thermal responsiveness, injectability and antibody release. Increasing the relative 
percentage of PEGDA in the formulation was accompanied by reduction in thermal 
responsiveness and injectability. The VPTTs were 34.3 ± 0.1, 35.50 ± 0.09, 35.6 ± 
0.4, and 36.2 ± 0.2oC as the PEGDA cross-linker was increased from 4 to 15 µL 
respectively. The degree of collapse was also reduced with increasing PEGDA 
percentage. The degree of collapse could be estimated based on the SR of the 
hydrogel at 37oC; the higher the SR the lower is the degree of collapse. The SR 
was 1.4 ± 0.5, 3.2 ± 0.8, 7.5 ± 0.7 and 9.6 ± 1.6 for 4, 8, 12 and 15 µL PEGDA 
respectively.  
Two methods for protein loading were screened to choose the method that 
offers maximum loading and prolonged release of the loaded protein; in situ 
polymerisation and imbibing methods. The release was studied using the PK-Eye 
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model that mimics the aqueous outflow in the eye and was developed to estimate 
human protein clearance times from the vitreous cavity. Both simulated vitreous 
and phosphate buffer solutions are used in the PK-Eye.  Phosphate buffer solution 
was used to evaluate the majority of the NIPAAm hydrogel formulations because 
release experiments can be conducted more quickly and still compare different 
formulations. Although bevacizumab loading was surprisingly similar from the two 
methods (~72% after washing) the release profile was significantly different 
(p<0.05) which indicated there was a difference in the mixing method. The half-life 
of bevacizumab when mixed by imbibing was 2.3 ± 0.8 compared to 3.7 ± 1.2 when 
the antibody was incorporated during polymerisation. The large size of 
bevacizumab (150 kDa) allowed better entanglement when mixed during NIPAAm 
polymerisation compared to imbibing method.  
NIPAAM derived hydrogels from polymerisation of 40 mg of NIPAAm with 4, 
8 and 12 µL PEGDA were loaded with bevacizumab (2.5 mg) using in situ 
polymerisation. The NIPAAm monomer was dissolved in 1 mL of bevacizumab drug 
solution (25 mg/mL) followed by addition of PEGDA and polymerisation. 
Bevacizumab release was compared. A half-life of 2 ± 0.01, 3.7 ± 1.2 and 2.60 ± 
0.03 days was observed with 4, 8 and 12 µL PEGDA respectively with a protein 
release of ~74%, ~87% and 95% respectively after a month. Although the 
calculated half-life was relatively similar between the prepared hydrogels and 
bevacizumab injection (2.3 ± 0.8 day for the injection), the release profiles were 
different. Nearly all of the bevacizumab was cleared after 10 days when injection 
was used (~95.1% ± 3.1) compared to ~61.9 ± 3.6%, 63.2 ± 8.3% and 75.0 ± 1.9% 
for 4, 8 and 12 µL PEGDA respectively. The release of bevacizumab followed a 
bimodal display profile from the NIPAAM hydrogels with the first phase following a 
first order profile for the first week and then a more sustained pesedo-zero order 
behavior for the remaining three weeks of the release study.  
Entangling a large molecule during the polymerisation process when 
formulating a hydrogel may affects the physical properties and mixing of a protein 
within the hydrogel. The effect of encapsulating bevacizumab during NIPAAm 
polymerisation on the properties of the prepared hydrogels were studied. A slight 
reduction in VPTT from 35.5 ± 0.09oC for unloaded hydrogel to 34.2 ± 0.5oC for 
loaded hydrogel. Although the SR was significantly different between loaded and 
unloaded hydrogels (p<0.05) at 25oC, there was no significant difference in SR at 
37oC. The SR of bevacizumab loaded hydrogels were 34.1 ± 2.1 and 3.1 ± 0.8 at 25 
and 37oC respectively. The entanglement of the protein in the hydrogel network 
restricts the movement of the hydrogel polymer chains resulting in reduced SR at 
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25oC. It appeared that the presence of the antibody had little impact on hydrogel 
collapse at 37oC. Overall, protein encapsulation during polymerisation had no effect 
on the general properties of the prepared hydrogels, which could imply that mixing 
was not as good as could be achieved. It is possible that polymer formation 
occurred where the majority of the forming polymer did not entangle and interact 
with the antibody.  Hence the observed macroscopic properties are indicative of 
hydrogel rich region of the samples that were evaluated. Release profiles did 
suggest that some mixing had occurred, but the release profiles were not to the 
extent that might have been hoped for.   
NIPAAm hydrogels fabricated with 15 µL PEGDA were non-injectable and 
hydrogels fabricated with 12 µL PEGDA were difficult to inject. The release of 
bevacizumab was also significantly faster (p<0.05) when compared to hydrogels 
made with 4 and 8 µL PEGDA. NIPAAm hydrogels made with 4 and 8 μL PEGDA 
showed similar characteristics, behaviour and sustained the release of protein to 
the same extent in vitro. At 25oC the SR of 4 μL is higher than 8 μL, which may 
cause the loss of higher percentage of the protein during washing. Washing is 
required to remove the unreacted monomers and other leachable oligomeric 
substrates from the hydrogel before injection. Also hydrogels made with 4 μL were 
very soft and difficult to handle. Based on these observations 8 μL PEGDA was 
chosen as the best formulation that would considered for further work to sustain the 
release of bevacizumab in the posterior segment.  
After the hydrogel polymerisation process, removal of unreacted monomers 
is essential as they are toxic in nature. Bevacizumab loaded hydrogels with 12 μL 
as cross-linker was washed and the release of the protein was compared between 
the washed and the unwashed hydrogels. Although ~28% of the loaded protein was 
lost during washing, there was no significant difference (p>0.05) in half-life and 
release profile between washed and unwashed hydrogels; the half-life was 3.1 ± 
1.3 and 3.7 ± 1.2 days for washed and unwashed hydrogels respectively.  
NIPAAm hydrogels are non-biodegradable and will be in direct contact with 
eye tissues for a long period of time. In an effort to improve biocompatabilty it was 
thought to incoprporate MPC in the formulation. MPC-co-NIPAAm 
thermoresponsive hydrogel with 8 μL PEGDA was prepared. Although a hydrogel 
was formed when MPC was incorporated in the formulation, the thermal 
responsiveness was reduced. Even when the percentage of MPC in the formulation 
was reduced to ~0.6% (w/w), weak thermal responsiveness was observed. 
In order to add PC zwitterionic group into the NIPAAm hydrogels and 
maintain the thermal responsiveness, PEGDA was replaced with PC bearing cross-
204 
 
linker. The same method used for the formulation of PEGDA cross-linked NIPAAm 
hydrogels (in situ polymerisation) was used for the synthesis of PC cross-linked 
NIPAAm hydrogels. When 8 µL PEGDA was replaced with PC 3059 as cross-linker 
no difference in behaviour was observed (25% (w/w)). PC 3059 is a 
macromolecular cross-linker provided to us from Vertellus. The cross-linker 
structure is complex and the molecular weight characteristics are not known. 
However, approximately 1% MPC is incorporated in PC3059. The VPTT of the 
PC3059 cross-linked NIPAAm hydrogels was significantly lower (p<0.05) (33.8 ± 
0.1oC) with PC compared to PEGDA (35.5 ± 0.09oC) cross-linker. There was no 
significant difference (p>0.05) in SR between PEGDA and PC NIPAAm hydrogels 
at 25 and 37oC. There also was no significant difference (p>0.05) in the release 
profile of bevacizumab from both hydrogels. Also similar to PEGDA, bevacizumab 
loading had no effect on the general properties of the prepared PC cross-linked 
hydrogels. PC 3059 is promising alternative of PEGDA as cross-linker with a 
potential of higher biocompatibility. These observations were surprising and were 
consistent with less than optimal mixing of the antibody within the hydrogel.   
From the previous work with PEGDA it was noticed that when the 
percentage of cross-linker increased in the formulation, hydrogels with different 
properties are formed. To examine whether the characteristics of all of the 
hydrophilic macromolecular cross-linkers are similar, hydrogels with increasing 
percentage of PC cross-linker (25% to 33.5% (w/w)) were prepared and compared 
regarding the physical properties of the hydrogels that were formed. Similar to 
PEGDA, the hydrogels fabricated using higher percentages of PC were difficult to 
inject and the VPTT was slightly increased with higher cross-linker percentage. The 
difference in behaviour between PEGDA and PC cross-linked hydrogels was 
observed in the collapse of the hydrogel at 37oC. The SR was not significantly 
increased (p>0.05) when PC percentage increased (as observed with PEGDA). 
The SR was 3.8 ± 1.9, 5.2 ± 1.8 and 5.1 ± 0.5 for 25%, 30% and 33.5% (w/w) 
respectively. A possible explanation is the hydrophilicity of the cross-linker used. 
While it is known that PEGDA can form hydrogen bonds with water, PC groups 
attract free water around their polymer chains that could be easily expelled during 
the collapse of the hydrogel. The results indicate that the interaction of the molecule 
with water is also important and should be considered.  
Both PEGDA and PC are non-biodegradable molecules. It was interesting to 
examine whether a biodegradable macromolecular hydrophilic cross-linker will 
behave in a similar way to non-biodegradable ones. It is also of an advantage if the 
NIPAAm hydrogel could be formulated as biodegradable hydrogel. Ac-HA 
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synthesised in our lab was used as biodegradable hydrophilic cross-linker. HA is a 
common component in many parts of the human body such as extracellular matrix, 
synovial fluid and the vitreous humour  and widely investigated component for drug 
delivery due to its biodegradability and biocompatibility (Widjaja et al. 2014; Mayol 
et al. 2008; Kogan et al. 2007). 
Different amounts of Ac-HA were used for the hydrogel synthesis (2, 4, 7 
and 10 mg) in the presence of NIPAAm (40 mg). The injectability was reduced and 
thermal responsiveness was reduced with increasing amounts of Ac-HA when used 
as a cross-linker. The hydrogels became non thermoresponsive when 7 and 10 mg 
Ac-HA were used. No significant difference in SR (p>0.05) at 25 and 37oC was 
observed with 7 and 10 mg Ac-HA hydrogels. NIPAAm hydrogels made with 2 and 
4 mg Ac-HA were loaded with infliximab (9.4 mg/mL). Infliximab and bevacizumab 
displayed similar MW (150 kDa). When both protein loaded hydrogels were washed 
to remove unreacted monomers, ~26.7% of infliximab was lost from hydrogels 
made with 2 mg Ac-HA compared to ~19.5%. The SR of hydrogels made with 2 mg 
was significantly higher (p<0.05) than the SR of 4 mg hydrogels. The higher SR 
indicated high water content which allows faster diffusion of the protein to the 
surrounding washing medium. Since protein loss was significantly evident with 
hydrogels made with 2 mg Ac-HA, it was decided that hydrogels fabricated with 4 
mg should be used for preliminary protein release studies. 
The initial studies on infliximab release from 4 mg Ac-HA cross-linked 
hydrogels revealed a difference in release profile when compared to 8 µL PEGDA 
and 25% (w/w) PC cross-linked hydrogels. Only ~25% of the loaded protein was 
released after 10 days from Ac-HA cross-linked hydrogels compared to ~60% from 
8 µL PEGDA and 25% (w/w) PC cross-linked hydrogels. The difference could be 
attributed to the molecular nature of HA. HA is used as viscosity agent in 
pharmaceutical formulations and the slow release of infliximab from Ac-HA cross-
linked hydrogels is a combined effect of thermal responsiveness of the NIPAAm 
hydrogel and viscosity enhancing effect of HA.  
The aim of our work was to screen different macromolecular hydrophilic 
cross-linkers for the formulation of sustained release protein thermoresponsive 
hydrogel as IVT injection. The three investigated molecules PEGDA, PC 3059 and 
Ac-HA demonstrated promising results in the ability to form a dosage form that is 
injectable, thermoresponsive and sustain the loaded protein for more than one 
month. The formulations also allow the formation of hydrogels with different 
concentrations of the protein by manipulation of the concentration of the starting 
protein solution during the polymerisation process.  
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A possible future work is the study of the potential proper NIPAAm hydrogel 
formulations with proteins of different molecular weights and study whether the 
molecular weight will have an impact on the properties of the hydrogel. Optimisation 
of the loading of the protein after washing of the hydrogel could also be 
investigated. The protein lost during washing could be compensated by rehydrating 
of the protein loaded dry hydrogel in protein solution. Biocompatibility and animal 
studies should be considered following optimisation of the formulation.     
The work described in this thesis set out to examine the use of hydrogels in 
two different parts of the eye: (i) subconjunctiva and (ii) vitreous cavity. The use of 
hydrogels in the form of implants was investigated in the subconjunctival space to 
improve current treatments available for glaucoma. Although HEMA-MPC hydrogels 
were unable to show sufficient permeability and hydraulic conductivity to be of any 
use to control aqueous outflow to regulate pressure in a GDD, the hydrogel films 
offer a platform for development of drug releasing combination GDD and drug 
releasing spacer after GFS. 
 Different hydrogel based formulations for the sustained delivery of protein in 
the vitreous using thermoresponsive hydrogels was investigated.using 
macromolecular hydrophilic cross-linkers. Modification in the type and percentage 
of cross-linker used allowed the preliminary screening and development of 
formulations that sustained the protein for more than one month.    
  
207 
 
Appendix 
Dynamic approach for flow measurements 
The equations for determining hydraulic conductivity were derived from first 
principles. A schematic representation (Figure 7:1) of the apparatus is shown in the 
below figure to develop the analysis. The analysis is based on D’Arcy’s law. 
D’Arcy’s law states that flow is proportional to the applied pressure. Thus for a 
membrane disc of radius a (m), flow per unit area is designated by: 
𝑭
𝝅 𝒂𝟐
= 𝑳  𝑷, 
Where L is the hydraulic conductivity of the membrane (m/s/Pa) and P is the 
applied pressure (Pa). 
 
Figure 7:1 A schematic representation of the apparatus used for permeability and hydraulic 
conductivity measurements. 
 
Since       
                                       𝑭 =
𝒅𝑽
𝒅𝒕  
,                                                        (7.1) 
 
                                
 𝒅𝑽
𝒅𝒕
=  𝝅 𝒂𝟐  𝑳  𝑷,                                                 (7.2) 
Pressure due to the column of fluid is given by   P = ƿ 𝑔 h 
Where  ƿ is the density of water (1000 Kg/m3), g is the gravitational constant 9.81 
m/s2 and h is the height of column in meters. Hence: 
                                          
𝒅𝑽
𝒅𝑻
= 𝝅 𝒂𝟐 𝑳 ƿ 𝒈 𝒉,                                    (7.3) 
After a time dt, change in volume is dV = -  r2 dh, where r is the radius of the 
capillary column, i.e., column height falls. Therefore: 
h (m)
-dh
radius a
radius r
tissue
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                              − 
𝝅 𝒓𝟐 𝒅𝒉
𝒅𝒕
= 𝝅 𝒂𝟐 𝑳 ƿ 𝒈 𝒉,                                       (7.4) 
Rearranging: 
                                         
𝒅𝒉
𝒉
= − 
𝒂𝟐  𝑳 ƿ 𝒈   
𝒓𝟐
 𝒅𝒕,                                    (7.5) 
Integrating: 
                            ∫
𝒅𝒉
𝒉
=  − 
𝒂𝟐 𝑳 ƿ 𝒈
𝒓𝟐
 ∫ 𝒅𝒕,                                             (7.6) 
Thus               
                                     𝐥𝐧 𝒉 =  − 
𝒂𝟐 𝑳 ƿ 𝒈
𝒓𝟐
 𝒕 + 𝒄,                                   (7.7) 
Where c is the constant of integration. 
Boundary conditions are: t= 0, h = ho and hence c = ln ho 
Hence: 
                           𝐥𝐧 𝒉 =  − 
𝒂𝟐 𝑳 ƿ 𝒈  𝒕
𝒓𝟐
  + 𝐥𝐧 𝒉𝟎 ,                                     (7.8) 
                            𝐥𝐧 𝒉 − 𝐥𝐧 𝒉𝟎 =   
𝒂𝟐 𝑳 ƿ 𝒈  𝒕
𝒓𝟐
   ,                                            (7.9)  
                           𝒍𝒏 (
𝒉
𝒉𝟎
) =  −  
𝒂𝟐 𝑳 ƿ 𝒈  𝒕
𝒓𝟐
 ,                                                   (7.10) 
From log b a = c,    b
c
 = a 
                                    
𝒉
 𝒉𝟎
=  𝒆
−  
𝒂𝟐 𝑳 ƿ 𝒈  𝒕
𝒓𝟐 ,                                                       (7.11) 
Or 
                                     𝒉 = 𝒉𝟎 𝒆
−  
𝒂𝟐 𝑳 ƿ 𝒈  𝒕
𝒓𝟐 ,                                           (7.12) 
 
From equation (7.10) a plot of (ln h/h0) against t should yield a straight line of 
gradient G. 
𝑮 = −  
𝒂𝟐 𝑳 ƿ 𝒈  
𝒓𝟐
 
This gradient can be obtained by linear regression of the above plot. If the gradient 
is designated G, then the hydraulic conductivity L is given by: 
 
                                         𝑳 = − 
𝒓𝟐
𝒂𝟐 ƿ 𝒈
  𝑮,                                       (7.13) 
Then permeability is calculated using L  
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                                            𝑲 = 𝑳 × 𝑻,                                              (7.14)  
Where T is the thickness in (m). 
Calculations of permeability 
As an example of the calculations used to measure permeability, the calculation for 
hydrogel made with 10% MPC is shown below. The values of water height (h) were 
taken at different time intervals and the results are listed (Table 7:1). These 
measured values were plotted (Figure 7:2). From the figure we measure the 
gradient to calculate the hydraulic conductivity using equation (7.13). The hydraulic 
conductivity was then used to calculate the permeability of the sample using 
equation (7.14). The permeability of all the received films was calculated in the 
same way as 10% MPC.  
 
Table 7:1 The values of height (h) of water column taken at different time intervals in 
seconds. 
Time 
seconds 
ln h/h0 h/h0 h m Time h cm 
0 0 1 0.27 12:25 pm 27 
8700 -11.061×10-3 0.989 0.267 2:50 pm 26.7 
13260 -18.775×10-3 0.9814 0265 4:06 pm 26.5 
15720 -22.45×10-3 0.9778 0.264 4:47 pm 26.4 
75480 -126.153×10-3 0.88148 0.238 9:23 am 23.8 
79860 -130.109×10-3 0.878 0.237 10:36 am 23.7 
83580 -134.675×10-3 0.874 0.236 11:38 am 23.6 
89040 -147.456×10-3 0.8629 0.233 1:09 pm 23.3 
 
 
 
Figure 7:2 The time verses ln h/h0 will yield a gradient which is -0.0017 for sample number 
(7/28). This gradient used to calculate the permeability of the sample tested.    
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The time verses ln h/h0 will yield a gradient which is -0.0017 for 10% MPC 
film. The gradient used to calculate the permeability of the sample tested.    
𝐿 = − 
𝑟2  
𝑎2   𝜌  𝑔
  𝐺 
𝐿 =  
(1.75 × 10−3)2  
(3 × 10−3)2  ×   1000  ×  9.81
 0.0017 × 10−3 
L = 5.897 × 10-11  m s-1 pas-1 
K= L × T 
K= 5.897 × 10-11  × 1× 10-3  
K= 5.897 × 10-14   m2 s-1 pas-1 
The estimated permeability required to flow through a devise with the 
following dimensions (1 mm thickness, 2 cm2 surface area) and with estimated flow 
rate of (2 µl/m) to lead to a pressure of (10 mmHg) was calculated using equations 
(7:14).  
Q = 2 µl/min = 1.6 × 10−11 m3/s      
T = 1 mm = 1 × 10−3 m    
A = 2 cm2 =  2 × 10−4m2            
P = 10 mmHg = 1333.2 pascal 
K ==
𝑄  𝑇
𝛥𝑃  𝐴
                                         
K  = =
1.6×10−11 𝑚3/𝑠     1×10−3 𝑚  
1333.2 𝑝𝑎𝑠𝑐𝑎𝑙   2×10−4𝑚2 
                                           
K = 6 ×10-14 m2 s-1 pas-1     
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